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All cells within an organism - including humans - contain the same DNA which is
approximately 2 meters in length. This DNA contains all the information required
for an organism to function. A human body has a large number of specialised
cells all of which have very specific roles, allowing the development of specialised
organs, for example a cardiac cell does a completely different job to that of a liver
cell. Each specialised cell uses (expresses) different and specific sections of DNA
called genes to allow it to perform its role in the organism. It is the specific genes
used by the cell which determine its role and function. How does each cell select
the relevant information from DNA in order to do their specific job?
All multicellular organisms develop from a single cell. These cells divide and
develop into an embryo; each cell still contains the same DNA yet expresses only
a small portion at any one time. These cells, called embryonic stem cells, can
become any type of cell in the organism. They become more specialised, a process
termed differentiation, as the embryo continues to develop and form different
tissues and organs. As the cells become more specialised they lose the ability
to become any type of cell and their differentiation potential becomes restricted.
The set of genes the cell can express becomes restricted to the differentiation
potential of the cell.
DNA is stored within the nucleus of the cell, because of the length of DNA
compared to the size of the nucleus, it needs to be compacted to fit. The DNA
is compacted by winding it around proteins, like thread on a spool, allowing
organised packaging of the DNA. The packing of the DNA helps determine
whether that section of DNA is used by the cell, as the cells need access to
the DNA in order to express it. Tightly packed DNA is not accessible by the cell
and can’t be used. Chemical modifications of the DNA and the proteins on which
it is stored help mark the DNA, determining whether it is used by the cell. These
chemical modifications (marks) bind (recruit) specific factors which help unwind
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the DNA and result in the cell accessing the DNA. These modifications and the
factors recruited can allow (active) or prevent (repressive) the cell’s access to the
DNA. It is the combination of chemical modifications and the factors recruited
to the DNA that determine whether the DNA is able to be utilised by the cell.
This project focusses on a particular combination of modifications that contain
both an active and a repressive mark on the same location of DNA called
bivalency or bivalent domains. The function of this combination of marks is
unknown, although they share characteristics of both active and repressed DNA.
However, they are present in large amounts in embryonic stem cells and signpost
genes important in the cell’s differentiation. During the organism’s development
and the cell’s differentiation, genes need to be timely regulated to allow correct
cellular specialisation. The combination is resolved after the cell has specialised,
with either the active or repressive mark being removed. The combination of
both marks, in addition to their presence at developmentally significant genes
suggests that they are important in allowing quick regulation of the gene during
development.
We think that by identifying the factors recruited (bound) by bivalent domains
we will be able to determine their function. I found the factors recruited by
bivalency, some of which were previously known to interact with either the active
or repressive mark. However, some factors are more likely to be recruited to
the bivalent state. Removal of one of these factors resulted in the cells being
unable to differentiate, potentially due to its role at bivalent domains. I also
demonstrated that the symmetry of the chemical modifications helps determine
the factors recruited. Further work needs to be done to investigate the other
factors identified at bivalent domains and isolate their function.
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Abstract
The combination and interaction of histone marks and DNA-associated proteins
are critical in the regulation of gene transcription. Individual histone marks
have been associated with different gene expression states - histone H3 lysine
4 trimethylation (H3K4me3) is associated with “open” chromatin and active
transcription while H3K27me3 is associated with “closed” chromatin and a
repressive transcriptional state. In certain cases, these marks have been shown to
co-localise at genomic loci, and on the same nucleosome. The co-localisation of
active H3K4me3 and repressive H3K27me3 marks at CpG promoters is a hallmark
of bivalent domains.
Bivalent domains have been implicated in priming developmental genes for timely
activation. However, the complex network of proteins that bind to these domains
to regulate and mediate their influence on transcription is unknown. This
study has developed tools to enable the characterisation of the protein networks
bound to bivalent domains and other specifically modified nucleosomes. In vitro
synthesised specifically modified nucleosomes were utilised in pulldown assays
with embryonic stem cell (ESC) nuclear extract to isolate the specific protein
binders for different combinations of histone marks. This assay was validated
by comparison of proteins bound to symmetrically modified nucleosomes with
previously identified protein binders.
A comparison of symmetrically and asymmetrically modified nucleosomes has
elucidated new binding preferences for known proteins. Analysis of proteins
bound to asymmetrically modified nucleosomes showed previously unknown
binding affinities and conformational preferences. TAF3, a known H3K4me3
mark binder, prefers to bind symmetrically rather than asymmetrically modified
nucleosomes, even when the same amount of the mark is present. Therefore, this
preference is not solely dependent on the amount of modification, but also due to
the conformation of the marks on the nucleosomes. We have identified multiple
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key proteins that prefer binding to this specific mark (H3K4me3/K27me3)
conformation, including the acetyltransferase KAT6B. Work in mouse ESCs
confirmed KAT6B binding to bivalent domains and showed a pronounced
differentiation defect in KAT6B−/− cells due to mis-regulation of genes important
in development. Further characterisation of these proteins and their interactions
will help to clarify bivalent domain function.
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1.1 Chromatin Organisation and Structure
1.1.1 Nucleosome Structure
There are approximately 2 meters of DNA in each human cell. This presents
several issues, primarily how to condense the DNA in the cell while keeping it
accessible. Chromatin packages DNA in such a way that these 1.7-2 metres of
DNA fit into a nucleus of approximately 6 µm diameter in eukaryotic cells. The
basic repeating unit of chromatin is termed the nucleosome core particle (NCP),
which consists of a 146 base pairs (bp) of negatively charged DNA wrapped
around the positively charged surface of a highly evolutionary conserved histone
octamer in 1.65 turns of a ‘flat left-handed superhelix’ (Fig. 1.1) (Richmond et
al., 1984; Luger et al., 1997a). The histone octamer consists of dimers of four
core histone proteins: H3, H4, H2A and H2A. A fifth histone—histone H1—is
referred to as a linker histone as it binds DNA between nucleosomes, helping
with the ordering and compaction of DNA. These NCPs are linked together with
the addition of further proteins including linker histones and further compacted
to form a solenoid fibre, which then undergoes higher-order packaging to form a
chromosome with the help of additional proteins such as Condensin (Tremethick,
2007; Kalashnikova et al., 2013; Zheng and Hayes, 2003b; Moraru and Schalch,
2019; Hirano, 2016).
In the nucleosome, the core histones form a symmetrical disc-like structure around
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which the DNA wraps. The histone octamer is composed of two H2A/H2B dimers
and one H3/H4 tetramer and can be split into four histone fold pairs (Fig. 1.1).
All four core histones share a very similar motif termed the histone fold, consisting
of 3 alpha helices connected by 2 loops, giving rise to a α1 -L1-α2-L2-α3 topology
(Fig. 1.1). This motif is integral for the core histone interactions and for ensuring
the binding and bending of the DNA around the octamer. The two H3/H4 dimers
interact through a four-helix bundle (histone fold pair) formed by the H3-H3’
histone folds to assemble the H3/H4 tetramer (Luger et al., 1997a; Richmond
et al., 1984). The H2A/H2B dimers interact with the tetramer through a similar
four helix bundle between H4 and H2B to form the octamer. Each histone fold
pair binds 2.5 turns of DNA double helix, generating a 140◦ bend and fixing 36-38
base pairs (bp) of DNA in place. Histone fold extensions bind a further 13 bp of
DNA (Luger et al., 1997a).
The DNA binds the octamer with a central bp at the particle two-fold pseudo-
symmetrical axis (Flaus et al., 1996; Luger et al., 1997a). The helices and loops
of the histone fold create two DNA binding sites: one composed of the two alpha
helices and the other of L1L2 and the termini of the α2 helices at the end of the
histone pair crescent. Hydrogen bonds between the main chain amide nitrogen
atoms and the phosphates of the DNA backbone help secure the DNA backbone
in place (Luger et al., 1997a; Moudrianakis and Arents, 1993). An arginine side
chain from the histone is inserted into the minor groove of the wrapped DNA when
the backbone faces the octamer, explaining why an A-T base pair is preferred in
the minor groove of the nucleosomal DNA, as this creates a narrower minor
groove allowing for stronger salt bridges with the arginine side chains. There
are multiple interactions between the DNA and histone octamer, from non-polar
interactions with deoxyribose groups, to salt bridges that help the histone octamer
bind and wrap the DNA (Davey et al., 2002; Luger et al., 1997a; Richmond and
Davey, 2003; Richmond et al., 1984). This wrapping of DNA around the octamer
causes the phosphate backbones of the two DNA strands to be closer together
on the side of the DNA closest to the histone octamer, narrowing the minor and
major grooves but widening the grooves on the outside of the wrapped DNA.
This bending of the DNA is energetically unfavourable but is maintained by
multiple interactions between the DNA and the arginine and lysine sidechains
of the histones (Luger et al., 2012; Kalashnikova et al., 2013; Zheng and Hayes,
2003b; Zheng and Hayes, 2003a; Luger et al., 1997a; Moudrianakis and Arents,
1993; Flaus et al., 1996).
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Figure 1.1 The Crystal Structure of the Nucleosome Core Particle (NCP). The
crystal structure of the NCP is composed of bacterially expressed Xenopus laevis core histone
proteins and human alpha satellite DNA at 2.7Åresolution (Luger et al., 1997a). The 2-fold
pseudo symmetry dyad axis and superhelical axis are indicated. A) NCP crystal structure: H2A
is yellow, H2B is red, H4 is green and H3 is blue. The 146 bp of DNA wrapped around the
octameric core is shown in green and gold to clearly delineate the different strands of the DNA.
Two different viewpoints of the NCP are shown: down the superhelix axis and perpendicular
to it. B) A blown-up view of the NCP particle. Half of the NCP is shown in order to be able
to clearly see interactions between the proteins of the histone core. The histone fold domain
dimer between H3 and H4 is indicated. The 4-helix bundles are labelled as H3’ H3 and H2B
H4; histone-fold extensions of H3 and H2B are labelled as αN’, αN and αC, respectively. The
4-helix bundle between H4 and H2B is highlighted. The N terminus and C terminus of each
protein is labelled N and C, respectively. The number of superhelix turns is shown indicating
the rotational orientation of the DNA relative to the central base pair, with superhelix location
zero (SHL0) defined as where the major groove faces the octamer and indicated on the figure,
each further SHL label indicates one more double helix turn away from SHL0. Figure adapted
from Luger et al., 1997a. Red arrows indicate sites of interaction between the minor groove of
the DNA and the arginine side chain from the histone core.
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Approximately 25% of each core histone is composed of its N-terminal (NT) tail
sequence. These N-terminal tails are flexible, resulting in poor definition within
crystal or electron-microscopy (EM) structures. The flexible tail regions can be
defined as the parts of the histone proteins that extend past or through the DNA
superhelix and are not an integral part of the histone octamer. The core histones
can still form an octameric complex when lacking their N-terminal flexible tails
(Biswas et al., 2011; Freeman et al., 1996). Both H3 and H2B N-terminal tails
have random coil regions that pass through superhelix channels formed from
the minor grooves of the DNA, spanning residues 39-43 and 26-34, respectively
(Luger et al., 1997a). Not all of the tails protrude out via a minor groove and
do not contact the octamer. The H2A and H4 N-terminal tails follow minor
grooves to the exterior of the nucleosome, while the C-terminal tail of H2A along
with its α3 helix forms a docking domain termed the acidic patch for the H4
C-terminal tail which is folded over its α3 helix (Kalashnikova et al., 2013; Luger
et al., 1997a). The core histone N-Terminal tails are sites of post-translation
modifications (PTMs), which are known to alter the accessibility of the DNA
bound to the nucleosome, nucleosome dynamics and to recruit binding proteins
and will be discussed later (Stützer et al., 2016; Luger, 2006; Li et al., 2005b;
Fletcher and Hansen, 1995; Zentner and Henikoff, 2013).
Although the histone octamer is normally made up of the 4 main canonical core
histones H2A, H2B, H3, and H4, there are many non-canonical variants, which
can be substituted for one or more of the canonical histones (Weber and Henikoff,
2014; Talbert and Henikoff, 2017). Each variant has a slightly different sequence,
recruiting different proteins, potentially altering the nucleosome structure and
affecting its biophysical properties (Chakravarthy et al., 2005; Suto et al., 2000;
Abbott et al., 2001; Park et al., 2004). The majority of the non-canonical histone
variants are replacements for canonical H3 and H2A (Weber and Henikoff, 2014;
Talbert and Henikoff, 2010). These variants vary in sequence from only a four
amino acid (αα) difference between H3.1 and H3.3 to a 50% change in sequence
between H3.1 and H3 CENPA (a centromere specific H3 variant) (Sharma et al.,
2019).
Packaging the DNA into the nucleosome allows for efficient compaction and
storage of the DNA; however, one major consequence of the wrapping of DNA
around the histone octamer is the occlusion of the DNA (Luger et al., 1997a;
Luger et al., 1997b; Lutter, 1979). There are multiple mechanisms that regulate
access to DNA including the nucleosome and modifications to it. The nucleosome
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is dynamic, with very few interactions between the DNA and the histones needing
to be broken in order for the nucleosome to partially unwrap (Li et al., 2005b;
Polach and Widom, 1995; Li and Widom, 2004). The DNA sequence incorporated
into the nucleosome can alter its stability (Hartley and Madhani, 2009; Lowary
and Widom, 1998; Gottesfeld and Luger, 2001).
As a consequence of the DNA having to be held in an energetically unfavourable
state the sequence of the DNA affects the positioning, and likelihood of
nucleosome formation (Meersseman et al., 1992; Widom, 2006; Gottesfeld and
Luger, 2001; Becker, 2002; Lowary and Widom, 1998; Widom, 2001; Yang
and Ullah, 2007; Flaus, 2011). This is demonstrated by CpG-rich, GC-rich
unmethylated DNA sequences, usually covering promoters, that destabilises
nucleosomes (Flaus, 2011). The position of the nucleosome is not fixed and the
histone octamer is able to slide along the DNA strand, exposing different DNA
sequences as it moves position, which can be facilitated by chromatin remodellers
in vivo (Meersseman et al., 1992; Hamiche et al., 1999; Park et al., 2004; Park et
al., 2005; Becker, 2002; Pennings et al., 1991; Tyagi et al., 2016). The placement
of the histone variants into the histone octamer can also alter the dynamicity of
the nucleosome, affecting the accessibility of the DNA (Fan et al., 2004; Zhang
et al., 2005). The histones’ N-terminal tails including their modifications also
modulate access to the DNA (Biswas et al., 2011; Lee et al., 1993; Polach et
al., 2000; Yang et al., 2005). The modifications present on the tails (Allan et al.,
1982; Fletcher and Hansen, 1995; Zheng and Hayes, 2003b; Pepenella et al., 2014)
and in the histone core (Fenley et al., 2018) and the presence of histone variants
can also prevent the formation of higher order chromatin structures (Luger et al.,
2012; Shogren-Knaak, 2006; Tremethick, 2007; Kebede et al., 2015; Abbott et al.,
2001) or affect the stability of the nucleosome itself (Fan et al., 2004; Jin and
Felsenfeld, 2007).
1.2 Chromatin Readers, Writers and Modifiers -
The Histone Code Hypothesis
Multicellular organisms require cellular specialisation and therefore differential
gene expression that arises during development and cellular differentiation. As
every cell in the human body contains the same DNA, the distinct expression
patterns between, for example, a pancreatic cell and a cardiac muscle cell are
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controlled through epigenetics. Although the genetic information is contained
purely within the DNA, gene expression is controlled not only by regulatory
factors such as histones or DNA-binding transcription factors (TFs) but also by
a wide array of posttranslational modifications (PTMs) on the DNA and on the
histones the DNA is wrapped around. The DNA sequence can have chemical
groups added, affecting its transcription state without affecting the information
contained. The addition of methyl groups to DNA, by DNA methyltransferases
(DNMTs), especially to the CpG-rich promoters of genes effectively silences the
transcription of the modified DNA sequence (Curradi et al., 2002; Bird, 2002;
Jones, 2012; Klose and Bird, 2006). The addition of methyl groups to DNA occurs
predominately at CpG dinucleotides (in mammals) and the majority of CpGs are
methylated (Jang et al., 2017; Siegfried and Cedar, 1997). CpG-rich regions
that make up regulatory regions including promoters of genes are protected from
the addition of methylation. The methylated DNA can recruit methyl-binding
proteins that protect the inactive DNA state (Bird, 2002; Jones, 2012; Jang et al.,
2017). Histones are also subject to a vast array of modifications, including – but
not restricted to – acetylation, phosphorylation, sumoylation and varying degrees
of methylation (see Fig. 1.2 (Vaquero et al., 2003; Bannister and Kouzarides,
2011; Campos and Reinberg, 2009; Kouzarides, 2007). These marks are mainly
located on the N-terminal tails, which protrude outwards from the nucleosome
core. Protein recruitment, DNA accessibility and the histone tail’s movement are
affected by the placement of PTMS.
The placement of these modifications can affect nucleosome dynamics and the
formation of higher order chromatin structures (see Section 1.1.1). Acetylation
of H4 lysine 16 (H4K16ac) not only inhibits the formation of more compact
structures (30-nanometer fibres) but also prevents interactions between fibers
(Shogren-Knaak, 2006). The acetylation of the lysine residue neutralises the
positive charge of the lysine, reducing the charge-dependent interactions with the
negatively charged DNA phosphate backbone, thereby increasing the accessibility
of the DNA to surrounding proteins (Zentner and Henikoff, 2013). Many
acetylated lysines recruit proteins that then translate their modification into a
biological function. Modifications not only to the histone tail but also the histone
core can have significant effects: phosphorylation of residues on or close to the
histone core near to the nucleosome DNA entry/exit point, such as H3Y41ph,
have been shown to increase the accessibility of the DNA (Brehove et al., 2015;
Lawrence et al., 2016). This phosphorylation can be combined with acetylation




Figure 1.2 Histone Post–Translational Modifications and the Proteins That Bind
Them. Schematic of protein reader domains binding the PTMs on the residues of the histone
H3 N-terminal tail. Figure taken from Musselman et al., 2012. Recognition of methylated
(me) lysines, methylated (me) arginines, acetylated (ac) lysines, phosphorylated (ph) serines
and theorines. BD - bromodomain, CD - chromodomain, DPF - double PHD finger, DBD -
double bromodomain, MBT - Malignant brain tumour, TTD - tandem tudor domain, PHD -
plant homeodomain, BAH - bromo-adjacent homology.
accessibility (Brehove et al., 2015).
It has been posited that the combination of the PTMs on the histones’ N-terminal
tails, in addition to the histone variants included in the nucleosome, recruit
proteins that bind these modifications and interpret them – providing a “histone
code” for proteins to read (Jenuwein and Allis, 2001). These modifications can
lead to the recruitment of proteins, resulting in alteration of chromatin structures,
inheritable transcriptional states, or higher order structures (see Fig. 1.3). The
PTMs are placed by chromatin “writers”, removed by chromatin “erasers” and
functions are regulated by chromatin “readers”.
Chromatin “readers” are proteins that contain protein domains that recognise a
particular PTM on a histone or a combination of marks and histone variants,
and direct a specific biological outcome. They can be further characterised
by the marks they bind. Both chromatin “writers” and “erasers” are enzymes
that are classified based on the specific modification they place or remove,
respectively. Histone methyltransferases (HMTs) place methyl groups while
histone acetyltransferases (HATs) catalyse the formation of acetylation. These
modifications can be placed on multiple residues on different histones, the
specificity of placement is determined by the catalytic site of the chromatin




Figure 1.3 Combinatorial Histone Modifications - Schematics of proteins binding one
or more histone PTMs. Figure from Su and Denu, 2016. Histone tail in green, protein reader
domain in orange and the catalytic domain in red. A) Schematic of the progressive nature
of histone modifications. B) Binding of a chromatin modifier and placement of a subsequent
mark in cis or trans C) Potential interplay between proteins of a multi-subunit complex. The
recruitment of the complex by one subunit via a specific PTM, in order to modify a residue on
a neighbouring nucleosome via a different catalytic subunit.
enzymes being further divided by the residues they can modify. Both SETD1A,
MLL2 and Polycomb Repressive Complex 2 (PRC2) are all HMTs but SETD1A
and MLL2 place H3K4me3 whereas PRC2 places H3K27me3. Although the
modification may be the same, the position of the residue modified and the
chromatin “reader” it recruits determines its function. Chromatin “erasers” are
divided similarly with enzymes that remove methylation or acetylation referred
to as histone demethylases (HDMTs) and deacetylases (HDACs), respectively.
Numerous enzymes catalyse the placement of each type of possible histone modi-
fication (chromatin “writers”). These enzymes can be clustered into larger groups
which are clearly evolutionarily related, have conserved mechanisms of function,
and structure - protein families. Acetylation is placed by enzymes belonging
to three protein families GNAT, MYST, and CBP/p300 while methylation is
placed by histone methyltransferases (HMTs) that can be divided by those that
modify lysines (HKMTs) and those that modify arginines (HRMTs) (Sterner and
Berger, 2000; Blanc and Richard, 2017; Hyun et al., 2017). All HKMTs with the
exception of DOT1 contain a SET (suppressor of variegation, enhancer of zeste,
and trithorax) domain and belong to the large SET family of methyltransferases
(see Fig. 1.4)(Schubert et al., 2003; Cheng et al., 2005). All chromatin “writers”
catalyse the exchange of chemical groups from a co-substrate, for example HKMTs
utilise SAM (S-Adenosyl Methionine) as a co-substrate, to catalyse the transfer
8
A) B)
Figure 1.4 Subunits of Trx and PRC Complexes Subunits of MLL, SET1 and PRC
complexes detailed. A) Figure detailing the subunits of the MLL and SET1 complexes. ASH2L,
DPY30, WDR5 and RBBP5 are shared between the different MLL and SET1 complexes. The
catalytic subunit determines the specific complex. SET1 also contains the subunits WDR82,
CFP1 and HCF1. B) Figure detailing PRC complex subunits. There are multiple variants of
the PRC1 and 2 complexes. The core subunits for PRC2 are showed and the accessory subunits
labelled. Canonical or non-canonical PRC1 complex subunits are shown.
of a methyl group from SAM to the histone substrate resulting in a methylated
histone substrate.
Each PTM placed by chromatin “writers” can be bound by a specific protein
“reader” domain contained in a chromatin “reader”. This allows the recruitment
of specific readers to particular histone marks and chromatin locations. Each
histone modification can be bound by one or more specific protein domains
designated reader domains: methylated lysines can be bound by plant home-
odomains (PHDs) (Ali et al., 2014; Champagne and Kutateladze, 2009; Sanchez
and Zhou, 2011) or chromodomains depending on the residue modified (Flanagan
et al., 2005; Yap and Zhou, 2011; Fischle et al., 2003; Pearce et al., 1992), while
acetylated residues are bound by bromodomains (see Fig. 1.2) (Fujisawa and
Filippakopoulos, 2017; Tamkun et al., 1992; Meslamani et al., 2016). H3K4me3
modification is bound by the PHD domains of multiple proteins including both
TBP associated factor 3 (TAF3) (Ingen et al., 2008; Vermeulen et al., 2007) and
inhibitor of growth 2 (ING2) (Peña et al., 2006), while H3K27me3 is bound by the
chromodomain contained in the chromobox (CBX) proteins (Pearce et al., 1992;
Morey et al., 2012; Min et al., 2003). Acetylated H3 and H4 act to recruit BRD4
through its bromodomain (Dey et al., 2003). Even the lack of a modification on a
residue can recruit specific reader domains for example the PHD finger in BRPF1
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is recruited to H3K4me0 (Qin et al., 2011).
The divisions between “writers”, “readers” and “erasers” can become unclear.
Chromatin modifiers (writers) need to be selectively recruited so that they modify
only specific sites. Often the enzymes that modify the histone residues are
recruited to the nucleosome by a combination of domains including DNA binding
domains and histone modification reader domains; therefore, chromatin “writers”
usually interact with or are also chromatin “readers”. While the “readers”
may contain a chromatin modifying function of their own, either catalysing a
placement of a mark or erasing one (Farcas et al., 2012; Tachibana et al., 2001;
Collins et al., 2008; Margueron et al., 2009). The SAGA complex contains both
chromatin “readers”, “writers” and “erasers” and therefore can be recruited to
multiple histone PTMs and perform multiple functions. SAGA can be recruited
by H4K16ac, as it contains multiple bromodomains, and then acetylates histone
H3. SAGA also contains a deubiquitylation (DeUb) module which is able
to remove ubiquitin from H2B, therefore the SAGA complex functions as a
chromatin “reader”, “writer” and “eraser” (Morgan et al., 2016; Koutelou et al.,
2010; Owen, 2000)
Certain marks are primarily associated with specific chromatin states because
they have been detected at these locations including active or repressed pro-
moters, enhancers, or exons by Chromatin Immunoprecipitation-Sequencing
(ChIPseq). Further investigation showed that these marks are recognised by
particular reader domains, and analysis of the function of these chromatin
“readers” enabled explanation of how their presence at those chromatin states
might bring about functional consequences of those states.
Chromatin can be split into two major categories based on how condensed or
“open” the chromatin is. Euchromatin is defined as “open” or transcriptionally
active chromatin that usually contains highly transcribed genes and is associated
with H3K4me1/2/3, H3K36me3, H3K14ac, H3K9ac, H3K27ac, and H3K79me3
(Bannister and Kouzarides, 2011; Kouzarides, 2007). Heterochromatin is
generally defined as more compact chromatin and generally repressive; however,
there are two accepted classes: facultative and constitutive heterochromatin.
Facultative heterochromatin consists of genes that are differentially expressed
during development and is usually enriched for H3K27me3 and Polycomb
Repressive Complexes 1 and 2 (PRC1/2) (Trojer and Reinberg, 2007; Wutz,
2011). Constitutive heterochromatin contains permanently silenced genes and
also includes pericentromeres and telomeres (Bannister and Kouzarides, 2011;
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Kouzarides, 2007; Saksouk et al., 2015). Although the correlation of histone
marks with transcription has been thoroughly researched, the functions of the
majority of histone marks are not completely understood and the placement of
PTMs does not always correlate with their known role.
The recruitment of a chromatin “reader” to a PTM or histone variant can lead
to direct alterations to chromatin and potential alteration of the chromatin
state. The modification of one histone residue could lead to a cascade in protein
recruitment and subsequent alteration of the chromatin environment, altering
the transcriptional state of the associated DNA. Unmethylated CpG-rich DNA
sequences (CpG islands) can lead to the recruitment of H3K4 methyltransferases
such as SET1 complexes via the Cfp1 – CXXC-type zinc finger protein 1 – subunit
binding the DNA with its CXXC domain (Clouaire et al., 2012; Brown et al.,
2017). The placement of H3K4me3 can recruit multiple proteins including ING2
(Peña et al., 2006; Shi et al., 2006) and TAF3 (Vermeulen et al., 2007; Ingen
et al., 2008). H3K4me3 is bound by a variety of factors mostly involved in
activating transcription including: the TAF3 subunit of the general transcription
factor TFIID, and JMJD2A (KDM4A) (Pedersen et al., 2014; Ingen et al., 2008;
Lauberth et al., 2013). The binding of TAF3 recruits the TFIID complex, helping
form the RNAPII transcription pre-initiation complex (PIC) (Nuland et al., 2013;
Lauberth et al., 2013; Vermeulen et al., 2007). The binding of an ING family
protein via its PHD domain such as ING2, ING5 or ING3, can lead to a variety of
effects on the local chromatin due to their incorporation into multiple complexes.
ING5’s or ING2’s recruitment by H3K4me3 can recruit histone acetyltransferases
(HAT), such as the MORF, NuA4 and HBO1 complex, or histone deacetylases
(HDACs) such as SIN3A (Peña et al., 2006; Shi et al., 2006; Champagne et al.,
2008; Ullah et al., 2008; Doyon et al., 2006).
Multiple residues can be modified simultaneously with different chemical groups,
thereby adding complexity to the histone code. In the simplest case of histone
combinatorial marks with only two PTMs, these could be present on the same
histone tail, in the same nucleosome, or on neighbouring nucleosomes. With the
number of histone residues available to be modified and the variety of possible
different modifications the amount of combinatorial possibilities is large. The
placement of one histone modification can affect the subsequent modifications
placed on the nucleosome. In the simplest terms, the chemical modification
of a histone residue will affect the chemical environment around it, potentially
affecting the placement of other marks. The recruitment of a protein to a histone
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PTM could decrease the likelihood of other modifications simply due to steric
hindrance as a result of the protein being bound.
There is evidence that this cross talk between marks and their placement is more
widespread and developed than purely alteration of the environment immediately
surrounding the modification. The active site of multiple different chromatin
modifiers binds to more than just the target residue, causing modifications
to nearby residues to prevent the modifier binding or conversely increase the
enzyme’s catalytic activity, this effect can be mediated by the interaction of
other subunits with the catalytic subunit (Voigt et al., 2012; Schmitges et al.,
2011; Liokatis et al., 2012). PRC2 is inhibited from placing H3K27me3 on the
same H3 N-terminal tail that carries H3K4me3 (Schmitges et al., 2011; Voigt
et al., 2012), but its catalytic activity is increased when bound to H3K27me3
(Margueron et al., 2009). G9A/GLP is unable to place H3K9me3 if residues
H3S10 or H3T11 are phosphorylated (ph) or H3R8 methylated (Rathert et al.,
2008; Chin et al., 2005; Collins et al., 2008). This cross talk may extend to
modifications present on different histone tails in the same nucleosome or even
on neighbouring nucleosomes. Cross talk between residues that are not situated
on the same histone tail may require the presence of proteins to form a bridge
between these modifications to mediate the cross talk. PRC2 can bind to H3 tails
from neighbouring nucleosomes, H3K27me3 binds PRC2 via one subunit and the
catalytic subunit places H3K27me3 on the unmodified tail of a neighbouring
nucleosome (Poepsel et al., 2018).
Chromatin modifiers can contain multiple and different reader domains for
example chromatin modifiers: UHRF1 and BPTF contain a combination of
tandem tudor domains, PHD domains and bromodomains. Not only can they
be recruited by multiple histone PTMs, ranging from H3K4me3, to H3K9me2/3,
to H3K4me0 to H4ac (Ruthenburg et al., 2011; Rothbart et al., 2013; Taverna
et al., 2007) but they may also require a combination of these marks to be
present in order to bind. The combination of histone marks can recruit different
proteins, potentially amplifying the effect desired or allowing one histone PTM
to contribute to multiple functions. As these marks can recruit multiple proteins,
it may be the combination of multiple histone marks that help select a specific
protein. Not all of these protein domains need to be bound in order for the whole
protein or protein complex to be recruited, however, it could be argued that
the more protein domains bound the stronger the recruitment of the complex to
chromatin.
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1.2.1 Polycomb and Trithorax Group Proteins
Polycomb group (PcG) and Trithorax group (Trx) proteins are mainly known
for their mutually antagonistic roles in regulating gene expression. These two
groups of proteins were initially discovered in Drosophila melanogaster but have
similar composition in mammals, although with more diverse and a greater
number of subunits (Slifer, 1942; Lewis, 1978; Kassis et al., 2017; Schuettengruber
et al., 2017; Grossniklaus and Paro, 2014; Bajusz et al., 2018; Poynter and
Kadoch, 2016; Geisler and Paro, 2015). They form a variety of complexes that
act to either repress or activate transcription (Aloia et al., 2013; Geisler and
Paro, 2015; Schuettengruber et al., 2017). PcG genes were first discovered in
Drosophila melanogaster as regulators of Hox gene expression (Lewis, 1978). PcG
proteins form a wide variety of complexes that are subdivided into 2 main classes:
Polycomb Group Complex 1 (PRC1) (see Fig. 1.5 and Figure 1.4) and Polycomb
Group Complex 2 (PRC2) (see Fig. 1.6 and Figure 1.4).
1.2.2 The Composition of Polycomb Repressive Complex 2
(PRC2) and its Accessory Factors
PRC2 mediates its function by the di- and trimethylation of histone H3 lysine
27 (H3K27me2/3), a hallmark of repressive chromatin (Margueron and Reinberg,
2011; Ferrari et al., 2014; Pasini et al., 2007; Pasini et al., 2010a). H3K27me3
may mediate chromatin repression by recruitment of PRC1 and compaction of
chromatin or by prevention of the placement of active marks (Kundu et al.,
2017; Francis et al., 2004; Grau et al., 2011; Lau et al., 2017). PRC2’s major
components are EZH2, SUZ12, EED, and RbAp46/48 (Højfeldt et al., 2019).
Deletion of any of the core subunits is embryonically lethal, and results in ESCs
with differentiation defects (Pasini et al., 2007; Pasini et al., 2004; Shen et al.,
2008; Chamberlain et al., 2008; Faust et al., 1995; O’Carroll et al., 2001; Collinson
et al., 2016). EZH2, EED, and SUZ12 are required for the stability and activity
of PRC2 (Fig. 1.6) (Pasini et al., 2007; Pasini et al., 2004; Cao and Zhang, 2004a;
Obier et al., 2015; Montgomery et al., 2005; Margueron et al., 2009; Wang et al.,
2002; Faust et al., 1995; O’Carroll et al., 2001; Ketel et al., 2005).
EZH2 and its homologue EZH1 contain the catalytic methyltransferase SET
domain and are mutually exclusive in the PRC2 complex (Wu et al., 2013;
Antonysamy et al., 2013; Lewis, 1978; Cao and Zhang, 2004b; Margueron et al.,
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Figure 1.5 Schematic of the Possible PRC1 Complex Variants. PRC1 complexes
consist of the RING1A/B subunits with varying types of PCGF proteins. The additional
subunits including CBX and PHC variants, or RYBP/YAF2 determine whether the complex is
considered canonical or non-canonical. A) Canonical PRC1 variants shown. Subunits involved
in chromatin compaction and oligermisation of PRC1 show in red and green respectively. B)
Non-canonical PRC1 variants shown. All subunits labelled. The function of each subunit is
detailed. Although canonical PRC1 complex has slight ubiquitylation activity, non-canonical
PRC1 places the majority of H2AK119ub. Figure taken from Illingworth, 2019.
Figure 1.6 Schematic Drawing of the Core PRC2 complex and Potential sites of
Accessory Subunit Binding. The core PRC2 complex shown in orange (RbAp46/48 referred
to as RBBP4/7 respectively), yellow (SUZ12), blue (EZH1/2) and green (EED). The subsidiary
subunits and their interaction sites with the core complex are indicated. JARID2 (turquoise),
and EPOP/PALI (dark green) both interact with SUZ12 at similar locations explaining their
exclusivity. AEBP2 (red) and PCL1/2/3 (purple) proteins also interact with the SUZ12 subunit,
albeit at a different location. Both AEBP2 and PCL1/2/3 complexes interact at a similar site
of the SUZ12 protein explaining their incorporation into different variant PRC2 complexes.
Figure from Laugesen et al., 2019.
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2008; Shen et al., 2008). EZH2 is the predominant H3K27me3 methyltransferase
in ESCs, and is specific to proliferating cells while EZH1 is the dominant subunit
in terminally differentiated cells (Margueron et al., 2008). These mutually
exclusive subunits have overlapping functions and partially compensate for the
removal of the other. The global levels of H3K27me3 decrease in EZH2(-/-) cells,
however, some genes retain H3K27me3, suggesting compensatory mechanisms
potentially relying on EZH1 or unknown maintenance factors (Shen et al., 2008),
although there are some distinct nonredundant features of EZH1 and EZH2
(Hidalgo et al., 2012; Mochizuki-Kashio et al., 2012; Shen et al., 2008; Margueron
et al., 2008). Deletion of EZH2 is embryonically lethal (O’Carroll et al., 2001),
and EZH2(-/-) ESCs demonstrate differentiation defects, albeit viable (Shen et al.,
2008; Collinson et al., 2016). Some of the genes that lose H3K27me3 in EZH2(-/-)
cells continue to be repressed, potentially due to the absence of their activating
transcription factors in ESCs (Margueron et al., 2008; Shen et al., 2008).
SUZ12 is a core component of PRC2 and is essential for stability and activity of
the PRC2 complex (Pasini et al., 2007). SUZ12 contains a zinc finger domain
and together with RbAp46/48 forms a binding site for the unmodified N-terminal
tail of histone H3 (Schmitges et al., 2011). SUZ12 has multiple functions; it is
involved in RNA binding, and integral for the formation and activation of PRC2
(Schmitges et al., 2011; Beltran et al., 2016; Jiao and Liu, 2015; Davidovich
et al., 2013; Antonysamy et al., 2013). PRC2 is unable to place H3K27me3 on
tails previously modified with H3K4me3. This inhibition of catalytic activity is
mediated by both SUZ12 and Rbbp4 (RbAp46/48) (Schmitges et al., 2011). The
presence of the active histone mark H3K4me3 also inhibits PRC2 binding to the
H3 N-terminal tail further impairing PRC2’s placement of H3K27me3 (Schmitges
et al., 2011; Voigt et al., 2012).
EED interacts with both SUZ12 and EZH2, helping modulate the catalytic
activity of PRC2. EED binds H3K27me3, helping recruit PRC2, and stimulating
PRC2’s catalytic activity, thus setting up a positive feed forward loop (Margueron
et al., 2009). This helps spread the H3K27me3 mark, explaining the large
domains of H3K27me3 seen and may also help the maintenance of the H3K27me3
mark either by binding it and preventing access to H3K27 demethylases or
by replacement of the mark as it is diluted during DNA replication and
cell division. RbAp46/48, although not always considered a core subunit, is
important for PRC2 nucleosomal recognition and enzymatic inhibition upon
binding of H3K4me3 (Nowak et al., 2011; Vizán et al., 2015; Nekrasov et al.,
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2005; Murzina et al., 2008; Schmitges et al., 2011). As confirmed by recent
structures of catalytically active subcomplexes of PRC2, EZH2’s SET domain
is in an autoinhibited conformation and requires interactions with both SUZ12
and EED to stabilise the active conformation of the SET domain necessary
for methyltransferase activity (Jiao and Liu, 2016; Jiao and Liu, 2015; Cao
and Zhang, 2004a; Chen et al., 2018; Wu et al., 2013; Justin et al., 2016).
Recent protein structures have shown how H3K27me3 binding by EED affects
PRC2’s activity or binding (Margueron et al., 2009; Poepsel et al., 2018). These
interactions allow conformational changes from one subunit to be communicated
to the whole enzyme complex resulting in alterations to PRC2 binding or to its
catalytic activity.
PRC2 has multiple subsidiary components that are not necessary for the core
function of the complex, for example AEBP2 or PHF1, but that help to specify
its function and recruitment. These accessory subunits may only be required
for a subset of PRC2 activity and some are mutually exclusive in their binding
to the PRC2 core complex. The core components of PRC2 can interact with
accessory factors such as JARID2, AEBP2, EPOP, PALI and the polycomb-
like (PCL) subunits (PHF1, PHF19 and MTF) (see Fig. 1.6). There are two
main types of PRC2 complexes, PRC2.1 is defined by its binding to one of the
PLC accessory subunits and EPOP or PALI while PRC2.2 is demarcated by its
binding to AEBP2 and JARID2 (Kasinath et al., 2018; Gao et al., 2012; Wong
et al., 2016; Laugesen et al., 2019; Grijzenhout et al., 2016; Pasini et al., 2010a;
Chen et al., 2018; Beringer et al., 2016; Liefke et al., 2016; Højfeldt et al., 2019;
Alekseyenko et al., 2014; Conway et al., 2018; Kim et al., 2009). These subunits
have roles in recruitment of PRC2 to specific genomic locations or in alteration
of the complex’s activity.
JARID2 and AEBP2 have been implicated in PRC2’s recruitment to genomic
loci (Peng et al., 2010; Kim et al., 2009; Vizán et al., 2015). In PRC2.2 JARID2
helps recruit PRC2 to locations containing H2AK119ub which is placed by PRC1.
JARID2 recruitment of PRC2 to chromatin is dependent on the presence of
H2AK119ub (Cooper et al., 2016; Kalb et al., 2014). PRC2 can methylate K116
of JARID2, which is bound in turn by the core PRC2 subunit EED, mimicking
a H3K27me3 methylated tail, and resulting in an increase in catalytic activity
(Sanulli et al., 2015; Kasinath et al., 2018). PRC2 may initially methylate
JARID2 before the methylated product binds and stimulates PRC2’s activity.
Knockout of JARID2 results in differentiation defects and a slight decrease in
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H3K27me3 placement (Landeira et al., 2010; Li et al., 2010; Pasini et al., 2010a;
Peng et al., 2010; Shen et al., 2009). The slight decrease of H3K27me3 upon
JARID2 KO may be due to the presence of redundant recruitment mechanisms.
JARID2 interacts with SUZ12 as well as with EED when methylated, while
AEBP2 binds to RbAp48 mimicking an unmodified H3 N-terminal tail (Kasinath
et al., 2018; Justin et al., 2016; Vann and Kutateladze, 2018; Cooper et al.,
2016). JARID2’s interactions with EED stabilise a region of SUZ12 named the
stimulatory response motif (SRM), which is normally disordered and interacts
with the active site located in EZH2, stabilising the active conformation (Kasinath
et al., 2018; Justin et al., 2016). The C-terminus of AEBP2 binds to RbAp48,
positioning its flexible N-terminal domain next to the SET domain, potentially
explaining the stimulation of activity seen when AEBP2 is part of the PRC2
complex (Cao and Zhang, 2004a).
The sites of interaction between PRC2 and the accessory subunits overlap, causing
the incorporation of these subunits to be mutually exclusive. JARID2, EPOP
and Pali all bind to the same area of SUZ12 while the PCL subunits binding site
overlaps with AEBP2 (Chen et al., 2018; Laugesen et al., 2019; Mierlo et al.,
2019). The PRC2.1 complex variant includes one of the three PCL subunits and
either EPOP or PALI (Alekseyenko et al., 2014; Beringer et al., 2016; Grijzenhout
et al., 2016; Liefke et al., 2016). The PCL subunits are PHF1, PHF19 and
MTF named PCL1, 2, and 3, respectively (Boulay et al., 2011; Perino et al.,
2018; Qin et al., 2013). The expression profiles of the PCL proteins dynamically
alter throughout development. The PCL proteins contain a winged helix motif
which specifically binds to unmethylated CpG motifs, helping recruit PRC2.1 to
chromatin (Li and Reinberg, 2011). Knockout of any of the PCL proteins results
in a global decrease of H3K27me3, due to the failure of PRC2.1 to be recruited
to chromatin (Li and Reinberg, 2011).
PHF1 and PHF19 bind to H3K36me3 via their tudor domains with redundant
functions (Cai et al., 2013; Brien et al., 2012; Musselman et al., 2012). PHF19
recruits both PRC2 and NO66 to H3K36me3 modified nucleosomes, resulting
in demethylation of H3K36 and placement of H3K27me3 (Ballaré et al., 2012;
Brien et al., 2012). PHF1 modulates PRC2’s catalytic activity, increasing
the overall catalytic activity but also mediating its inhibition when bound to
H3K36me3 (Musselman et al., 2012; Li and Reinberg, 2011; Cai et al., 2013;
Sarma et al., 2008; Qin et al., 2013). PRC2 containing PHF1 mutants unable
to bind H3K36me3 exhibit greater methyltransferase activity (Musselman et al.,
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2012) than PRC2 complexes containing wild-type PHF1. MTF regulates PRC2
activity in X-chromosome inactivation, pluripotency and recruitment of PRC2
to unmethylated CpG islands (CGIs) via its DNA binding activity (Casanova
et al., 2011; Walker et al., 2010; Perino et al., 2018). The PCL subunits may act
to recruit PRC2 to H3K36me3 containing sites and mediate their demethylation
and the de novo placement of H3K27me3.
The PCL proteins are usually found in a PRC2 complex with either EPOP
or PALI. EPOP helps mediate the interaction between PRC2 and Elongin
BC complex (Beringer et al., 2016). The PRC2 complex containing EPOP is
abundant in ESCs but is downregulated during differentiation (Beringer et al.,
2016; Liefke et al., 2016). The Elongin BC complex helps promote the elongation
of transcriptional engaged RNAPII (Bradsher et al., 1993; Liefke et al., 2016).
The interaction between Elongin BC and PRC2, mediated by EPOP, may help
to sustain transcriptionally capable RNAPII at specific PRC2 target genes and
prevent the binding of JARID2 containing PRC2, as deletion of either protein
increases the presence of the other at target locations (Beringer et al., 2016).
PALI, which is mutually exclusive with both JARID2 and EPOP, stimulates
PRC2 activity in vitro and a knockout results in a slightly decreased level of
H3K27me3 (Alekseyenko et al., 2014; Hauri et al., 2016; Conway et al., 2018).
1.2.3 Polycomb Repressive Complex 1 Variants
The PRC1 group of complexes is highly heterogeneous due to the existence of
multiple homologs for each subunit as well as unique accessory factors. So-
called canonical PRC1 complexes contain one each of multiple chromodomain
proteins (CBX), ubiquitinating enzymes RING1A/B, three polyhomeotic ho-
mologs (PHCs) and one of six Polycomb group ring fingers (PCGF) (Fig.
1.5). Combinatorial association of different PCGF proteins leads to functionally
distinct PRC1 complexes (Gao et al., 2012; Vandamme et al., 2011; Gil and
O’Loghlen, 2014; Aranda et al., 2015; Fursova et al., 2019; Blackledge et al.,
2014; Scelfo et al., 2019). Both RING and YY1 binding protein (RYBP) and
YY1 associated factor 2 (YAF2) are only found in complexes without both CBXs
and PHCs, and therefore help to define non-canonical PRC1 complexes.
Each distinct complex occupies distinct genomic loci and thus may have
individual functions within the cell. PRC1 complexes have been shown to catalyse
the monoubiquitination of histone H2A at Lysine 119 (H2AK119ub) and to
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be involved in compaction of chromatin (Vidal, 2009; Napoles et al., 2004).
PRC1 and PRC2 are linked together in repression of genes as CBX-containing
PRC1 complexes recognise H3K27me3 deposited by PRC2, while H2AK119ub
has recently been shown to help recruit PRC2 through interaction with JARID2
and AEBP2 resulting in a feedforward mechanism (Simon and Kingston, 2009;
Blackledge et al., 2015; Kalb et al., 2014; Cao et al., 2002; Min et al., 2003;
Mujtaba et al., 2008; Wang et al., 2004b). Although both canonical and non-
canonical PRC1 complexes have been shown to ubiquitinate H2AK119 in vitro,
non-canonical complexes (Fig. 1.5) have a markedly higher level of catalytic
activity (Gao et al., 2012; Scelfo et al., 2019; Blackledge et al., 2014; Wang et
al., 2004a; Tavares et al., 2012; Rose et al., 2016; Fursova et al., 2019). Global
levels of H2AK119ub were unaffected by in vivo depletion of EED, suggesting
that non-canonical PRC1 recruited independently of H3K27me3 is responsible
for the majority of H2AK119ub genome-wide (Tavares et al., 2012).
1.2.4 PcG Complexes and Repression
PRC1 and PRC2 act to reinforce and maintain repression. They largely share
target genomic loci, but also have unique genomic targets and thus likely partially
distinct roles in genomic regulation (Ku et al., 2008; Blackledge et al., 2015).
PRC1 is also able to be recruited to chromatin in the absence of H3K27me3.
KDM2B has been implicated in having a major role in recruitment of PRC1 to
unmethylated CGIs (Farcas et al., 2012; Wong et al., 2016). Accessory subunits
can also help PRC1’s recruitment to chromatin for example PCGF4 interacts
with H3 and H4 histone folds. PRC1 can interact with the H2A/H2B acidic
patch of nucleosome via an arginine anchor mechanism, mediated by arginines
and lysines from RING1B inserting into the acidic patch (Leung et al., 2014).
The recruitment of PRC2 to chromatin is a complicated mechanism that is still
not fully understood. The dynamic composition of PRC2 complexes complicates
understanding the recruitment of PRC2. PRC2 is recruited to specific DNA
sequences in Drosophila called PREs; however, no such sequences have been found
in mammals (Du et al., 2017; Kassis and Brown, 2013; Bauer et al., 2016; Chan et
al., 1994). Artificial sequences with high CpG content and no conserved sequence
motifs recruit PRC2 in vivo partially explained by PRC2’s accessory subunits
such as PCLs affinity for CpGs (Li and Reinberg, 2011; Perino et al., 2018;
Lynch et al., 2012; Mendenhall et al., 2010; Wachter et al., 2014). PRC2 is
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recruited to chromatin by multiple interactions of its subunits with chromatin:
from JARID2 with H2AK119ub and EED with H3K27me3 to PCL based DNA
binding. Together with PRC1’s recruitment by H3K27me3, this helps to explain
the co-occupancy of PRC2 and PRC1 at specific genomic locations (Cooper et al.,
2016; Cooper et al., 2014; Blackledge et al., 2014; Kalb et al., 2014; Laugesen
et al., 2019).
PRC2’s potential recruitment to chromatin by RNA is still debated. RNA has
been implicated in the recruitment of PRC2 to areas needing repression including
X-chromosome inactivation (Kohlmaier et al., 2004; Rinn et al., 2007). However,
RNA has been shown to be dispensable for PRC2 recruitment and repression
(Rocha et al., 2014; Portoso et al., 2017). Multiple studies have demonstrated
that PRC2 binds non-specifically to RNA by interaction sites on EZH2, JARID2
and SUZ12 (Cifuentes-Rojas et al., 2014). This has been posited to recruit and
tether PRC2 to areas of active transcription to repress them (Kanhere et al.,
2010; Davidovich et al., 2013; Kaneko et al., 2013; Kaneko et al., 2014; Zhao
et al., 2010). Others have suggested that the binding of RNA and DNA to PRC2
is mutually exclusive and inhibits PRC2’s catalytic activity (Kaneko et al., 2014;
Cifuentes-Rojas et al., 2014; Beltran et al., 2016; Wang et al., 2017). Previous
studies have shown PRC2 bound to nascent RNA at essentially all active genes
suggesting that RNA prevents PRC2 recruitment to chromatin at active genes
(Beltran et al., 2016). The dissimilar findings of PRC2’s interaction with RNA
suggests that different RNAs may have different functions, with some leading to
the recruitment of PRC2 and subsequent repression while PRC2’s non-specific
binding to RNA prevents PRC2’s recruitment to active genes.
PRC2 is affected by nucleosome density and it prefers to methylate nucleosomal
arrays compared to mononucleosomes (Wang et al., 2017; Yuan et al., 2012).
PRC2 genomic targets are usually unmethylated at the DNA level but in areas
with low CpG density DNA methylation and PRC2 can co-exist (Brinkman et
al., 2012; Murphy et al., 2013; Li et al., 2018). PRC2 and DNA methylation
help to co-regulate each other with EED knockout resulting in elevated DNA
methylation and DNA methylation preventing the spread of H3K27me3 (Li et
al., 2018; Brinkman et al., 2012; Reddington et al., 2013; King et al., 2016;
Neri et al., 2013; Rose and Klose, 2014; Hagarman et al., 2013). PRC2 binds
poorly to methylated nucleosomes partially due to AEBP2 and EZH2’s affinity
for unmethylated CpG sequences (Bartke et al., 2010; Boyer et al., 2006; Lynch
et al., 2012). PRC2 has been shown to be recruited by H2AK119ub, placed by
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PRC1, which can bind to and be recruited by unmethylated CpG-rich DNA (Wu
et al., 2013; Farcas et al., 2012).
There are two main methods by which Polycomb complexes repress chromatin;
compaction, and placement of histone modifications H2AK119ub and H3K27me3,
which inhibit transcription (Eskeland et al., 2010; Zhou et al., 2008; Wang
et al., 2004a; Dellino et al., 2004; Francis et al., 2004; Grau et al., 2011;
Lau et al., 2017; Collinson et al., 2016; Cao and Zhang, 2004a; Pasini et al.,
2007). H2AK119ub represses the placement of H3K4me2/3 and inhibits the
placement of H3K36me3 (Yuan et al., 2013; Nakagawa et al., 2008). The
ability of H2AK119ub to repress chromatin by the inhibition of transcription
is separate to PRC1’s ability to compact chromatin (Kundu et al., 2017). The
placement of H3K27me3 reduces H3K4me3 deposition by methyltransferases and
limits the recruitment and activity of RNAPII (Dellino et al., 2004; Brien et
al., 2012; Kim et al., 2013). Removal of H2AK119ub and H3K27me3 results in
an increase in gene transcription, although the mechanism of this is debated
(Stock et al., 2007; Endoh et al., 2012). Both H2AK119ub and H3K27me3
may help to establish a repressive chromatin state by prevention of H3K4me3
establishment and therefore a reduction in transcription initiation or by ensuring
direct recruitment of Polycomb complexes (Schuettengruber and Cavalli, 2009;
Zhou et al., 2008; Wang et al., 2004a; Napoles et al., 2004; Agger et al., 2007;
Burgold et al., 2008; Nakagawa et al., 2008; Farcas et al., 2012; Wang et al., 2017;
Margueron et al., 2009; Schwartz and Pirrotta, 2014; Morey et al., 2012; Wang
et al., 2004b). PRC2 can also recruit H3K36me3 demethylases helping to repress
the gene (Abed and Jones, 2012; Brien et al., 2012).
PRC1 can compact chromatin potentially restricting access of transcription
factors to the compacted region (Eskeland et al., 2010; Francis et al., 2004;
Illingworth, 2019; Grau et al., 2011; Lau et al., 2017; Simon and Kingston,
2013; Kundu et al., 2017). This mechanism involves the compaction region of
CBX2 and a dimerization domain of PHC2 (Isono et al., 2013; Lau et al., 2017;
Wani et al., 2016; Kundu et al., 2017). However, although PRC1 compacts
chromatin and removal of this function leads to derepression of target genes,
whether compaction represses genes via restriction of access is debated (Hodges
et al., 2018; King et al., 2018; Isono et al., 2013; Lau et al., 2017; Wani et al., 2016;
Kundu et al., 2017). Although Polycomb complexes have been mostly associated
with transcriptional repression, there is some suggestion of its involvement in
transcription activation (Creppe et al., 2014; Kondo et al., 2014), potentially via
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helping maintain contacts between the promoter and enhancer of target genes
(Kondo et al., 2014; Gentile et al., 2019; Cruz-Molina et al., 2017).
1.2.5 H3K4 methyltransferases of the SET1 and MLL
families
Members of the Trx protein family form multiple important complexes in
mammalian cells that are named after their catalytic subunits, including
MLL1/2/3/4 and SET1A/B (Fig. 1.4). SET1A/B and MLL1/2 complexes place
methylation at histone H3 lysine 4 (H3K4me3), a hallmark of active chromatin
(Woo et al., 2017; Geisler and Paro, 2015; Poynter and Kadoch, 2016). SET1A/B
and MLL complexes share many subunits including ASH2, WDR5, ASH2L,
DPY30 and RBBP5, which form a stable core complex (the WRAD complex)
independent of the catalytic subunit, resulting in a complex that can associate
with any of MLL1/2 and SET1A/B (Dillon et al., 2005; Herz et al., 2013; Qian
and Zhou, 2006; Ernst and Vakoc, 2012). The C-terminus of the SET1 and MLL
proteins is conserved and contains the WDR5 interaction motif as well as the SET
domain responsible for their histone methyltransferase (HMT) activity (Patel et
al., 2009). Although the RBBP5 and ASH2L heterodimer is the minimum that
is required for activation of the MLL proteins, WDR5 is important for maximal
catalytic activity and proper targeting of the MLL complexes (Li et al., 2016).
Components of the WRAD complex also interact with other transcriptions factors
outside the Trx family such as OCT4 (Ang et al., 2011) and MYC (Ullius et
al., 2014; Bochyńska et al., 2018; Ernst and Vakoc, 2012). This large range of
interactions and roles of the WRAD subunits both with SET/MLL complexes
and TFs may explain why these subunits are essential for mouse embryogenesis
and development (Stoller et al., 2010; Yang et al., 2016; Yang and Ernst, 2017).
SETD1A/B are responsible for the global levels of H3K4me3 while MLL1/2 are
more specific in H3K4me3 placement. Both SETD1A/B contain the CFP1 (CxxC
zinc finger protein 1) subunit (Fig. 1.4) which helps the recruitment of all SET1
complexes to unmethylated CpG islands and links them to H3K4me3 via its
recruitment to H3K4me3 via its PHD domain (Clouaire et al., 2012; Xu et al.,
2011; Thomson et al., 2010). Deletion of this protein mainly affects H3K4me3
placed at highly expressed active genes (Hui Ng et al., 2003; Clouaire et al.,
2012). MLL1 and MLL2 are homologous and can share two subunits in addition
to those that form the WRAD complex: MENIN and LEDGF (FitzGerald and
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Diaz, 1999; Hughes et al., 2004; Yokoyama and Cleary, 2008). MLL1 and MLL2
are both targeted to Hox genes and may be able to partially compensate for each
other although they have distinct functions (Glaser et al., 2009; Denissov et al.,
2014; Yokoyama and Cleary, 2008; Hughes et al., 2004; Murai et al., 2014).
The MLL2 protein (600 kDa) contains a CXXC zinc finger, three PHD
zinc fingers, a bromodomain and a SET domain. MLL2 is recruited to
chromatin through multiple mechanisms including interactions with sequence
specific transcription factors (TFs) (Ang et al., 2011; Mo et al., 2006; Demers
et al., 2007) and histone variants including H2A.Z (Hu et al., 2013b). The CXXC
domain contained within MLL2 is important for its targeting to chromatin while
the SET domain is required for catalytic activity (Risner et al., 2013; Hu et al.,
2017; Birke et al., 2002; Bach et al., 2009). The third PHD finger is able to bind
H3K4me3 and therefore may be able to recruit MLL2 to H3K4me3 initiating
a feedbackward loop (Ali et al., 2014). MLL2(-/-) ESCs are viable but display
proliferation defects, however the phenotype is more severe in a double knockout
of MLL1(-/-) and MLL2(-/-) (Glaser et al., 2009; Denissov et al., 2014; Lubitz et
al., 2007; Hu et al., 2013b). This suggests at least partial redundancy between
MLL2 and MLL1. Knockout of MLL2 results in embryonic lethality suggesting
its function is important in early development (Glaser et al., 2009). Although a
knockout of the MLL2 does not affect genome-wide levels of H3K4me3 in ESCs,
due to the presence of multiple of H3K4 methyltransferases, it does affect the
expression of a large group of genes (Denissov et al., 2014) and is required for
global H3K4 methylation in oocytes.
1.2.6 SET-domain Family Methyltransferases
There are a large variety of PTMs including methylation that can be placed
on a number of residues on multiple core histones. Methylated residues are
a significant player in the epigenetic control of gene expression. A number of
enzymes that place these methyl groups are part of the SET-domain family
methyltransferases including SETD1A/B, MLL1-4, and PRC2. The SET domain
is approximately 130 residues long, and proteins containing SET domains are
present in all eukaryotic organisms (Cheng, 2014; Dillon et al., 2005; Qian and
Zhou, 2006; Herz et al., 2013). Both PRC2 and MLL2 contain SET domains and
transfer a methyl group from the co-factor SAM to the ϵ amino group of the target
lysine of either H3K4 or H3K27 on the substrate. The SET domain is composed
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of β strands folding into three sheets that surround a knot-like structure formed
by the C-terminus of the SET domain (see Fig. 1.7).
The SET domain contains the core SET domain which is usually flanked by both
a N-terminal SET region (nSET) and a C-terminal SET region (cSET) that are
not part of the SET domain itself. The nSET domain helps stabilise the active
site, while the cSET domain forms part of the active site, usually by providing an
aromatic residue to pack against the SET active site helping form a hydrophobic
channel required for the enzymatic activity of the SET domain (Qian and Zhou,
2006; Zhang et al., 2002). Some SET domains have a third component of the
active site referred to as I-SET which is inserted into the active site. This inserted
region varies in length and sequence between enzymes that contain the I-SET,
when combined with the structure of the SET domain it potentially helps to
confer substrate specificity to the enzyme (Qian and Zhou, 2006). The residues
either side of the substrate lysine contribute to substrate specificity. A narrow
hydrophobic channel, which contains an invariant tyrosine residue implicated in
the enzymatic mechanism, links the substrate lysine and the cofactor SAM, has
been seen in all crystal structures of SET domains so far (Qian and Zhou, 2006).
The substrate and cofactor are placed at opposite sides of the active site. The
sulphur atom of the SAM cofactor is positioned at the ϵ-amino group of the target
lysine. There are a few mechanisms that would allow the transfer of the methyl
group from the cofactor to the substrate. A theoretical study on SET7/9 supports
the methyl transferase from the SAM to the target lysine proceeding by a direct
in-line SN2 nucleophilic attack (Qian and Zhou, 2006). However, this mechanism
has not been confirmed and there are several alternatives including deprotonation
of the substrate lysine by the active site before methyl transfer. The tyrosine may
provide a charge-dipole interaction between its phenoxyl and positive charged
sulphur of SAM or may interact with and align the amino nitrogen of the lysine
to the methyl carbon of the SAM to facilitate the SN2 methyl transfer (Dillon
et al., 2005; Qian and Zhou, 2006; Herz et al., 2013).
The SET domain of PRC2 is contained within the EZH2 subunit and has many of
the features associated with the classic SET domain structure (see Fig. 1.7). The
SET domain has the classic beta sheet harbouring the active site and the typical
pseudoknot (Wu et al., 2013). The I-SET contains a β-hairpin, which helps
to form the substrate binding cleft, while the methyl-lysine channel is formed
from aromatic residues including the invariant tyrosine. Nevertheless, the PRC2
SET domain does contain some divergent elements. The N-terminal region of
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Figure 1.7 Various SET domains Structures. A) The structure of human SET7/9
enzyme’s classic SET domain. NSET in yellow, pseudoknot in purple, SET domain in green
and CSET in grey. The H3 peptide is in red, and cofactor byproduct S-adenosyl-L-homocysteine
(AdoHcy) in blue. Figure taken from Dillon et al., 2005. B) The crystal structure of active and
inactive EZH2’s SET domain are overimposed to demonstrate the 22◦ rotation of the I-SET.
All domains are labelled. I-SET is depicted in purple, Sal in green, nSET in light blue, cSET
in dark blue and the H3 peptide in yellow. Figure taken from Jiao and Liu, 2015.
the catalytic domain comprises of two Zn3Cys9 motifs (CxC), whereas the SET
domain is part of the C-terminal region of EZH2 with a I-SET that partially
forms the active site cleft and a cSET motif which diverges from the classic
SET structure (see Fig. 1.7). The CxC domains interacts with the DNA of the
nucleosome, helping position the nucleosome and H3K27 for modification (Wu
et al., 2013; Poepsel et al., 2018) potentially helping regulate PRC2’s response to
varying nucleosome density.
In the active conformation of SET domains, the cSET contributes to the
formation of both the substrate and cofactor binding site, in EZH2 the cSET
is positioned towards the CxC domains, partially blocking the active site and
preventing formation of the co-factor site (see Fig. 1.7). When EZH2 is in
the autoinhibited conformation the I-SET is also close to the cSET, causing the
closure of the methyl-lysine binding channel (Jiao and Liu, 2015; Wu et al., 2013;
Antonysamy et al., 2013). In addition, the cofactor binding cleft in the active
PRC2 complex that is formed by the I-SET and the cSET domains, does not
form fully in the autoinhibited conformation, this autoinhibition is relieved upon
EZH2 binding to SUZ12 and EED (Wu et al., 2013; Jiao and Liu, 2015; Jiao and
Liu, 2016).
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There are multiple interaction points between EED, EZH2 and SUZ12. The
interaction of the SET activation loop (SAL) of EZH2 with EED and the VEFS
domain of SUZ12 is critical for the stabilisation of the active conformation of the
SET domain and results in the movement of the I-SET 20 degrees anti-clockwise,
away from the co-factor binding site and towards the substrate site, see Figure
1.7 (Jiao and Liu, 2015). This allows entry of the substrate into the active site
and catalytic activity is restored. The SAL of EZH2 extrudes from between the
SET domain and the VEFS to interact with the stimulatory recognition motif
(SRM) of EZH2. PRC2 binds methylated H3K27 or JARID2 K116 in a sandwich
like assembly between the EED WD40 aromatic cage and the SRM. SRM marks
extensive contacts with the I-SET of the SET domain, in addition to the contacts
SRM makes with the SAL potentially helping communicate structural changes
from one to the other. Mutations to the SAL, I-SET, SEM and VEFS domains
decrease or completely obliterate H3K27me3-meditated simulation of catalytic
activity (Jiao and Liu, 2016; Wu et al., 2013; Antonysamy et al., 2013; Justin et
al., 2016; Jiao and Liu, 2015). Both the EED and the SRM bind the H3K27me3
peptide stabilising the position of the I-SET stimulating the SET domain (Jiao
and Liu, 2015).
1.3 Bivalent Domains
1.3.1 Discovery and Composition
H3K4me3 and H3K27me3 are largely segregated throughout the genome, marking
different transcriptional states. However, these marks were found to co-occur on
the majority of developmental gene’s transcription start sites (TSS) in embryonic
stem cells (ESCs). Their sites of coexistence were termed bivalent domains (see
Fig. 1.8) (Bernstein et al., 2006a; Azuara et al., 2006). Bivalent domains are
located at CpG islands and the genes on which they are located are expressed at
very low levels in ESCs (Bernstein et al., 2006a; Mikkelsen et al., 2007; Azuara
et al., 2006). H3K27me3 at bivalent domains is placed by PRC2 (Laugesen
et al., 2019; Sharif and Koseki, 2018; Bernstein et al., 2006a; Azuara et al.,
2006), and H3K4me3 is placed by MLL2 (Hu et al., 2013b; Denissov et al., 2014;
Clouaire et al., 2012). The initial discovery of bivalency was obtained by the
use of chromatin immunoprecipitation (ChIP), re-ChIP, and hybridisation arrays
and therefore could have been present only in a fraction of the cell population
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or the marks present on neighbouring nucleosomes. Several studies used various
re-ChIP techniques to address these areas of concern (Geisberg and Struhl, 2004;
Truax and Greer, 2012; Kinkley et al., 2016; Brookes et al., 2012) and confirmed
the presence of both marks on the same nucleosome. The genome-wide re-ChIP-
seq used by Kinkley et al. (2016), Vastenhouw et al. (2010), Mikkelsen et al.
(2007), and Sen et al. (2016) confirmed wide-spread bivalency at hypomethylated
CpG islands coinciding with inactive promoters of developmental regulators.
Although some previously discovered bivalent promoters may have been due to
previously undiscovered heterogenous bivalency of the cellular population further
work utilising multiple techniques confirmed the existence of bivalency within a
cell (Shema et al., 2016; Voigt et al., 2012; Kinkley et al., 2016; Brookes et al.,
2012; Mikkelsen et al., 2007).
The existence of both H3K4me3 and H3K27me3 in the same nucleosome but on
separate histone H3 tails was established by mass spectrometry analysis of H3
histone N-terminal tails and reChIP on purified mononucleosomes, however these
results do not place asymmetric nucleosomes in the context of the genome (Young
et al., 2009; Voigt et al., 2012). This asymmetric nucleosome conformation
is supported by in vitro data from multiple studies. PRC2 is inhibited from
placing H3K27me3 when nucleosomes are symmetrically but not asymmetrically
modified with H3K4me3 (Voigt et al., 2012). This inhibition is reciprocated
by histone-lysine N-methyltransferases (KMT2) enzymes which place H3K4me3,
the placement of H3K27me3 reduces their catalytic activity (Kim et al., 2013).
The combination of these techniques both in vitro and in vivo suggest that the
bivalent domains present in cells consist of asymmetrically modified nucleosomes.
ChIP techniques rely on populations of the cells, and sequential ChIP does not
distinguish between nucleosomes modified on separate H3 tails or on the same H3
tail, while re-ChIP distinguishes between nucleosomes from different alleles. MS
techniques only compares PTMs on the same histone peptides or within the same
nucleosome but does not give any information on the genomic location of these
marks. Shema et al. (2016) gave the definitive evidence of the bivalent asymmetric
nucleosomes in combination with their genomic location in vivo. The distance
between the different histone PTMs distinguishes between marks present on the
same H3 tail or those on separate H3 tails, while sequencing of the DNA in the
nucleosomes allows placement of the bivalent asymmetric nucleosome in specific
genomic location.




Figure 1.8 Schematic of bivalent domain composition. Bivalent domains are composed
of asymmetrical nucleosomes with one H3 modified with H3K4me3, and the sister H3 in the
same nucleosome modified with the H3K27me3 mark. One H3 copy in green, the sister H3’
copy in purple, H3K4me3 modification in green, and H3K27me3 modification in red.
confirmation of their existence in both early pre and post implantation embryos
(Rugg-Gunn et al., 2010; Alder et al., 2010; Dahl et al., 2010). The existence of
bivalent domains in vivo was further confirmed by their presence in developing
zebrafish (Vastenhouw and Schier, 2012; Lindeman et al., 2011). There is a
strong degree of conservation in bivalent domains between human and mouse
ESCs (Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007) suggesting
a link between bivalency and CpG islands and some maintenance of bivalent
domains during evolution. Bivalent domains are not universal in all organisms,
as studies on Xenopus embryos found very few true bivalent domains composed
of nucleosomes asymmetrically modified with H3K4me3 and H3K27me3 (Akkers
et al., 2009). Investigation into bivalent domains in Drosophila initially suggested
that they may have bivalent domains consisting of the combination of H3K4me3
and H3K9me3 (Saha et al., 2019). Although recent research has shown evidence
of the co-occurance of H3K4me3 and H3K27me3 forming bivalent domains
(Akmammedov et al., 2019) where their function has been posited to be the same
as in mammals, helping to poise the gene for quick regulation during development.
Bivalent domain composition may have been solved but the function of bivalent
domains has yet to be ascertained, although, multiple hypotheses have been
posited. As these marks were initially thought to be segregated in the genome due
to their association with completely different transcriptional states, the overlap of
both active and repressive marks is generally thought to ‘poise’ the gene for quick
regulation during development (Bernstein et al., 2006a; Azuara et al., 2006). The
low level of transcription of bivalent genes supports this juxtaposition of the marks
ready for quick regulation. This hypothesis has been supported by the discovery
that the majority of these bivalent domains found in ESCs are resolved during
differentiation (Bernstein et al., 2006a; Mikkelsen et al., 2007). If a bivalent
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domain is activated upon differentiation then it retains the H3K4me3 and loses
H3K27me3, while other bivalent domains lose the H3K4me3 mark and gain more
H3K27me3 to become completely silenced.
There are some bivalent domains that remain bivalent in terminally differentiated
cells but they are a much lower number than that seen in ESCs. Approximately
8% of genes bivalent in ESCs remain bivalent in neuronal progenitor cells (NPCs)
and may be due to the lack of expression of any transcription factors (TFs) that
would activate them, therefore the loss of H3K4me3 is not required (Mikkelsen et
al., 2007). Some bivalent domains lose both marks during differentiation and are
silenced by DNA methylation (Sharov and Ko, 2007). The formation of bivalent
domains may alter with different cell types as the PcG recruitment mechanism
alters (Oliviero et al., 2016; Kloet et al., 2016), therefore the function of bivalent
domains may change between cell types.
The theory that bivalent domains are important in differentiation is supported by
the phenotypes observed in cells deficient in MLL2 and PRC2 subunits. Knockout
of MLL2 results in removal of H3K4me3 specifically from bivalent domains and
severe defects in differentiation (Lubitz et al., 2007; Hu et al., 2013b; Denissov
et al., 2014). Surprisingly, if DPY30 is removed some studies have seen an
alteration of H3K4me3 placement at bivalent domains, suggesting a function
of DPY30 specific to bivalency (Jiang et al., 2011). The number of bivalent
domains in ESCs vary slightly depending on the method used to quantify them,
approximately 2500 bivalent domains are found in ESCs. Mikkelsen et al. (2007)
stated that of the CGIs with H3K4me3, 22% of were bivalent. Voigt et al.
(2012) estimated that 15% of all nucleosomes modified with H3K4me3 were co-
modified with H3K27me3, while Shema et al. (2016) suggested the presence of
approximately 0.5% of all nucleosomes are bivalent which decreased upon ESC
differentiation. As the number of bivalent nucleosomes that make up a domain is
unknown, and likely variable, a comparison of bivalent nucleosomes and domains
is impossible. As a result of the different techniques and cell lines used, the
percentages of bivalent domains or nucleosomes found in different studies are
unable to be directly compared.
Bivalent domains are resolved differently depending on the differentiation
pathway activated, further supporting the premise that bivalent domains are
important during development (Mikkelsen et al., 2007). The number of bivalent
domains present in terminally differentiated cells was proposed to correlate
with their differentiation potential. The majority of bivalent domains in ESCs
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are repressed during differentiation, while the majority of bivalent domains
overlapping with developmentally important transcription factor promoters lose
H3K27me3 (Pan et al., 2007; Zhao et al., 2007; Cui et al., 2009). If bivalent
domains include developmentally important genes, for example TF and lineage
specific genes, requiring quick regulation during differentiation then only a small
subset of these would need to be activated during development as the vast
majority would not be required for that specific lineage.
Nevertheless, there are non-bivalently modified genes that are activated quickly
upon differentiation, indicating multiple methods of poising genes for regulation
(Pan et al., 2007). As bivalent domains are found in multiple cell types and
there are several genes that become bivalently modified during differentiation
including pluripotency factors such as SOX2, this suggests that bivalent domains
are not unique to ESCs and do not solely poise gene requiring quick expression
(Mikkelsen et al., 2007; Mohn et al., 2008; Pan et al., 2007; Roh et al., 2006;
Cui et al., 2009; Barski et al., 2007). It could be argued that the pluripotency
genes need to be switched off quickly to allow for successful differentiation and
the quickest way to do this, is to establish a bivalent domain as this requires only
the removal and replacement of one mark and decreases expression of that gene
to negligible levels (Bernstein et al., 2006a; Mikkelsen et al., 2007; Pan et al.,
2007; Zhao et al., 2007).
Some cell types retain bivalent domains on genes required for rapid responses,
such as immune response, even if they are not developmental genes. In CD8+
memory T cells, genes required for their activation are in a bivalent chromatin
state (Weng et al., 2012; Kinkley et al., 2016; Roh et al., 2006; Araki et al.,
2010). However, some bivalent genes remain in terminally differentiated cells
that are not important in development or rapid response, the reason why these
genes remain bivalent is not fully understood. These genes may remain bivalent
as the TF that would activate them is not expressed or they could have a different
function. A consequence of bivalency is the presence of poised RNAPII at bivalent
domains (Pan et al., 2007; Dao et al., 2016; Stock et al., 2007). Studies have
suggested that bivalency and the RNAPII poising may mark the gene ready for
or silenced after an expression burst. This still suggests a role for bivalency in
quick regulation of gene expression and a plausible answer for the formation of
bivalency on pluripotent genes after differentiation.
Artificial CpG-rich sequences introduced into cells obtain both H3K4me3 and
H3K27me3, indicating that bivalency may be the default position of inactive
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CpG-rich promoters (Mendenhall et al., 2010; Thomson et al., 2010; Woo et al.,
2010; Lynch et al., 2012). Unmethylated CGIs recruit H3K4 methyltransferases
such as SET1 and MLL1/2 (Clouaire et al., 2012; Bach et al., 2009; Birke et
al., 2002; Risner et al., 2013; Hu et al., 2017). The presence of H3K4me3
prevents de novo DNA methylation, while the absence of activating transcription
factors leads to the establishment of H3K27me3 and thus bivalency (Ku et al.,
2008; Morselli et al., 2015). An extension of the existing model, which still
links bivalent domains with transcriptional regulation, is posited by Kinkley
et al. (2016); bivalent domains may be a dual repression control mechanism.
The presence of H3K4me3 prevents DNA methylation of the promoter, while
H3K27me3 prohibits productive elongation (Ferrai et al., 2017; Rada‐Iglesias,
2017; Brookes et al., 2012; Aranda et al., 2015). The behaviour of H3K27me3
with DNA methylation is more complicated with most evidence suggesting the
antagonistic role of H3K27me3 and DNA methylation (Reddington et al., 2013;
Lynch et al., 2012; Xie et al., 2013; Li et al., 2018; Neri et al., 2013; Hagarman et
al., 2013), however some studies have shown that a depletion of DNA methylation
results in a decrease of H3K27me3 peaks and there is evidence for H3K27me3
and DNA methylation coexisting (Brinkman et al., 2012; Viré et al., 2006;
Wang et al., 2017), although only at very low levels of both PRC2 and DNA
methylation. This could be the point at the exchange between the different types
of repression either caused by PRC2 or by DNA methylation. If H3K27me3
excludes DNA methylation then this extension of the model fails to explain
H3K4me3’s role at bivalent domains. Ku et al. (2008) suggested that bivalency
may buffer the pluripotent state of ESCs by reinforcing the repression of factors
that induce differentiation. Although the removal of either functional PRC2 or
MLL2 affects the differentiation of stem cells the maintenance of EZH2(-/-) cells
is possible making bivalency the only method of controlling self-renewal unlikely
(Chamberlain et al., 2008; Shen et al., 2008).
1.3.2 Further Modification at Bivalent Domains
Not all bivalent domains are created equal; there are further marks and
modifications that co-exist with bivalency (see Fig. 1.9), potentially leading to
differences in the proteins that interact with them. Multiple studies have looked
into which chromatin modifications co-localise with bivalent domains hoping to
elucidate bivalent domain function and discover why certain bivalent domains are
resolved differently. The distribution of H3K27me3 vs H3K4me3 varies between
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A) B)
Figure 1.9 Diagram of Bivalent Nucleosomes and Potential Further Modifications.
A) Simplified bivalent nucleosome. One H3 copy with H3K4me3 and the sister H3 copy with
H3K27me3. B) A schematic of a more complex and potentially more biologically accurate
bivalent nucleosome. One H3 is modified with H3K4me3K14ac, while the sister H3’ copy
contains H3K9ac27me3. This nucleosome contains H2A.Z variants modified with ubiquitin and
acetylation (H2A.Zub/ac). One of the 2 canonical core H3 copy (H3.1) has been replaced with
the H3.3 variant.
bivalent domains resulting in some studies classifying bivalent domains by the
either wide or narrow H3K27me3 distribution (Mantsoki et al., 2018; Ku et
al., 2008). Bivalent promoters containing a wide spread of H3K27me3 tend to
coincide with the presence of PRC1 on the domain (Ku et al., 2008). Bivalent
domains can also be classified by the presence or absence of PRC1. The presence
of PRC1 at bivalent domains has been suggested to be important for multiple
reasons: PRC1+ bivalent domains are more likely to retain H3K27me3 during
differentiation, they are better evolutionary conserved than PRC1- domains, and
they affect the levels of poised RNAPII present (Ku et al., 2008; Min et al.,
2011). 90% of PRC1 target sites correspond to PRC2 bivalent regions, suggesting
a large overlap of PRC1 and PRC2 also at bivalent domains. The wider spread
of H3K27me3 may make it easier for PRC1 to be recruited by H3K27me3 by
its CBX subunits (Wang et al., 2004b; Morey et al., 2012). The presence of
PRC1 has been shown to compact chromatin (as discussed earlier), and may help
reinforce the repressive effect of H3K27me3.
Bivalent domains contain poised RNA polymerase II (RNAPII), are enriched for
developmental genes and are dynamically regulated during development (see Fig.
1.10). The function of poised RNAPII at any gene, including bivalent domains,
is debated. The presence of poised RNAPII may help to explain the low level of
transcripts of bivalent genes. The presence of poised RNAPII at bivalent domains
(Fig. 1.10) was first discovered by Stock et al. (2007). They classify bivalent
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domains into two groups, based on the presence of PRC1. They attributed the
presence of poised RNAPII to the presence of PRC1 and H2AK119ub. They
find that the bivalent domains bound by PRC1 have a higher amount of poised
RNAPII. The deletion of core PRC1 subunits resulted in the loss of poised
RNAPII and an increase of gene repression. Min et al. (2011), however, found
less RNAPII at bivalent domains where PRC1 was present.
Mantsoki et al. (2018) found poised RNAPII at bivalent genes, however, they
divide bivalent genes into classes by different levels of RNAPII. Poised RNAPII is
an accepted feature of bivalent domains although the mechanism of its placement
and function is debated (Ku et al., 2008; Min et al., 2011; Mantsoki et al.,
2018; Cui et al., 2009; Vastenhouw et al., 2010). The poised RNAPII along
with the presence of both PTMs could contribute to the timely regulation of
the bivalent genes during development. The class with higher RNAPII poising
(1) is enriched for genes involved in transcriptional and cell cycle control while
the other class (2) are more tissue specific and developmentally important genes.
Class one is more likely to be bivalent across cell types as they consistently change
from poised to not poised upon cell activation. Dao et al. (2016) suggested
that poised RNAPII marks genes that are silenced after or before a quick burst
of transcription supporting theory of bivalent domains being used for quick
regulation. Mantsoki et al. (2018) and Xu et al. (2017) suggest another possible
function of bivalent domains in achieving mono-allelic expression in different cell
types. Poised RNAPII is an accepted feature of bivalent domains although the
mechanism of its placement and function is debated (Ku et al., 2008; Min et al.,
2011; Mantsoki et al., 2018; Cui et al., 2009; Vastenhouw et al., 2010). The
poised RNAPII along with the presence of both PTMs could contribute to the
timely regulation of the bivalent genes during development.
There are certain chromatin signatures that further characterise subsets of
bivalent domains (see Fig. 1.9 and Fig. 1.10) (Cui et al., 2009; Roh et al., 2006;
Ku et al., 2012). H2A.Z is a variant of the core histone H2A, enriched at active
and bivalent genes and essential for development although its function is still
controversial (Cui et al., 2009; Sen et al., 2016; Hu et al., 2013b; Ku et al., 2012;
Margueron and Reinberg, 2010). It has been implicated in nucleosome stability,
dynamics (see section 1.1.1), histone exchange, transcriptional activation and
Polycomb repression. Its function may therefore depend on the surrounding
environment that it is placed in, in the genome (Hu et al., 2013b; Giaimo
et al., 2019; Guillemette et al., 2005; Jin and Felsenfeld, 2007; Bönisch and
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Hake, 2012; Park et al., 2004; Li et al., 1993; Abbott et al., 2001; Suto et al.,
2000; Zhang et al., 2005). H2A.Z is found flanking nucleosome deficient sites in
nucleosomes containing histone variant H3.3, both of which have been associated
with transcriptional repression and activation in a context dependent manner (Shi
et al., 2017; Sen et al., 2016; Ku et al., 2012; Jin et al., 2009; Hardy et al., 2009;
Szenker et al., 2011). The combination of both H3.3 and H2A.Z has been thought
to render nucleosomes labile, and the chromatin containing them susceptible to
nuclease digestion and high ionic conditions (Ku et al., 2012; Suto et al., 2000; Jin
and Felsenfeld, 2007). The incorporation of H3.3 has been suggested as necessary
for the proper establishment of bivalency (Banaszynski et al., 2013).
H2A.Z has been implicated in the recruitment of RNAPII and it can facilitate
the association of both MLL2 and PRC2 to chromatin, potentially explaining its
inclusion at bivalent domains (Hu et al., 2013b; Weber et al., 2014; Guillemette
et al., 2005; Li et al., 2005a; Creyghton et al., 2008). The H2A.Z incorporated
into bivalent promoters contains the H2A.Zub/ac mark (Ku et al., 2012). The
ubiquitylation is placed by PRC1 on K119 and is associated with silencing, while
the acetylation is associated with activation (Millar et al., 2006; Morales and
Richard-Foy, 2000; Draker et al., 2012; Valdes-Mora et al., 2012; Sarcinella et
al., 2007; Endoh et al., 2012; Napoles et al., 2004). Bivalent domains contain
H2A.Z which is itself dually modified with both ubiquitylation and acetylation;
potentially helping maintain bivalency and poised RNAPII until the gene is
regulated during differentiation (Ku et al., 2012).
The PTMs of bivalent domains are not curtailed to the H3K4me3 and H3K27me3
marks (Fig. 1.10). In addition to H2A.Zub/ac marks, further PTMs may be
placed on the nucleosomes. Cui et al. (2009) showed that the bivalent domains
that are most likely to be activated are associated with higher levels of H2A.Z,
H3K4me1, H4K20me1 and RNAPII. Additional studies performed on bivalency
in differentiated cells including T cells demonstrated the presence of H3K14ac
and H3K9ac at bivalent promoters (Roh et al., 2006; Barski et al., 2007). The
presence of all these PTMs and chromatin modifications allow an insight into how
bivalent domains functions and emphasise the complexity of the histone code and
the difficulty of isolating the function of any specific chromatin state.
In addition to the transcription factors and chromatin modifiers that have been
shown to localise to bivalent domains two proteins, NONO and ASF1A, were
discovered that bind to a subset of bivalent domains. Both of these proteins




















Figure 1.10 Schematic of Bivalent Domain Composition with Additional
Modifications and Potential Protein Interactions. Bivalent domains are composed of
more than H3K4me3, and H3K27me3 co-occurrence. Details of added modifications depicted
in the diagram. Possible recruitment of PRC2, PRC1, RNAPII and MLL2 is shown. Nono
and Asf1a bivalent domain interactors are depicted, however, as yet their potential recruitment
mechanism is unknown.
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component of para-speckles, interacts with ERK at bivalent domains with a high
level of poised RNAPII (Ma et al., 2016). ERK helps keep RNAPII in a paused
state (Tee and Reinberg, 2014). Culturing of mouse ESCs in 2i media containing
MEK inhibitors results in a loss of ERK and NONO from chromatin and altered
RNAPII activity at the NONO positive bivalent genes, potentially causing a
switch to a more robust self-renewing phenotype (Ma et al., 2016). The increased
pluripotency of the 2i ESCs may be partially due to the altered regulation of a
subgroup of bivalent domains marked by NONO (Silva et al., 2008; Sim et al.,
2017; Marks et al., 2012; Ma et al., 2016). Removal of NONO at these genes may
partly explain the lower numbers of bivalent domains found in ESCs in 2i media.
Asf1 is a histone chaperone involved in nucleosome assembly and disassembly
(Mousson et al., 2007). Removal of Asf1 isoforms compromises the activation of
certain lineage specific genes that are bivalent in ESCs (Gao et al., 2018) and
impairs cellular proliferation in human cells (Corpet et al., 2011). Asf1a has
been suggested to bind to H3.3-H4 dimers, removing bivalent nucleosomes and
therefore helping to resolve the bivalent domain (Gao et al., 2018). How and why
Nono and Asf1 are recruited to only a subset of bivalent domains is unknown
(Fig. 1.10), this partial recruitment suggests that their function and importance
is not applicable to all bivalent domains.
1.4 Aims
The roles of chromatin states are mediated by the proteins that bind them,
for example H3K4me3 correlates with active transcription as it is bound by
proteins that stimulate transcription (Lauberth et al., 2013). Bivalency is more
complicated due to the presence of both activating and repressive marks, however,
its role should be communicated in a similar manner. We hypothesize that the
biological function of bivalent domains will be elucidated by the identification
and analysis of the proteins that bind them. The primary aim of this study was
to identify the proteins that bind bivalent asymmetric nucleosomes in order to
clarify the nature of bivalent domains. Although the majority of previous studies
hypothesize that bivalent domains act to poise the gene for timely regulation
during differentiation there is a deficiency of functional data to support this. A
secondary aim of this study was to elucidate the functional difference between
the proteins recruited to a symmetrically modified and asymmetrically modified
nucleosome. An in vitro approach was selected to ensure control over the factors
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present and parameters tested. This requires the generation and purification
of specifically modified histones and assembly of modified nucleosomes. The
use of mononucleosomes avoids the complications of proteins binding to a
specific combination and orientation of nucleosomes in an array. Specifically
modified nucleosomes will be generated and incubated with nuclear extract
from mouse embryonic stem cells. Removal of non-specific protein binding
will then allow identification of proteins bound specifically to the differently
modified nucleosomes, and consequently insight into the nucleosome’s function.
Once initial findings have been analysed, more complex in vitro studies can
be completed with additional modifications or with nucleosomal arrays. Mouse
embryonic stem cells (ESCs) were chosen for the experiment as the vast majority
of information on bivalency has been obtained with them, helping with the
interpretation of results. Once proteins have been identified as binding to bivalent
nucleosomes in vivo and in vitro, further characterisation of their function will
be required to identify their role at bivalent domains.
The overview of the complex nature of bivalent domain chromatin signatures
given above illustrates the complicated nature of chromatin. As the simplest
of bivalent domains are composed of both H3K4me3 and H3K27me3, and no
chromatin modification acts in isolation. Each histone modification recruits
specific proteins and in turn may affect the recruitment of proteins to nearby
modifications and so on, therefore understanding how each protein functions in
combination to help interpret the biological function of bivalent domains will be
extensively complicated, even if the biological function is simple. Each different
modification present at bivalent domains may alter the specific combination of
proteins recruited, possibly resulting in slightly different outcomes.
Though multiple studies have been completed on bivalent domains and their
coexisting marks, more modifications are being continuously found. Although
the presence of additional marks at bivalent domains helps shed light on potential
functions none elucidates the universal role of bivalent domains. The purpose of
most of the modifications found to co-exist with bivalency are context dependent,
for example, H2A.Z deposition is suggestive of both transcriptional activation and
repression. This versatility of function depending on the context of deposition
is not helpful in the investigation of the general role of bivalent domains.
The simplest bivalent state was therefore chosen for analysis (mononucleosomes
asymmetrically modified for H3K4me3 and H3K27me3) as it will isolate proteins
that prefer to bind to the bivalent asymmetric mark conformation which is present
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at all bivalent domains. This will hopefully elucidate a universal role of bivalent





2.0.1 General Lab Chemicals
β–Mercaptoethanol (Sigma), Bovine Serum Albumin (Sigma), IPTG (Melford
Biolaboratories Limited), Bambanker (Lymphotech Ltd), Bradford Reagent
(BioRad), Ethylenediaminetetraacetic acid (EDTA) (Sigma), HEPES (Sigma),
NaCl (Fisher Chemical), KCl(Sigma Aldrich), Glycine (ITW Reagents), Glycerol
(Fisher Chemical), IGEPAL (Sigma), Formaldehyde (Thermo Scientific), Gelatin
(Sigma), Tris (Thermo Fisher Scientific), MgCI2 (BDH Laboratory Supplies), Su-
crose (Fisher Chemical), Dithiothreitol (DTT) (Melford Biolaboratories Limited),
TEMED (Tetramethylethylenediamine) (Sigma), Acrylamide (Severn Biotech
ltd), Ammonium persulfate (APS) Acros Organic, Sodium dodecyl sulfate (SDS)
(Severn Biotech ltd), DMEM (Gibco), Pyruvate (Gibco), Trypsin (Gibco),
Glutamine (Gibco), Penicillin Streptomycin (Pen/Strep) (Gibco), Non-essential
amino acids (Gibco), Foetal Bovine Serum (Gibco), Triton-X (Sigma), HCl
(Fisher Chemical), N-Lauryl-Sarcosine (Sigma), Imidazole (Sigma), Dimethyl
Sulfoxide (DMSO) (Sigma-Aldrich), Stripping buffer (Thermo Scientific), Tween
(VWR Life Science), Imperial Protein Stain (Thermo Scientific), NaOH (Fisher
Chemical), Agarose (Fisher Chemical), Urea (Sigma), Sodium Azide (Scientific
Lab Supplies), KOH (Fisher), Bromophenol Blue (Sigma-Aldrich).
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2.0.2 Antibodies
Antibodies for Western botting are listed in Table 2.1 and Table 2.2. While
antibodies used for chromatin immunoprecipitation (ChIP) are listed in Table
2.7.
Target Host Catalogue Number Company
H3K27me3 Rabbit C36B11 Cell Signalling
EZH2 Mouse 612667 BD Transduction Laboratories
SRCAP Rabbit ESL104 Kerafast
H3.1 Rabbit ABE154 Millipore
H3.3 Rabbit 09838 Millipore
Lamin A/C Rabbit SC20681 Santa Cruz Biotechnology
H4 Rabbit D2X4V Cell Signalling
RING1B Rabbit D22F2 Cell Signalling
PHF2 Rabbit D45A2 Cell Signalling
H3 Rabbit AB1791 Abcam
H3K4me3 Rabbit AB8580 Abcam
CBX7 Rabbit AB21873 Abcam
TAF3 Rabbit AB188332 Abcam
HA-Tag Rabbit AB9110 Abcam
HA-Tag Mouse 3724S Cell Signalling
EZH1 Rabbit ABE281 Abcam
H2A.Z Rabbit AB4174 Abcam
ING2 Rabbit AB109594 Abcam
His-Tag Mouse H1029 Sigma
Strep-Tag Mouse 21507001 IBA
Flag-Tag Mouse F3165 Sigma
Table 2.1 Primary Antibodies used for Western blotting.
Target Host Catalogue Number Company
Rabbit Donkey 711-035-152 Jackson Immunoresearch
Mouse Donkey 715-635-150 Jackson Immunoresearch
Table 2.2 Secondary Antibodies used for Western blotting.
2.0.3 Vectors and Primers
Plasmids and primers for cloning and genotyping used are listed in Tables 2.3
and 2.5, respectively. Primers used in ChIP and qPCR experiments are listed in
Tables 2.4 and 2.6.
40
Vector Backbone Size Comments
pGEM-3Z approx 2.7 Kbp Ampicillin
Resistant
p177 approx 2.7 Kbp Ampicillin
Resistant
pET3A approx 4.7 Kbp Ampicillin
Resistant






pET3b approx 4.7 Kbp Ampicillin
Resistant
Table 2.3 Plasmid vectors used for cloning.











Pou5f1 (Oct4) forward GGCTCTCCAGAGGATGGCTGAG
Pou5f1 (Oct4) reverse TCGGATGCCCCATCGCA
HoxA7 forward GAGAGGTGGGCAAAGAGTGG
HoxA7 reverse CCGACAACCTCATACCTATTCCTG
Fabp7 promoter f TGAGCAAATCACAAGGAGGA
Fabp7 promoter reverse TGGAGGAACTCGGGTCTTAC
Bcor CGI forward GTAAAACCGAAAGCGAGCAA
Bcor CGI reverse GAGGGTTTCTCCTCCGACTT
Bcor body forward GGGGGTAACTGTGGGAATCT





Table 2.4 Primers used in ChIP experiments
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Number Primer Name Primer Sequence
1 1x 601 209bp forward Biotin Biotin-GCTTCACCTCGTGACCC
2 1x 601 209bp reverse CGCTCTAGACCATGATGC
3 H3MT32C forward ATGCGATCATCATATGTGCGGCGGAGTCAAGAAACC
4 H3MT32C STOP reverse CTGATCGGTACCCTAAGCCCTCTCGCCTC
5 H3MT32C tagged reverse CTGATCGGTACCGCCAGCCCTCTCGCCTCGG
6 H3T45C forward CACCGTTACCGGCCCGGCTGTGTCGCTCTCCGCGAGATC
7 H3T45C reverse GATCTCGCGGAGAGCGACACAGCCGGGCCGGTAACGGTG
8 Human H2A forward GCATGATCTACATATGTCCGGCC
9 Human H2A reverse GATCATGGATCCTTATTTGCC
10 Human H2B forward GCATGATCTACATATGCCGGAAC
11 Human H2B reverse GATCATGGATCCTTACTTTGC
12 EZH2 KO exon 3 mut spec forward CAAGTCATCCCGTAAAACACCTA
13 EZH2 KO exon 3 mut spec reverse AGGCGAATGCATTTAGGTGTTTT
14 EZH2 KO exon 3 forward AAACGTGCTACAGATCAGGCT
15 EZH2 KO exon 3 reverse TGGCCATCAGGCAACTAAGAA
16 EZH1 KO exon 8 forward GTCCCAGTGCCAGTTGTTCT
17 EZH1 KO exon 8 reverse GGAGTCTGTTGACAAGCCCT
18 EZH1 KO exon 8 mut spec forward GATCCTAGTAACAGTTTCCAAACCAT
19 EZH1 KO exon 8 mut spec reverse CAATGGCGCTGAATATCATATGG
20 KAT6B NT tag FLAG forward GACTACAAGGACCACGACGG
21 KAT6B NT tag FLAG reverse CCTTATAATCGCCGTCGTGGT
22 KAT6B NT tag HA forward ACGATGTGCCAGATTACGCT
23 KAT6B NT tag HA reverse CAGCGTAATCTGGCACATCG
24 KAT6B NT tag geno reverse ATCATTACACGGCGGTCCTTT
25 KAT6B NT tag geno forward AGCCTGTTTGACAGATGTGGT
26 KAT6B KO geno forward AAGACAACTCTCCACGTTGC
27 KAT6B KO geno reverse ATATCTCCAGGGCGTCGATAC
28 KAT6B NT KO mut spec reverse CGTAGATCTTAGCATGGCTATCA
29 KAT6B NT KO mut spec forward GGTCCTAATGATAGCCATGCTAA
30 MLL2 Y3944A 696 geno forward GAAGGTAAGTGGCGTGAAGG
31 MLL2 Y3944A 696 geno reverse CAACCACAGTAATAAGGCACG
32 MLL2 Y3944A 744 geno forward CTCTGGCATTGTCATTCGCT
33 MLL2 Y3944A 744 geno reverse TAATAAGGCACGGAAAGACCACC
34 MLL2 Y3944A mut spec forward TGAGGAGCTGACATATGACGC
35 MLL2 Y3944A mut spec reverse CATCTTCAATGGGAAACTTGGC
36 KAT6A exon3 KO 753 geno forward GTTCCCATCCTCCGAGAATCC
37 KAT6A exon 3 KO 753 geno rev CGTGAACGTGACTCCTATGCT
38 KAT6A exon 3 KO 413 mut spec forward CTTCCTAAACCTCGGAACCATTGAT
39 KAT6A exon 3 KO 401 mut spec forward CGGAACCATTGATAATAGGATACTTAGTG
40 KAT6A exon 3 KO 389 mut spec reverse CGACACTTCACTAAGTATCCTATTA
Table 2.5 Primers used in cloning and genotyping PCRs
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Table 2.6 Primers used in qPCR experiments
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2.1 Cell Culture
Basic Cell Culture Media : DMEM (Gibco 41965-039) supplemented with 15%
FBS (Gibco A3160802), 1 mM Sodium Pyruvate (Gibco 11360-039),1% L-
glutamine (Gibco 01853), 1% MEM non-essential amino acids (Gibco 11140-
035), 0.5% Penicillin Streptomycin (Gibco 15140-122), 0.2 mM BME (β–me) and
30 ng/ml heterologously expressed recombinant LIF (made in-house and batch-
tested for maintenance of self-renewal)
E14 mouse Embryonic Stem Cells (ESCs) were grown in basic cell culture media.
E14 ESCs were thawed at 37 ◦C and plated on pre-warmed 10 cm plates coated
with gelatin. After 4 hours media was changed. ESCs were grown on 10 cm plates
coated in gelatin (Sigma G1393), and routinely split 1:15 every two days. During
passaging, cells are washed in PBS (Phosphate Buffered Saline) and trypsinised
with 0.05% Trypsin (Gibco 25300-062), quenched with equal amounts of media
and replated.
Each embryonic stem cell line was cryo-preserved for storage in liquid nitrogen
(LN2). These cells were grown to the required number of plates for the required
number of vials. The cells are treated as above, once quenched, the cells are
counted and resuspended in Bambanker - 500 µl per 2 000 000 cells - in cryogenic
vials (Corning) and placed in freezing containers (Nalgene) in a −80 ◦C before
transferring to liquid nitrogen for long time storage.
2.2 DNA Extraction
2.2.1 Cultured Cells
10 × 105 of ESCs were resuspended with 100 µl of QuickExtract DNA (Epicentre)
solution, and extraction followed the manufacturer’s instructions.
2.2.2 Agarose Gel Extraction
The desired DNA is run on an 1-2% agarose (manufacturer) gel at 100V in TBE
buffer (100 mM Tris-HCl, 100 mM boric acid,2 mM EDTA pH8) and stained with
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SYBER safe (Invitrogen 1:10,000 dilution) to check the identity and purity of
the DNA and exercised from the gel. The gel fragment is weighed and then the
DNA is extracted with the E.Z.N.A. gel extraction kit (Omega Bio-tek) following
manufacturer’s instructions.
2.3 Nuclear Extraction
TMSD Buffer : 20 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 250 mM
sucrose, 0.5 mM DTT, 0.2 mM PMSF
BC420 Buffer : 20 mM HEPES pH 7.9, 420 mM KCl, 20% (w/v) glycerol, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
BC150 Buffer : 20 mM HEPES pH 7.9, 150 mM KCl, 20% (w/v) glycerol,
1.5 mMMgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
E14 ES cell nuclear extract (NE) was prepared based on the protocol by (Conaway
et al., 1996; LeRoy et al., 1998). E14 ESCs were washed in PBS (Gibco) and
harvested by scraping into PBS containing 1 mM EDTA. All subsequent steps
were performed at 4 ◦C. E14 ES cells were collected by centrifugation at 500 g for
8 min and washed with 100 ml of TMSD and collected by centrifugation as before.
The cells were resuspended in 10 cell pellet volumes (CPV) TMSD containing
0.01% NP40 and incubated on ice for 5 min to allow for cell lysis to occur. After
successful cell lysis was confirmed by staining an aliquot of the cell suspension
with Trypan Blue (Gibco), nuclei were pelleted by centrifugation for 10 min at
1000 g. The supernatant (cytosolic fraction) was removed and the nuclei pellet
resuspended in 6 nuclei pellet volumes (NPV) of BC150 before slowly adding
approximately 3.5 NPV of BC1000 dropwise until the conductivity is equal to
420 mM KCl and incubated at 4 ◦C with gentle rotation for 1 h. After a 15 s
vortex, the suspension was spun for 30 min at 25.000 g. The supernatant was
dialysed three times against 50 volumes of BC150 buffer for 1 h. The dialysate
was centrifuged at 25.000 g for 20 min. The pellet contains DNA and protein
that is insoluble in 150 mM salt. The resultant supernatant is the nuclear extract
(NE) and contains proteins normally residing in the nucleus, although proteins
strongly bound to the chromatin will not have been extracted. A higher salt
extraction or solubilisation of the remaining proteins via the use of ammonium
sulphate would help to extract more strongly bound proteins. For all NE used
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in nucleosome pulldowns, three independent extractions were performed and NE
combined to compensate for potential differences in any individual preparation.
The resultant NE was flash frozen and stored at −80 ◦C until use.
2.4 Purification of endogenous tagged KAT6B
Kat6B was endogenously tagged using CRISPR as described below. Roughly
1.625 billion cells were grown as described above. Cells were washed in PBS
(Gibco) and were harvested by scraping cells into PBS containing 1 mM EDTA
before collecting to 250 ml centrifuge tubes (Corning). All subsequent steps were
performed at 4 ◦C. The cells were collected by centrifugation at 500 g for 8 min.
Cell pellets were washed with 10 cell pellet volumes (CPV) of TMSD + 0.1%
NP40 and incubated on ice for 5 min to allow for cell lysis to occur. An aliquot
of the cell suspension was mixed with Trypan Blue (Life Technologies, T10282)
to visually confirm cell lysis. Nuclei were collected by centrifugation for 10 min
at 1000 g. The supernatant (cytosolic fraction) was removed and the nuclei pellet
resuspended in 6 nuclei pellet volumes (NPV) of BC150 before slowly adding
approximately 3.5 NPV of BC1000 dropwise until the conductivity is equal to
420 mM KCl was obtained. This was then incubated at 4 ◦C with gentle rotation
for 1 h. After a 15 s vortex, the suspension was spun for 30 min at 25.000 g.
The supernatant was collected and KCl concentration determined as 300 mM
by conductivity (Mettler Toledo). ANTI-FLAG® M2 affinity agarose beads
(Sigma) were treated with 100 mM glycine, washed with 1 M HEPES pH 7.9,
and equilibrated with BC300 buffer. The treated anti-flag beads were added
to the supernatant and incubated for 2 h, after which they were collected by
centrifugation at 800 g. The anti-flag beads were washed twice with BC300 buffer
and then once with BC100 buffer. KAT6B was eluted using 3X FLAG® tag
peptide (Sigma) at a concentration of 0.3 µg µL−1 in 120 µl of BC100 Buffer for
1 h with gentle rotation. No dialysis was performed. The purified KAT6B was
frozen with liquid nitrogen and stored at −80 ◦C.
TMSD Buffer : 20 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 250 mM
sucrose, 0.5 mM DTT, 0.2 mM PMSF
BC420 Buffer : 20 mM HEPES pH 7.9, 420 mM KCl, 20% (w/v) glycerol, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
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BC300 Buffer : 20 mM HEPES pH 7.9, 300 mM KCl, 20% (w/v) glycerol, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
BC100 Buffer : 20 mM HEPES pH 7.9, 100 mM KCl, 20% (w/v) glycerol, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
2.5 Histone Acetyltransferase Assays
Recombinant nucleosomes were reconstituted as described below using plasmid
p177 DNA (see Fig. 2.1). Nucleosomes and KAT6B enzyme were combined in
HAT buffer. Reactions were initiated by the addition of 3H-acetyl coA (90 kBq;
Hartmann) and the reactions incubated at 30 ◦C for 2 h. Reactions were stopped
by boiling for 5 min at 95 ◦C with 3x SDS sample buffer before running on SDS
page gel, transferred to PVDF membrane and stained with coomassie. Activity
was imaged using Carestream® Kodak® BioMax® MS film (Sigma) and the signal
was amplified using Carestream® BioMax® Transcreen LE (Sigma). The films
were incubated with the PVDF membrane and transcreen at −80 ◦C for 24 h to
72 h, dependent upon signal strength, before developing.





























Figure 2.1 p177 Plasmid Map - Plasmid map of p177. The plasmid contains the pMB1
replicon rep, responsible for the replication of the plasmid, while the bla gene encodes for beta-
lactamase that confers resistance to amplicillin. An array of 12 X 601 209bp sequences are
cloned into the multiple cloning site (MCS) located in the lacz part of the lac operon from
E.coli. Each 601 sequence is separated by two enzyme restriction sites Eco52 and Not1 allowing
the digestion of the 12X array into individual 209bp sequences. The 601 array can be separated
from the vector by use of EcoRV enzyme restriction sites, spaced approximately 200-400bp
around the vector backbone.
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2.6 CRISPR
CRISPR is a technique that allows introduction of precise double strand breaks
of DNA at a specific genomic location (Cong et al., 2013; Gasiunas et al., 2012;
Martin Jinek et al., 2012; Sander and Joung, 2014). It is highly efficient and has
a relatively low number of off-target effects. The Cas9 nuclease combined with
a guide RNA, containing both crRNA and tracrRNA, allows targeting of the
Cas9 nuclease to cleave the complementary target-DNA sequence if adjacent to a
PAM (protospacer adjacent motif). DNA repair by NHEJ (non-homologous end
joining) lends itself to creation of insertion/deletions or indels, which can be used
to create knockout of genes, while HDR (homology directed repair) can generate
specific modifications at the target locus in the presence of a repair template.
Both strategies were used in creation of the desired specific cell lines.
To perform genome editing in E14 ES cells, sgRNAs specific to the gene of
interest were cloned into pX458 (addgene 48138, (Ran et al., 2013)). For
ease of description an example of CRISPR editing will be described (EZH2
KO), for further details about CRISPR strategy and primers used in specific
cases refer to the Table 2.5 and the Figure 6.1. For homology repair, single
stranded oligonucleotides were designed encoding the desired mutations flanked
by homology regions (synthesized by IDT, E14 mESCs were transfected with
pX458 plasmid (Ran et al., 2013) encoding a guide RNA targeting exon 7 of
the mouse Ezh2 gene (20-bp target sequence CAGCAGGAAATTTCCGAGGT),
along with a single-stranded DNA oligonucleotide for homology-directed repair
to introduce three consecutive stop codons at the 5’ end of exon 7 (resulting
sequence ATtAAtAAgCTTGatCACCTC, mutated bases in lower case). After
fluorescence-based sorting for GFP-positive transfected single cells, single cell
colonies were expanded, genotyped, and analysed for target expression by Western
Blot. Correct genotypes were confirmed by Sanger sequencing on PCR-amplified
genomic material.
2.6.1 Transfection and Flow Activated Cell Sorting (FACS)
Low passage number ESCs were used for CRISPR/gene editing. 400 000 cells were
plated in non-antibiotic containing media. 5 µl of Lipofectamine was added to
100 µl of OptiMEM while 1 µg of pX458 plasmid containing the desired construct
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was combined with 2 µl of 10 µM of single stranded oligodeoxoynucleotide
(ssODN) donor template in 100 µl OptiMEM. These solutions were combined,
incubated for 30 minutes and added to the freshly plated cells. The media was
changed 24 hours after transfection.
Forty-eight hours after transfection, the cells were trypsinised and passed
through a 70 µm cell strainer into FACS sorting media (basic cell culture media
supplemented with 0.1% FBS, 25 mM HEPEs, and 1.5% Pen/Strep). These cells
underwent FACS in FACS collection media (basic cell culture media supplemented
with 20% (v/v) FBS, 1.5% Pen/Strep and 25 mM HEPEs) with an argon laser
488 nm, 15 000 GFP+ cells were sorted for plating on a 15 cm in cell culture media
supplemented with 1.5% Pen/Step and 100 000 cells were sorted to confirm/check
transfection and PCR screening. GFP is co-expressed with Cas9 from pX458 as
a 2A fusion.
One week after plating single cell colonies were picked manually by dislodging
and aspirating colonies, separated by trypsin and plated on duplicate 96-well
plates. Allowing one plate for genotyping and one for maintenance of cell lines.
After 2 days to 3 days growth single cell colonies from the genotype plate were
screened by PCR and sequenced before verification by Western blot. Initial PCR
verification uses primers one of which anneals to the genomic sequence adjacent
to the targeted sequence and one which recognised the homology repair template
see Figure 6.1. PCR positive cell lines were sequenced across the entire target
sequence to check for indels, missense mutations and correct homology directed
recombination. The protein expression levels of cell lines with the correct repaired
DNA sequence were confirmed by western blot analysis. All verified cell lines were
frozen and kept in liquid nitrogen storage.
2.7 Western Blot
Protein samples were prepared by boiling protein at an appropriate concentration
at 95 ◦C for 5 min in SDS sample buffer before loading on an 1.5 mm acrylamide
gel of an appropriate percentage. Gels were run at 120 V through the stacking
gel and then 200 V for the separation gel. SDS-PAGE gels were transferred
to nitrocellulose membrane (Biorad), via the semi-dry Trans-blot turbo transfer
system (Biorad), and blocked with 5% milk in TBST for 1 h before incubation
with primary antibody in 2% BSA in TBST overnight. Membranes were then
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washed 3 x 5 min in TBST and incubated with 1:5000 dilution of HRP conjugated
secondary antibody in 2% BSA in TBST for one hour. Membranes were washed 3
x 5 min in TBST and developed with Clarity ECL reagents (Biorad) and imaged
with Chemidoc MP imaging system (Biorad).
TBST : 20 mM TRIS-HCl pH 7.6, 137 mM NaCI, 0.1% Tween 20
3XSDS Sample buffer: 190 mM Tris-HCl, 30% (w/v) glycerol, 6%SDS, 150 mM
DTT, 0.3% bromophenol blue.
2.8 Chromatin Immunoprecipitation (ChIP)
Fixation Buffer : 10 mM HEPES pH 7.6, 15 mM NaCl, 1% formaldehyde, 0.15 mM
EDTA, 0.075 mM EGTA in DMEM (Gibco 41965-039)
Lysis Buffer 1 : 50 mM HEPES pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% (w/v)
glycerol, 0.5% (v/v)Igepal, 0.25% (v/v) Triton-X
Lysis Buffer 2 : 10 mM Tris-HCl pH 8.0,200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA
Lysis Buffer 3 : 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 0.5%
N-lauryl sarcosine
TE Buffer : 10 mM Tris pH8, 1 mM EDTA
2XIP Buffer : 300 mM NaCI, 2%(v/v) Triton X-100 in TE buffer
RIPA Buffer : 10 mM HEPEs pH 7.6, 1 mM EDTA, 500 mM LiCI, 1% (v/v)
NP-40, 0.1% N-lauroyl Sarcosine
TEN Buffer : 10 mM NaCl in TE buffer.
Elution Buffer : 100 mM NaHCO3, 1% SDS, 200 mM NaCI,0.4 µg µg−1 Proteinase
K, 0.4 µg µg−1 RNAse A
2.8.1 Chromatin Preparation
For chromatin immunoprecipitation cells were grown as described above, approxi-
mately 130 million of cells were grown on four 15 cm plates coated with 0.1% (v/v)
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gelatin. Media was removed and 15 ml of Fixation Buffer was added per plate for
10 min at RT (room temperature 25 ◦C) with gentle rocking. Fixation was stopped
by quenching with 2.5 M glycine at 0.125 M final concentration for 3 min at RT
with gentle rocking. Fixation buffer was removed, cells were washed with 10 mL
cold PBS, and 3 mL more cold PBS was added. Cells were scraped off the plate
and centrifuged at 2500 g for 5 min at 4 ◦C and the supernatant removed. Cell
pellets were weighed, snap frozen in LN2 and stored at −80 ◦C. All subsequent
steps were performed at 4 ◦C. The cell pellets were thawed and resuspended in
Lysis Buffer 1 to obtain a suspension of 75 µg ml−1 and placed on a rotator for
10 min. Cells were centrifuged at 3000 g for 5 min and the supernatant removed
before resuspending in Lysis Buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1
mM EDTA, 0.5 mM EGTA) to the same volume as used for Lysis Buffer 1. These
samples were rotated for 10 min and then centrifuged at 3000 g for 5 min before
removing the supernatant. Pellets were resuspended in Lysis Buffer 2 to obtain
75 µg ml−1. The suspension was transferred to polystyrene tubes (BD Falcon, cat:
352099) and sonicated using a Bioruptor (Diagenode) at maximal output using
30 s ON, 30 s OFF cycles. Number of cycles was experimentally determined to
yield 1.5 kb sized fragments of cross-linked DNA - approximately 250-300 bp
when decrosslinked. The size of the DNA fragment was confirmed by 1% agarose
gel analysis. A sample was decrosslinked overnight, purified and analysed on
high sensitivity DNA chip in a 2100 Agilent bioanalyser - as below. Sonicated
suspensions were centrifuged at 20.000 g for 10 min. DNA concentration was
determined by Nanodrop ND-1000 (Thermo Fisher Scientific) and aliquots were
snap frozen in LN.
2.8.2 Immunoprecipitation
Crosslinked chromatin was thawed and spun at 25.000 g for 10 min. The thawed
chromatin is combined with an equal volume of 2XIP buffer, 10% by volume of
each ChIP is removed for an input sample and stored at −20 ◦C. The desired
antibody is added, mixed and incubated at 4 ◦C rotating overnight. Protein A
(10002D) and Protein G (10004D) beads are prepared separately and all spins
are at 800 g for 30 s at 4 ◦C. Beads are washed 2x in 1 ml PBS (supplemented
with 0.5% (w/v) BSA) and then blocked with 1 ml PBS (supplemented with 0.5%
(w/v) BSA) overnight.
The blocked beads are washed five times with 1 mL TE buffer and resuspended in
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TE buffer. The ChIP samples are spun at full speed at 10 min and the supernatant
of sample is added to 50 µl of bead suspension. The samples are incubated on the
rotatory machine for 2 h to 4 h. Beads are washed 5 X with 1 ml of ChIP RIPA
buffer for 2 min. Beads are transferred to a new eppendorf tube and washed with
TEN buffer. 200 µl of elution buffer is added to the beads and thawed input
sample. These are incubated in a thermocycler at 800 rpm at 37 ◦C for 1 h and
left at 65 ◦C overnight to decrosslink.
Samples are collected by centrifugation and the supernatants were used for
subsequent steps. The decrosslinked DNA is purified with NEB monarch Kit
following manufacturer’s instructions and eluted in 50 µl of elution buffer. The
ChIP samples were analysed by qPCR and excess eluted DNA was stored at
−20 ◦C.
2.8.3 qPCR
Eluted DNA was diluted 1:30 before use in qPCR experiments. qPCR experi-
ments were carried out on a Lightycler 480 (Roche) using a 10 µl reaction volume
with 2 µl of DNA, 5 µM primers and 1x SyGreen Blue Mix (PCRBiosystems).
Enrichments were calculated as percentage of Input.
Antibody Company Catalogue No. µl µg−1(antibody/chromatin)
H3K4me3 CST C42D8 4 µL/40 µg
H3K27me3 CST C36B11 4 µL/40 µg
H3K23ac Abcam AB177275 2 µL/40 µg
H3K14ac Abcam AB52946 4 µL/40 µg
HA-tag CST C3724 4 µL/200 µg
Table 2.7 Antibodies used in ChIP Experiments
2.9 Expression and purification of histones
Xenopus H3 and H4 and human H2A and H2B were expressed from pET-3a or
pET-3d vectors in BL21 (DE3) pLysS for H3, H2A, and H2B or BL21 (DE3) for
H4 through induction with 0.2 mM IPTG for 4 h at 37 ◦C. Histones were purified
from inclusion bodies and solubilised in unfolding buffer. Extracted histones were
dialysed against three changes of urea dialysis buffer, this and all subsequent
histone dialysis steps were carried out at 4 ◦C, and then purified further by
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passing over a HiTrap Q column (GE Healthcare) before binding to and NaCl
gradient elution from HiTrap SP cation exchange chromatography columns (GE
Healthcare). The progression and quality of the purification was continuously
evaluated by measuring the absorbance of the solution at 280 nm (A280) and 260
nm (A260) as demonstrated in the chromatogram (see Fig. 3.6). The sample’s
A280 can be used in conjunction with Beer’s law and the known histone sequence
to calculate the protein concentration, this was combined with Bradford assays
to estimate protein concentrations. Fractions containing histones were pooled
and dialysed three times against water containing 5 mM β–me and lyophilised for
long-term storage at −80 ◦C.
To express histones for native chemical ligation (NCL), constructs encoding
truncated Xenopus histone H3 were generated in pET-3a. For generation of
H3K4me3-modified histones, truncated H3 lacking residues 1-31 after the initiator
methionine, with a threonine-to-cysteine substitution at position 32 of Xenopus
H3 and a cysteine-to-alanine substitution at position 110 (H3∆1–31 MT32C
C110A) was expressed in BL21 (DE3) pLysS and purified as above, except for the
final dialysis, which was carried out as two rounds of dialysis against 1 mM DTT
in H2O and one round against 0.5 mM TCEP before lyophilisation and storage.
For generation of H3K27me3-modified histones, a similarly truncated Xenopus H3
construct was used, either lacking the first 44 or the first 32 residues and carrying a
threonine-to-cysteine mutation at residue 45 (H3∆1–45 MT45C C110A or H3∆1–
32 MT32C C110A) For the mass spectrometry experiments H3∆1–32 MT32C
C110A was used, for all other experiments including nucleosome titrations H3∆1–
45 MT45C C110A was used .
Urea Dialysis Buffer : 10 mM Tris HCl pH 8, 7 M urea, 100 mM NaCl, 1 mM
EDTA, 5 mM β–me
2.9.1 Generation of Modified Histones by Native Chemical
Ligation (NCL)
8 mg of purified truncated histone is dissolved in 150 µl of Methoxyamine buffer
and incubated at 25 ◦C ovenight which helps resolve any N-terminal adducts that
may have formed during its expression in E.coli, masking the N-terminal cysteine
and preventing the ligation reaction. The treated truncated histone is dialysed
against the NCL buffer for 1 hour at 4 ◦C. After dialysis 6 µL of 0.5 M TCEP is
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added and 5 M NaOH added to keep the pH of the solution at pH6.5. 2 mg of
the modified peptide is resuspended in 100 µL of NCL buffer containing 200 mM
mercaptophenylacetic acid (MPPA) and combined with the dialysed histone.
This is incubated for 72 h at room temperature with constant agitation with 3 µl
of 0.5 M TCEP being added after 24 h. Reactions were then dialysed three times
against urea dialysis buffer (see above, but with 1 mM DTT instead of 5 mM
beta-mercaptoethanol). Ligated full-length modified histones were separated
from unligated histone through cation exchange chromatography on a HiTrap
SP column (GE) and then dialysed against three changes of water containing
5 mM beta-mercaptoethanol before lyophilization and storage at −80 ◦C until
use. For H3K4me3-modified histone, H3∆1–31 MT32C C110A was reacted with a
synthetic peptide spanning residues 1–31 of histone H3.1 containing trimethylated
lysine at position 4 and a C-terminal benzyl thioester (Peptide Protein Research
Ltd., Fareham, UK). For H3K27me3-modified histones, H3∆1–44 MT45C C110A
was reacted with a synthetic peptide spanning H3.1 residues 1–44 including
trimethylated lysine at position 27 and a C-terminal benzyl thioester.
Methyoxyamine Buffer : 6 M Guanidine HCl, 200 mM Methoxyamine, 20 mM
TCEP.
Native Chemical Ligation (NCL) Buffer : 6 M Guanidine HCl, 250 mM sodium
phosphate buffer pH 7.2, 150 mM 4-mercaptophenylacetic acid (MPAA), 50 mM
TCEP
2.9.2 Reconstitution of Recombinant Nucleosomes
To reconstitute histone octamers, the four core histones were resuspended in un-
folding buffer (see above), mixed in a mass ratio of 1:1:1.2:1.2 (H3:H4:H2A:H2B),
and dialysed against three changes of refolding buffer at 4 ◦C. After centrifu-
gation to remove precipitate formed during dialysis, correctly assembled histone
octamers were purified by size exclusion chromatography in refolding buffer on a
S200 column (GE Healthcare), using an Akta PURE system (GE Healthcare).
Asymmetrically modified octamers required further purification; the different
copies of H3 incorporated into asymmetric octamers were differentially tagged
with either His or Strep tag. Affinity chromatography was performed on the
combined fractions from the S200 containing the required asymmetric protein
complexes by first using a Ni-sepharose column (GE) and then a Streptactin
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column (GE). Proteins were eluted from the Ni-sepharose column with a
gradient (0 mM to 250 mM) of imidazole in elution buffer (2 M NaCl, 25 mM
Tris-HCl pH 8). Elution fractions containing His/Strep- and His/His-tagged
histone H3-H4 tetramers were combined and loaded onto a HiTrap Streptavidin
HP column (GE). Proteins were eluted in elution buffer containing 2.5 mM
desthiobiotin. After each chromatography step, elution profiles and sample purity
were confirmed by Western blot.
Refolding Buffer : 10 mM Tris HCl pH 8, 2 M NaCl, 1 mM EDTA, 5 mM β–me.
Unfolding Buffer : 20 mM Tris-HCl pH 7.5, 7 M guanidine HCl, 10 mM DTT
2.9.3 Generation of 601 DNA
DNA template for mononucleosome assembly was generated by PCR with a
biotinylated forward primer, amplifying a 209-bp fragment centered around the
147-bp 601 nucleosome positioning sequence, followed by PCR purification and
elution into TE buffer. To reconstitute recombinant mononucleosomes, DNA and
histone octamers were combined in refolding buffer supplemented with 5 M NaCl
to compensate for reduction in NaCl concentration due to introduction of TE
buffer with the DNA, followed by gradient dialysis against TE buffer down to
400 mM NaCl and then a step dialysis against TE buffer at 4 ◦C. Optimal ratios
of DNA and histone octamer were determined so that at least 95% of DNA was
complexed, but without over-assembly and unspecific DNA binding of histones.
Assemblies were routinely checked by native gel electrophoresis on 6% acrylamide
gels in TGE buffer.
TGE buffer: 12.5 mMTris HCl pH8 , 96 mM Glycine, 0.5 mM
2.10 Pulldowns
For pulldown assays with recombinant modified nucleosomes and E14 ES cell
NE, streptavidin sepharose high performance beads (GE Healthcare, 10.5µl of
slurry per pulldown) were briefly washed three times with pulldown buffer. All
centrifugation steps were carried out at 1500 g for 2 min at 4 ◦C. All incubation
steps were carried out at 4 ◦C. After washes, beads were incubated overnight
with 10.5 µg of assembled recombinant nucleosomes (in TE buffer diluted with
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pulldown buffer and adjusted to a final concentration of 0.1% NP-40 and 150 mM
NaCl by addition of 10% NP-40 and 5 M NaCl, respectively) with constant
rotation in the cold room. For pulldown titrations with increasing amounts
of recombinant nucleosomes, nucleosomes were assembled in 4 batches of 10 µg
each, combined, and incubated with beads in the amounts given in the Figure
5.4 and Figure 5.5. The amount of beads used was scaled with the amount of
nucleosomes (1 µl slurry per 1 µg of nucleosomes). Beads were then collected by
centrifugation and washed briefly with three changes of pulldown buffer. Bead-
bound nucleosomes were incubated with 500 µg of NE for 2 h under constant
agitation in the cold room. Beads were then washed with pulldown buffer by 5 min
incubations under rotation first with two washes of pulldown buffer containing
NP-40 followed by three washes of pulldown buffer without NP-40. After washes,
bound proteins were eluted from the beads.
For Western Blot analysis, elution was performed by boiling for 5 min at 95 ◦C
with 1.5x SDS sample buffer (95 mM Tris HCl pH 6.8, 15% (w/v) glycerol, 3%
SDS, 75 mM DTT, 0.15% bromophenol blue). 30% of bound sample was loaded
for western blot analysis.
Pulldown Buffer : 20 mM HEPES KOH pH 7.9, 150 mM NaCl, 10% (w/v)
glycerol, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF, 0.1% (v/v) NP-40
2.11 Mass Spectrometry Analysis and Sample
Preparation
2.11.1 Preparation of Protein Samples for Mass
Spectrometry
For analysis of pulldown samples by LC-MS/MS, beads were resuspended in
elution buffer (2 M Urea, 100 mM Tris pH7.5, 10 mM DTT ) and incubated for 20
min on a shaker. All shaker steps were carried out at 1,000 rpm at RT (25 ◦C).
After incubation Iodoacetamide was added to a final concentration of 55 mM
and incubated for 10 min on the shaker. The eluted proteins were digested with
0.3 µg of trypsin for 2 h whilst shaking and then spun at 1500 g for 2 min. The
supernatant was removed and 50 µl of elution buffer incubated with the beads
for 5 min on the shaker. The beads were spun for 2 min at 1500 g and the two
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supernatant elutions combined. 0.15 µg of trypsin were added and the solution
was digested overnight at RT before digestion was stopped by the addition of 10%
TFA. Following digestion, half of each sample was diluted with an equal volume
of 0.1% TFA and spun onto StageTips as described by (Rappsilber et al., 2003).
Peptides were eluted in 40 µl of 80% acetonitrile in 0.1% TFA and concentrated
down to 1 µl by vacuum centrifugation (Concentrator 5301, Eppendorf, UK).
Samples were then prepared for LC-MS/MS analysis by diluting them to 6 µl
with 0.1% TFA.
Purified KAT6B complexes were boiled at 95 ◦C in 4X NuPAGE LDS Sample
buffer (Invitrogen) and 5% of 1 M DTT for 5 min before running on a NuPAGE
4-12% Bis-Tris Protein Gel (Invitrogen) at 200 V with MOPS buffer (Invitrogen)
for 5 min. Gels were washed three times with deionized water for 5 min and
visualised using Imperial protein stain (Sigma-Aldrich, UK) for 1 h. Gels were
washed again three times with deionized water for 5 min each to remove excess
stain.
Gel bands were excised and de-stained with 50mM ammonium bicarbonate
(Sigma Aldrich, UK) and 100% (v/v) acetonitrile (Sigma Aldrich, UK) and
proteins were digested with trypsin, as previously described (Shevchenko et al.,
1996). Briefly, proteins were reduced in 10 mM dithiothreitol (Sigma Aldrich,
UK) for 30 min at 37 ◦C and alkylated in 55 mM iodoacetamide (Sigma Aldrich,
UK) for 20 min at ambient temperature in the dark. They were then digested
overnight at 37 ◦C with 12.5 ng µl−1 ￿L-1 trypsin (Pierce, UK).
2.11.2 Mass Spectrometry Parameters and Analysis
LC-MS-analyses were performed on a Q Exactive mass spectrometer (Thermo
Fisher Scientific, UK) (for samples that were digested on beads) and on Orbitrap
Fusion™ Lumos™ Tribrid™ Mass Spectrometer (Thermo Fisher Scientific, UK)
(for samples that were subjected to in-gel digestion) both coupled on-line to
Ultimate 3000 RSLCnano Systems (Dionex, Thermo Fisher Scientific, UK).
Peptides were separated on a 50 cm EASY-Spray column (Thermo Scientific,
UK) assembled in an EASY-Spray source (Thermo Scientific, UK) and operated
at 50 ◦C. In both cases, mobile phase A consisted of 0.1% formic acid in water
while mobile phase B consisted of 80% acetonitrile and 0.1% formic acid. Peptides
were loaded onto the column at a flow rate of 0.3 µl/min and eluted at a flow rate
of 0.25 µl/min according to the following gradient: 2 to 40% buffer B in 150 min,
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then to 95% in 11 min. For Q Exactive, FTMS spectra were recorded at 70,000
resolution (scan range 350-1400 m/z) and the ten most intense peaks with charge
geq2 of the MS scan were selected with an isolation window of 2.0 Thomson for
MS2 (filling 1.0E6 ions for MS scan, 5.0E4 ions for MS2, maximum fill time 60 ms,
dynamic exclusion for 50 s). For Orbitrap Fusion™ Lumos™, survey scans were
performed at 120,000 resolution (scan range 350-1400 m/z) with an ion target of
4.0e5. MS2 was performed in the ion trap at a rapid scan rate with ion target
of 2.0E4 and HCD fragmentation (Olsen et al., 2007) with normalized collision
energy of 27. The isolation window in the quadrupole was 1.4. Only ions with
charge between 2 and 7 were selected for MS2.
2.11.3 Visualisation of Mass Spectrometry Data
The MaxQuant software platform (Cox and Mann, 2008) version 1.6.1.0 was
used to process raw files and searches were conducted against the Mus musculus
reference proteome (Uniprot, released in July, 2017), using the Andromeda search
engine (Cox et al., 2011). The first search peptide tolerance was set to 20 ppm
while the main search peptide tolerance was set to 4.5 pm. Isotope mass tolerance
was 2 ppm and maximum charge to 7. A maximum of two missed cleavages
was allowed. Carbamidomethylation of cysteine was set as fixed modification.
Oxidation of methionine and acetylation of the N-terminal were set as variable
modifications. Label-free quantitation analysis was performed by employing
the MaxLFQ algorithm as described by Cox et al., 2014. Peptide and protein
identifications were filtered to 1% FDR.
Data was analysed and visualised in Perseus (version 1.6.5.0) (Tyanova et al.,
2016). Data was filtered to remove proteins identified with less than 3 peptides,
false positives and potential contaminants before missing values were filtered to
retain only proteins quantified in at least two replicates across all nucleosome
pulldown conditions and replicates analysed. Proteins were considered enriched
in a condition if their Log2 fold change was greater than 1.5 – approximately a 3
fold enrichment - and their p-value was lower than 0.01.
Data was analysed and visualised in R version 3.5.3. DEP 1.4.1 package (Zhang
et al., 2018) was used to determine differential enrichment of proteins between nu-
cleosome pulldowns. Data was filtered on reverse hits and potential contaminants,
before missing values were filtered to retain only proteins quantified in at least
two replicates across all nucleosome pulldown conditions and replicates analysed.
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The data was normalized using vsn, and imputation was carried out using the
MinProb function in DEP. Proteins were considered differentially enriched when
the log2 fold change was greater than 1.5, and the p-value was lower than
0.01. Single protein bar plots were generated in DEP using the Shiny package.
Volcano plots were generated in ggplot2. Proteins that were significantly altered
(FDR=0.01, pvalue=0.05 and fold change ≥ 3) bound to the bivalent nucleosome
in comparison to one of the other modified nucleosomes were visualised via a
heatmap. Hierarchical clustering was performed by the Multiple Experiment
Viewer tool (MeV), the Pearson correlation metric and average linkage clustering
as linkage method.
2.12 Neuronal Differentiation Assays
Neuronal differentiation was performed following the protocol described by (Bibel
et al., 2007). Embryoid body formation was induced by removal of LIF, on day 0
ES cells were plated onto non-adherent 10 cm bacterial plates (Greiner) in 10 ml
EB medium (basic cell culture media without LIF and with FBS reduced to 10%)
at a density of 4 × 106 cells per 10-cm plate. Embryoid bodies began to form after
one day. On day 2 the media was changed by gently transferring to a 15 ml falcon
tube, allowing EBs to settle for 5 min then aspirating the supernatant. 13 ml of
fresh media was then added to EBs before gently resuspending and transferring
them to a fresh plate using a 5 ml serological pipette (Sarstedt). On day 4 media
was changed and increased to 15 ml of EB medium containing 10 ￿M all-trans
retinoic acid (Sigma). On day 6, media was changed again maintaining the same
volume of EB medium + retinoic acid. On day 8 the EBs were transferred to
a 50 ml falcon tube (pooling 2 plates per tube) and EBs were allowed to settle
for 5 min before aspirating the supernatant. EBs were then washed 3 x in 20 ml
PBS allowing EBs to settle between each wash. Trypsin (Sigma) was prepared at
0.5 µg µl−1 in 0.05% v/v EDTA/PBS. After the final wash EBs were trypsinised
in 1 ml trypsin per 50 ml falcon, for approximately 3 min at 37 ◦C with agitation
and then quenched in 10 ml EB medium. Cells were then centrifuged for 5 min at
300 g, resuspended in 10 ml EB medium and passed through a 40 µm cell strainer
to remove clumped cells and undigested EBs. Cells were then counted, centrifuged
again at 300 g for 5 min and resuspended in Advanced DMEM/F12 (Gibco) with
1x N2 supplement (Gibco) before being plated onto poly-D-lysine (Sigma) and
laminin (Sigma) coated 6 cm dishes at a density of 3x106 cells/plate. On day 9
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half the medium was replaced with Neurobasal medium (Gibco) containing 1x
B27 supplement (Gibco), this was repeated on day 12.
2.13 RNA preparation and qRT-PCR
BTE Buffer : 10 mM bis-tris pH6.7, 1 mM EDTA
Cells were resuspended in 1ml TriPure isolation reagent (Sigma) per 10 cm plate
(or per 2 x 6 cm plate for plated NPCs) and RNA extracted by isopropanol
precipitation. The resulting pellet was resuspended in 44 µl BTE buffer before
treating with Turbo DNAse (Thermo Fisher) for 30 min at 37 ◦C. 1 ml TriPure
was then added and isopropanol precipitation repeated before resuspending the
final RNA pellet in 50 µl BTE. Concentration was then measured on a Nanodrop
and the quality of RNA samples further assessed using RNA 6000 Nano chip on
an Agilent Bioanalyser. Samples were stored at −80 ◦C.
cDNA samples were prepared from starting material of 1 µg RNA to which was
added 2.5 µM oligodT and 0.5 mM dNTP mix. Samples were incubated at 65 ◦C
for 5 min to anneal primers to the RNA then returned to ice. To the annealed
RNA/primer solution was added 1 µL SuperScript IV reverse transcriptase and
4 µL 5X Superscript IV buffer with RNAase inhibitor and 100 µM DTT. Samples
were transferred to thermocycler for 10 min each at 42 ◦C, 50 ◦C, 55 ◦C and 80 ◦C
in succession. The resulting cDNA samples were then diluted at least 1/30 in
water before being used in qPCR experiments and stored at −20 ◦C.
2.13.1 qRT-PCR
qRT-PCR experiments were carried out on a Lightycler 480 (Roche) using a
10 µl reaction volume with 2 µl of DNA, 5 µM primers and 1x SyGreen Blue Mix
(PCRBiosystems). Results were analysed using the 2-DDCT method with Gapdh
as the reference gene.
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2.14 Immunofluorescence Analysis
Cells were grown on 16 mm glass coverslips in 12 well plates. In preparation
for plating coverslips were soaked overnight in ethanol before drying and washing
twice in PBS before coating. Coverslips for mESCs were coated with 0.1% gelatin,
coverslips for neuronal cells were coated with PDL and lamin. Before fixation,
cells were washed 3 x 10 min in PBS, and then fixed with 4% PFA for 20 min.
To carry out immunofluorescence, the cells fixed on coverslips were blocked in
10% donkey serum (Sigma) in 0.1% Triton X-100 for 1 h and incubated o/n with
primary antibodies at 4 ◦C. The following day, cells were incubated with Alexa
fluor secondary antibodies (Invitrogen) at a dilution of 1:1000 in 1% donkey serum
in 0.1% Triton X-100 for 1 h at room temperature in the dark. The cells were
then washed 3x with PBS for 10 min. Nuclei were counterstained with 50 nM
DAPI for 5 min, and washed 2x 10 min PBS before being mounted on slides using
vectashield. Imaging was carried out using a Zeiss Axio imager with 40x objective.
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Chapter 3




The aim of this study is to elucidate the biological function of bivalent domains.
We hypothesise that the proteins that bind to bivalent domains mediate its
function. Identification of these proteins will help to elucidate the biological
role of bivalency. An in vitro approach was chosen to investigate bivalent domain
function due to its ability to remove the complicating factors present in vivo. In
order to investigate which proteins bind to bivalent domains in vitro, a reliable
method of creating purified specifically modified nucleosomes is required. Once
this has been established, proteins binding bivalently modified nucleosomes can
be compared against those bound to differently modified (control) nucleosomes -
detailed in later chapters. Thus the function of each of these modified nucleosomes
can been seen by virtue of the proteins that bind them; therefore insight can be
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Nucleosome or octamer containing
unmodified untagged histone H3s.
Nucleosome or octamer containing
tagged unmodified histone H3s 
His/Strep tagged.
Nucleosome or octamer symmetrically
modified with H3K4me3.
Nucleosome or octamer symmetrically
modified with H3K27me3.
Nucleosome or octamer containing 
H3K4me3-His  and unmodified 
H3-Strep. 
Nucleosome or octamer containing
H3K27me3-His and unmodified
H3-Strep. 
Nucleosome or octamer containing
H3K27me3-Strep and 
H3K4me3-His.
Nucleosome or octamer containing 
H3K4me3-Strep and 
tailless H3-His.
Nucleosome or octamer containing
H3K27me3-Strep  and 
tailless H3-His.
Figure 3.1 Steps Required for Histone Purification and Nucleosome Assembly
A) Flowchart giving an overview of the experimental steps required to purify histones and
create specifically modified nucleosomes. The potential optimisation steps for each experimental
technique are detailed to the left. B) Notations and detailed explanations for the octamers and
nucleosomes used in this thesis.
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3.2 Aims
The aim of this chapter is to detail the development and establishment of
the generation of specifically modified nucleosomes, both symmetrically and
asymmetrically modified. These will be used to investigate how the presence
of certain modifications effects the presence of proteins bound. This will allow
analysis of the proteins bound to bivalent asymmetric nucleosomes and therefore
insight into their function. In order to use an in vitro approach recombinant
bivalent asymmetric nucleosomes including controls need to be generated (see
Fig. 3.1 ). To produce specifically modified nucleosomes there are a number of
steps required - detailed in Figure 3.1 - including histone expression, modification,
octamer assembly and nucleosome reconstitution. Each of these steps requires
establishment and optimisation which will be detailed in this chapter using
various core histones as examples. This chapter will focus on the establishment
and optimisation of the techniques required for modification and purification of
histones, and reconstitution of nucleosomes is demonstrated.
3.3 Histone Expression and Purification
To generate modified nucleosomes, the four core histones needed to be expressed
along with the histone constructs required for the generation of modified histones.
Xenopus laevis histone sequences were used for histones H3 and H4 because Mus
musculus and Xenopus laevis histones H4 and H3.1 are 100% identical. The
expression of Xenopus Laevis histones for use in biochemical assays has long
been established (Luger et al., 1999a; Luger et al., 1997a; Dyer et al., 2004) and
does not necessitate further codon adaption. Human H2A and H2B sequences
were used as they are identical to mouse while the Xenopus laevis H2A and H2B
sequences vary considerably - 94% sequence identity.
The histone constructs were expressed in bacterial cultures and the effect of
different E. coli strains on protein expression levels was tested (see Fig. 3.2).
BL21 strains are deficient in Lon protease (cytoplasm) and OmpT protease
(outer membrane) and are thus more amenable to production of protein from
the transformed/inserted plasmid. DE3 bacteria contain the ￿DE3 lysogen that
carries the gene for T7 RNA polymerase under control of the lacUV5 promoter.
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Figure 3.2 Expression and solubility test of truncated H3 and core histones. A)
i) SDS-PAGE analysis of expression tests of tagged H3-His in both BL21 (DE3) and BL21
(DE3) (PLYS) E.coli. H3-His expression is toxic to BL21, the yield is better from BL21 (DE3)
(PLYS) as there is tighter control of expression and therefore better survival rate. Truncated
and core histone expression upon induction of protein production by the addition of IPTG is
shown. UI – uninduced, ID - induced. ii) Solubility test of tagged histone H3 (H3-Strep) and
H2A supernatant and pellet - containing bacterial inclusion bodies.
the addition of IPTG. PLYS strains contain a pLYS plasmid which produces T7
lysozyme which degrades T7 polymerase. This reduces background expression
of the recombinant gene under the T7 promoter but does not affect protein
expression induced by the addition of IPTG. PLYS therefore allows for tight
control of target gene expression which is useful when expressing proteins which
are toxic to the bacteria. The pLYS plasmid also contains a chloramphenicol
resistance gene, the addition of chloramphenicol to the overnight culture ensures
that BL21 DE3 pLYS strain retains the PLYS plasmid. All the core histones
were expressed and mostly secluded in inclusion bodies by BL21 strains, although
histone H4 was more soluble and thus yielded a lower amount of protein from the
inclusion body purification.
There are two main and well-established ways of generating modified histone H3,
through native chemical ligation (NCL) which generates modified histones with
a cysteine point mutation or through alklyation chemistry which generates a
methyl-lysine analogue (MLAs) (see Fig. 3.7). The NCL method was chosen
to create modified histones due to MLAs not giving satisfactory results (see
Chapter 4). The NCL method relies on ligation between a truncated histone
with an N-terminal cysteine and a N-terminal tail peptide thioester carrying the
modification of interest. In order to produce specifically modified histones via
the NCL method, H3∆1-31T32C truncated histones are expressed and purified,
before ligation to a modified H3 N-terminal tail peptide resulting in histone H3
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with a threonine to cysteine mutation at residue 32 (T32C). The T32C mutation
is not expected to disrupt nucleosome structure as residue threonine 32 is well
outside the globular domain of the nucleosome (Luger et al., 1997a), additionally
Thr32 is not well conserved in eukaryotes (Wells and Brown, 1991).
To allow purification of asymmetrically modified octamers, constructs containing
a C-terminally tagged (either with His or Strep) truncated H3 were cloned. The
truncated histones are tagged via their C-terminus to reduce the likelihood of
the tag affecting proteins binding to the H3’s N-terminal tail. Tagged histones
assemble into octamers and nucleosomes indicating that the tag’s presence does
not affect their assembly with other histones (see Fig. 3.9 & Fig. 3.11).
Truncated H3 expression constructs from the lab of Till Bartke (Bartke et al.,
2010) were expressed in bacterial cultures (Fig. 3.3). The plasmid containing
these histone constructs contains a start codon followed by a modified TEV
cleavage site (ENLYFQ↓C) followed by the H3.1 sequence starting from glycine
33 (Fig. 3.3). The presence and cleavage of the TEV protease site is to help
expose the cysteine in front of the histone core sequence in E. coli required
for NCL. The desired outcome is a fully cleaved truncated histone H3 peptide,
with an exposed N-terminal cysteine, ready for purification by size exclusion and
ion affinity chromatography. However, these constructs were not fully cleaved
by the TEV protease (expressed from the same plasmid pET28a under the
control of a AraC/PBAD-promoter) in the bacteria (Fig. 3.4). The cleavage of
these truncated histones was optimised by testing a range of different arabinose
concentrations. As the TEV protease is under the control of the PBAD, the
expression of the TEV protease is induced by the addition of arabinose. The
higher the amount of arabinose the more TEV protease is expressed. However,
even at high concentrations of arabinose cleavage at the TEV cleavage site was
still incomplete (Fig. 3.4). All histones expressed and purified are detailed in
Figure 3.3.
As a result of the incomplete cleavage of these constructs, in order to maximise
yield of the differently tagged truncated H3 we decided to generate the truncated
histone by relying on bacterial cleavage of the initiator methionine followed
directly by the T32C mutation or T45C mutation - if the truncated histone
is destined for H3K27me3 (Fig. 3.2). The T45C mutation and truncation site
was chosen for the creation of H3K27me3 histones as this places the site of the
mutation further away from the site of modification reducing the likelihood that































Figure 3.3 Plasmid map and table of expressed histones. A) Plasmid map
of pET28a(+)-AraC-PBAD-His6TEV/pro-H3.1∆1-31T32C obtained from Till Bartke’s lab
containing Tev cleavage site H3.1∆1-31 T32C,and the His tagged Tev protease. B) Table
of all the expressed histones and the species their sequence comes from.
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Figure 3.4 Optimisation of the Yield of H3 T32C Cleaved Histones A) Solubility
test of tagged histone H3 (H3-His H3-Strep) used for asymmetric histone octamer formation
and H4 supernatant and pellet - containing bacterial inclusion bodies. B) Optimisation of TEV
protease cleavage of the expressed histone. A range (0–1% (w/v) ) of arabinose was added to
optimise cleavage of the histone. Arabinose was added once (at the 0 h timepoint) or twice (3 h
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H3 T32C - adduct?
Figure 3.5 Initiator Methionine Residue Cleavage. Spectrum for theoretical mass
charge ratio of the truncated histone protein and the actual spectra of the truncated histones
purified from the E.coli culture. The initial spectrum is obtained from the purified T32C
truncated histone with the peaks identities labelled. There are two main peaks, the first is
of the truncated histone H3 T32C protein and the second peak is prominent suggesting the
presence of a truncated histone adduct. The second spectrum is the theoretical spectra of the
truncated histone H3 T32C with cleaved methionine and no adduct. The third is the spectrum of
the purified truncated histone H3 T32C in the presence of methoxylamine hydrochloride having
resolved the adduct.
generated and successful expression of all of the histones was confirmed (Fig.
3.2). The initiator methionine was cleaved for all truncated H3 histones and
consequently these constructs could be used for NCL reactions and the TEV
cleavage approach could be abandoned (see Fig. 3.5).
After inclusion body purification (as described in materials and methods),
although relatively pure, the histones were further purified by tandem ion
exchange in a urea-based buffer (Fig. 3.6). Further histone purification will
be illustrated using H2B as an example. Ion exchange chromatography is used
to separate histone proteins from other proteins present in the solution. The
anion exchange column removes proteins with a negative net charge resulting in
a solution that contains only positively charged proteins. This is further purified
by running the flow-through through the cation exchange column which binds
overall positively charged proteins. Histones have a net positive charge, largely
due to their positively charged tail, this allows them to bind to the negatively
charged resin of the cation exchange column - stationary phase. After the proteins
are bound, a 0.1 M to 1 M NaCl gradient (Fig. 3.6) elutes the proteins bound
to the cation column. As the concentration of NaCl ions increase, the proteins
bound to the stationary phase of the cation column are released. Proteins with
weaker ionic interactions will be released at lower ion concentrations compared
with proteins with a higher ion interactions and consequently a higher affinity for
the stationary phase. To perform ion exchange chromatography with truncated
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histones, the running buffer contained 50 or 75 mM NaCl to allow binding of the
N-terminally truncated and thus less positively charged histones to the cation
exchange column. This combination of both anion and cation exchange columns
allow purification of both full length and truncated histone proteins from the
solubilised inclusion body preparation.
In this way, all required core histones were successfully purified (see Fig. 3.6
for a sample purification for histone H2B). The sample bound to the monoQ
(anion) column and flowthrough of the ion exchange columns both have low
A280/260 ratios, indicating that they have high DNA contamination. Contrary
to the fractions eluted from the cation column which have a high A280/260 ratio
indicating not only the presence of protein shown in the SDS-PAGE analysis
(Fig. 3.6) but also very little DNA contamination. Separation of the histone
from the majority of the contaminants is clear (Fig. 3.6). On average 24 1-ml
fractions were pooled, with regards to the example shown (Fig. 3.6) fractions
B3 to D5 were considered to contain sufficiently pure histone and thus pooled
and dialysed against 3 mM beta-mercaptoethanol in water before lyophilisation.
Once purified, the truncated histones are ready for native chemical ligation while
other purified core histones can be used immediately for octamer assembly.
Prior to the start of this project H3 expression constructs used for the methyl-
lysine analog approach were expressed ready for cysteine alkylation. However,



















































Elution from Cation Column
InP FT B3 B5 B7 B10 C1 C5 C9 D1 D5F4
H2B
HiTrap - 225 - 460 mM NaCI 
Figure 3.6 Full-length Histone H2B Purification. A) A chromatogram of the ion
exchange purification of histone H2B. The elution was monitored by A260 and A280. The
solution’s A280/260 ratio helps to assess DNA contamination of the solution. The flowthrough
(FT) (0 ml to 53 ml) and monoQ (118 ml to 130 ml) mainly consists of DNA. Fractions B3 to
D5 were pooled and lyophilised. B) SDS-PAGE analysis of ion exchange purification of H2B.
InP - Input. FT- Flowthrough. Fraction F4 (115 ml)- Analysis of proteins bound to monoQ
column. Fractions B3-D5 protein eluted from HiTrap column, mainly consisting of H2B.
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3.4 Methyl-lysine Analogs
Cysteine alkylation chemistry as first performed by the group of Kevan Shokat
to site-specifically modify histones (Simon, 2010; Simon et al., 2007; Simon and
Shokat, 2012; Chen et al., 2014; Chatterjee and Muir, 2010) resulting in the
generation of methyl-lysine analogs (MLAs). MLAs (Fig. 3.7) are widely used
as proxies for specifically modified histones in studies investigating nucleosome
binders and modifiers (Lauberth et al., 2013; Francis et al., 2009; Margueron
et al., 2009; Simon et al., 2007; Shen et al., 2009). Histone sequences are
well conserved between eukaryotes (Wells and Brown, 1991) and many species’
histone H3 contain only one cysteine (position C110) which can be mutated
to alanine without noticeable effects on histone or nucleosome structure or
function (Simon et al., 2007). Thus the site-specific mutation to cysteine at the
desired modification site allows the use of a variety of methods including cysteine
alklyation to create specifically modified histones. The cysteine is alkylated to
a N-methylated aminoethylcysteine (Kc) which is an analog of methylated lysine
with sulphur replacing the γcarbon of the lysine (Fig. 3.7) (Simon et al., 2007).
It allows the production of modified histones with multiple sites of methylation -
N-methylated aminoethylcysteine - although it does result in all the sites being
equally methylated.
In spite of aminoethylcysteine’s similarity to lysine, these early pulldown
experiments showed an inability of proteins including PRC2 present in the nuclear
extract to distinguish between differently modified nucleosomes (see Chapter 4
Fig. 4.9). EZH2 is used as a indicator of PRC2 binding as it is the catalytic
subunit and an integral member of the protein complex. Due to the inability of
PRC2 to distinguish between different MLA substrates in pulldown experiments,
it was decided to change the method of in vitro synthesis of specifically modified





















































































































Figure 3.7 Aminoethylcysteine and Lysine residues. Structure comparison of cysteine,
and variously modified methyl-lysine analogs and lysines A) i) unmethylated residues ii)
monomethylated residues iii) dimethylated residues and v) trimethylated residues.
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3.5 Native Chemical Ligation
Native Chemical Ligation (NCL) was developed by the Kent lab (Dawson et
al., 1994) and developed for use on histone proteins in the Peterson lab, among
others (Shogren-Knaak et al., 2003; Chen et al., 2014). In the NCL method,
2 peptides, one containing a C-terminal thioester (peptide-R-thioester) and
one with a N-terminal cysteine, are joined together via a three-step process.
Firstly, a thiol-thioester exchange between the thioester containing peptide and
an externally added alkyl which results in a new thioester containing peptide and
then a transthioesterifcation reaction between the new thioester and the peptide
containing an N-terminal cysteine to produce a new thioester linked intermediate
(Fig. 3.8) - these steps are reversible. The third step - a spontaneous S to N acyl
shift resulting in an native amide bond joining the two peptides - is irreversible.
The product polypeptide resulting from the NCL reaction is chemically identical
to the endogenous protein except with a cysteine at the site of ligation. In the
case of the NCL method, as the reaction is between an N-terminal cysteine and
a peptide-R-thioester, the C110A mutation in histone H3 that is necessary for
the MLA reaction is not obligatory. The cysteine at the site of ligation can
be resolved by desulfurization to an alanine if required (Dawson et al., 1994;
Dawson, 1997; Dawson and Kent, 2000; Kent, 2006; Thapa et al., 2014; Wang
et al., 2011; Chatterjee and Muir, 2010). We did not perform this step as both
threonine and cysteine are both polar amino acids with relatively long side chains
capable of forming hydrogen bonds while alanine is hydrophobic; therefore the
desulfurization step would result in a greater alteration to the sequence than
leaving the T32C mutation in place.
To create specifically modified histones via this method (Fig. 3.8), a truncated
histone peptide lacking residues 1-31 or 1-44 with a threonine to cysteine
substitution/mutation at residue 32 or 45 respectively, is reacted with a peptide
consisting of the histone H3.1 N-terminal tail and a C-terminal thioester. This
mutation is not expected to cause any disruption to the histone or nucleosome
structure as the residue mutated is outside the structured domain of the
nucleosome (Luger et al., 1997a; Bartke et al., 2010). The tail peptide can
include any desired modification at any preferred location for example, H3K4me3
or H3K4me3K27ac. Initially the truncated histone peptide is reacted with
methyoxyamine to help resolve any N-terminal adducts that may have formed
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Figure 3.8 Native Chemical Ligation (NCL) reaction scheme. A) Native chemical
ligation mechanism Steps 2 (transthioesterification) and 3 (S to N acyl shift) shown. B) i)
Cation exchange chromatography profile of ligated histone H3 purification. Ligated H3 eluted
around 330 mM NaCI. SDS-PAGE analysis of purification shown below, with gradient of NaCl
indicated. ii) Coomassie stained SDS-PAGE analysis of the native chemical ligation: pre-ligation
reaction, post-ligation reaction and after cation exchange purification.
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the ligation reaction (Virdee et al., 2011; Chen et al., 2010; Chen et al., 2014)
(Fig. 3.5). The NCL reaction is carried out in the presence of MPAA, an aryl
thiol catalyst which reacts with the thioester containing peptide to create a more
active thioester on the C-terminus of the peptide, increasing the speed of the
transthioesterifcation reaction (Johnson and Kent, 2006).
As can be seen from the chromatogram and corresponding SDS-PAGE gel, the
ligated H3 histone is purified away from the unligated histone by cation exchange
chromatography (Fig. 3.8). The ligated histone contains a positively charged
tail which allows it to bind to the monoS resin with greater affinity than the
unligated histone. A gradient of NaCl helps separate out these proteins. The
ligated histone elutes from approximately 325 mM NaCl onwards. The coomassie
shows the progress of the NCL reaction, yield of ligated H3 and quality of the
purification (Fig. 3.8).
3.6 Assembly of Histone Octamers
Once the histones have been successfully expressed and purified they need to
be combined in order to assemble a histone octamer. The histones are mixed
together in a mass ratio of H3:H4:H2A:H2B (1:1:1.2:1.2) and assembled into
octamers through salt gradient deposition removing the guanidinium chaotrope
while dialysing into 2 M NaCl (Luger et al., 1997a; Luger et al., 1999a). The
excess of H2A and H2B ensures optimal octamer assembly of the H3-H4 tetramer,
reducing contamination with hexamer particles. The (H3-H4)2 tetramer and the
(H2A-H2B) dimer is thought to form separately before forming the complete
histone octamer (Flaus, 2011). The dialysed solution contains both assembled
histone octamers, unassembled histones and potential aggregates (Fig. 3.9). The
histone octamers are purified by size-exclusion chromatography (Fig. 3.9).
As can be seen from Figure 3.9 when purifying histone octamers by size-exclusion
chromatography (S200) a characteristic five peak chromatogram is obtained. The
initial peak in the void volume (<8 ml) contains aggregates, the second peak
around 13 ml contains histone octamers and the third (15 ml), fourth (16.5 ml)
and fifth (17 ml) peak contains tetramers, dimers and unassembled histones. If
only one type of histone H3 is used then the purified symmetrically modified
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Figure 3.9 Histone Octamer Assembly and Purification A) Scheme of nucleosome
assembly B) i) S200 Size-exclusion purification of Unmodified untagged histone octamer.
Chromatogram peaks labelled. Aggregated protein elutes in the void volume. Octamers elute
first followed by: hexamers, tetramers, dimers and unassembled histones. ii) IMAC (NiNTA)
of Unmodified His/Strep tagged octamer. The absorbance at A(280) steadily increases along with
the concentration of Buffer B due to the absorbance at A(280) by the contaminates present in the
imidazole used in Buffer B. iii) Affinity (Streptactin) purification of Unmodified His/Strep tagged
octamer. C) Analysis of symmetrically and asymmetrically modified nucleosomes. Presence of
H3K4me3, H3K27me3 and H4 shown by western blot. H3K4me3 antibody binds better to the
untagged than tagged H3K4me3 modified histone. Loading and ratio of histones in octamer
demonstrated by SDS-PAGE. D) Assembly of Unmodified, H3K4me3/3 and H3K27me3/3
untagged nucleosomes.
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To create asymmetrically modified octamers two types of histone H3 are used
with different modification states as described by (Voigt et al., 2012). Each
of these differently modified H3 histones are tagged with either a 6XHis (H)or
Strep (S) tag. They are mixed together with other core histones in a mass ratio
H3S:H3H :H4:H2A:H2B (0.5:0.5:1:1.2:1.2). Formation of octamers is unaffected by
the presence of the tags (Voigt et al., 2012). The purified octamer fractions from
size-exclusion chromatography contain a mixture of 3 octameric species (Fig. 3.9),
only one of which contains the correct combination of the desired modifications.
These octameric species are separated out by two rounds of affinity purification.
First the solution is passed through a Nickel column, which binds H3H , removing
octamers containing only H3S and thus symmetric for the His tagged H3 species
(Fig. 3.9). During nickel affinity purification the H2A/H2B dimers are stripped
from the H3/H4 tetramer. Secondly, the mixture is passed over a streptactin
column which binds tetramers containing H3S and consequently separates out the
tetramers which only contain H3H (Fig. 3.9). This leaves a solution containing
only histone tetramers comprising of both histone H3S and H3H and are therefore
asymmetrically modified.
3.7 Optimisation of Nucleosome Assembly
A nucleosome consists of approximately 147 base pairs (bp) of DNA wrapped
around a histone octamer. Additional base pairs can be added to allow various
lengths of overhangs on either side of the octamer. The DNA used to make
octamers in this study consists of 209 bp of DNA - approximately 31 bp overhang
on each side of the 601 Widom Positioning Sequence (Lowary and Widom,
1998). The polymerase chain reaction (PCR) generating the desired 209 bp 601
DNA fragment was optimised to improve its yield, higher primer and MgCl2
concentrations increased the DNA yield by threefold, from 180 µg from a 96-well
plate reaction to 540 µg (Fig. 3.10).
The assembly of the nucleosome from DNA and histone octamer is completed
via salt gradient dialysis (Luger et al., 1999a; Luger et al., 1999b). As
the concentration of salt decreases this allows the DNA to wrap around the
histone octamers. When assembling asymmetrically modified nucleosomes, the
specifically modified tetramers are mixed with the H2A/H2B dimers in a 1:1
ratio. The protein to DNA ratio is determined on a individual protein basis by
78
Primer
1.5 mM 2mM 2mM2mMMgCI2





Figure 3.10 601 Nucleosome DNA PCR Optimisation. An 1% agarose gel showing the
amount and purity of DNA from each of the 209bp PCR conditions. Optimisation conditions
including a range of PCR (30-40) cycles and different MgCI2, and primer concentrations are
indicated above the gel.
titrating the protein against a constant amount of DNA (Fig. 3.11).This ratio was
kept constant for all subsequent nucleosome assemblies from the same octamer
purification and re-adjusted when a new octamer or DNA purification was used.
In asymmetric nucleosome assembly the tetramer and dimer bind the DNA once
the solution has reached different ionic strengths, the tetramer binds the DNA
at approximately 0.85 M, and the dimer at around 0.65 M before reaching an
equilibrium at 0.5 M and below (Flaus, 2011).
The reconstituted nucleosomes are run on a 6% TGE gel to verify their assembly
and stained with Sybr Safe to ensure both the free DNA and DNA incorporated
into the nucleosomes is visible. The incorporation of the DNA into the nucleosome
causes a shift of the DNA on the gel, from free un-assembled DNA running at
approximately 200 bp to fully assembled DNA running equivalent to 1 kb free
DNA.
Although the method by which Sybr Safe binds to DNA is unclear, as it is a
cyanine dye and a deriviative of thiazole orange it is reasonable to assume it
intercalates between the base pairs of minor groove of DNA (Zipper et al., 2004;
Bunkenborg et al., 2000; Petersen et al., 1999). The decreased efficiency of its
binding to DNA incorporated into nucleosomes in comparison to free double
stranded (ds)DNA could be due to two possible reasons. As the DNA is wound
around the histone octamer this will obstruct intercalation sites, thus reducing
the total amount of Sybr Safe able to bind the DNA and therefore decreasing the
signal. Intercalation requires DNA to open up space between the DNA base pairs
to allow the intercalating molecule to bind (Lerman, 1961), this movement may
be restricted by the preceding co-ordination of the DNA by the histone octamer.

















































































































Figure 3.11 Nucleosome Assembly Optimisation shown on native 6% TGE gels
A) Nucleosome assembly of unmodified H/S tagged H3 histone octamer at a range of
H3/H4:H2A/H2B ratios B) Nucleosome assembly of unmodified untagged H3 histone octamer at
a range of DNA:Histone Octamer ratios C)i)Heat-shift assay at 4 ◦C to 55 ◦C on symmetrically
modified and asymmetrically modified nucleosomes. UnM H/S - Histone octamer containing
unmodified His/Strep tagged histone H3, H3K4me3/3 - Histone octamer containing untagged
H3K4me3, K4/K27 - Histone asymmetrically modified octamer containing one H3 modified with
H3K4me3-His and one modified with H3K27me3-Strep ii) Optimised nucleosome assembly.
unmodified - Histone octamer containing unmodified untagged histone H3, UnM H/S -
Histone octamer containing unmodified His/Strep tagged histone H3, H3K4me3/3 - Histone
octamer containing untagged H3K4me3, H3K27me3/3 - Histone octamer containing untagged
H3K27me3, H3K4me0/3- Histone octamer containing H3K4me3-His and unmodified H3-
Strep , H3K27me0/3 - histone octamer containing H3K27me3-Strep and Unmodified H3-His,
K4me3/K27me3 (bivalent)- histone octamer containing H3K4me3-His and H3K27me3-Strep D)
Analysis of symmetrically and asymmetrically modified nucleosomes. Presence of H3K4me3,
H3K27me3 and H4 shown by western blot. H3K4me3 antibody binds better to the untagged
than tagged H3K4me3 modified histone. Loading and ratio of histones in octamer demonstrated
by SDS-PAGE. E) Simplified depiction of the various modified nucleosomes generated. The
presence of the tags is indicated by the colour of the H3 copies - green (His) or red (Strep),
while the blue indicates the absence of tags. Red modification H3K27me3 and green modification
H3K4me3.
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the DNA incorporated into the nucleosome even if there is no unassembled DNA
in that sample. This effect also means that Sybr Safe will skew the assessment
of unbound:bound DNA ratios by exaggerating the amount of unbound DNA.
Due to the presence of the DNA overhangs, the assembled nucleosomes can be
heterogeneous with respect to the position of the octamer on the DNA. As
the TGE gel separates based on the sample’s size and shape this is visible as
two slightly separated bands around 1000 kb (Fig. 3.11). This difference in
nucleosome placement is resolved by one hour incubation at 40 ◦C to 55 ◦C (Fig.
3.11).
3.8 Conclusion
The yield of all of the histone constructs were optimised for expression and
purification from E. coli BL21 (DE3) bacteria cultures. The yield of the truncated
histones was originally reliant on the expression and activity of the TEV protease.
Resulting in incomplete cleavage of the TEV cleavage site, and a low yield of the
fully truncated histone. Therefore the method of expression was altered to rely
on bacterial cleavage of the initiator methionine residue, generating a higher yield
of fully truncated histone.
Successful purification protocols for all histones were established, consisting of
inclusion body purification followed by ion-exchange purification. Purification of
truncated histone H3 required alterations to the established purification protocols.
Various methods of creation of specifically modified histones were tried and native
chemical ligation was chosen. Production of specifically modified H3 by native
chemical ligation followed similar parameters as optimised in Chen et al., 2014.
Ligated H3 was separated from unligated H3 by cation exchange chromatography.
Purification of modified octamers was established, with three rounds of chro-
matography: size-exclusion chromatography then two rounds of affinity chro-
matography - strep-tactin and nickel. Affinity chromatography purifies the
asymmetrically modified octamers by relying on differential binding of the
histones containing a His or Strep tag. Resulting in the elution of purified
octamers monitored by absorbance at A280, A260 and A280/260 ratios.
Nucleosome assembly was optimised for each specific modified octamer. The gen-
eral assembly of the nucleosomes was optimised by titration of the H3/H4:H2A/H2B
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ratio and Octamer:DNA ratio. Once assembled the placement of the octamer on
the DNA was made homogenous by heat shift assay at 40 ◦C to 55 ◦C.
The generation of specifically modified histones and nucleosomes was successfully
established and optimised. The specifically modified nucleosomes can be used in
subsequent experiments to isolate the proteins that bind them.
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Chapter 4
Establishment and Optimisation of
Pulldown Approach
4.1 Introduction
Multiple studies have established recruitment of specific proteins to histone
modifications, using modified peptides or nucleosomes in vitro or a combination of
techniques. The in vitro techniques which show direct binding are often coupled
with ChIP assays showing correlation with certain histone modifications in vivo
(Musselman et al., 2012; Taverna et al., 2007; Bartke et al., 2010; Vermeulen
et al., 2010; Vermeulen et al., 2007). Recently, a number of labs have shown how
multiple modifications on the same nucleosome or histone tail either in peptide
form or as part of a nucleosome, affects protein binding (Nuland et al., 2013;
Brown et al., 2017; Ruthenburg et al., 2011). All of these studies have focused
on either one histone tail by using peptides or a nucleosome containing the same
modifications on both sister H3 copies. However, asymmetrical nucleosomes do
exist in vivo and are likely present in multiple cell types (Bernstein et al., 2006a;
Azuara et al., 2006; Roh et al., 2006; Pan et al., 2007; De Gobbi et al., 2011;
Voigt et al., 2012; Mikkelsen et al., 2007).
The reason for using an in vitro approach to investigate the proteins that bind
to bivalent nucleosomes was simple; it allows a non-biased view and comparison
of all proteins bound to the differently modified nucleosomes without any of the
additional complicating factors present in vivo. The use of a nucleosome rather
83
than simply modified peptides allows us to determine how the conformation of the
nucleosome and its histone tails might influence binding of proteins, as they would
in vivo (Chen et al., 2014; Nuland et al., 2013; Chen et al., 2018). This gives a
much more accurate picture of the proteins’ binding and allows sites on the histone
modifiers that might bind to nucleosomal DNA, neighbouring histones, or parts
of the histone apart from the modification in question to contribute to protein
binding affinity. Using nucleosomes allows influences of all core histone tails and
their modifications to be accounted for and quantified. Mononucleosomes allow a
clear read out of binding rather than arrays where it is difficult to ensure a specific
arrangement of nucleosomes and to attribute the result to a single nucleosome.
Once proteins that bind a specifically modified mononucleosome are known, the
effect of nucleosomal arrays could be assessed in future work.
4.2 Aims
In the previous chapter the generation of the specifically modified nucleosomes
was detailed. In this chapter, the optimisation and establishment of the
pulldown assay using these modified nucleosomes will be shown. H3K4me3/3
and H3K27me3/3 nucleosomes will be used to validate the method, as the
proteins known to bind either the H3K4me3- or H3K27me3-modified peptides
or nucleosomes are well established (Lauberth et al., 2013; Ingen et al., 2008;
Clouaire et al., 2012; Kim et al., 2016; Chang et al., 2010; Peña et al., 2006;
Simon, 2010; Bernstein et al., 2006b; Xu et al., 2010; Eberl et al., 2013; Vermeulen
et al., 2010; Bartke et al., 2010). Validation of the assay will be accomplished
by comparison of the proteins bound to the modified nucleosomes used here and
proteins known to bind them in the current literature.
4.3 Optimisation of Pulldown Approach
Once the specifically modified nucleosomes have been made and purified (see
Chapter 3) they can be used in pulldown experiments. The theory of the pulldown
assay is simple (Fig. 4.1); the bait protein, in this case the specifically modified
nucleosome, is immobilised on beads, and incubated with nuclear extract (NE)
that contains potential binding partners. The proteins bound non-specifically or











































Figure 4.1 Pulldown Theory Diagram. The purified recombinant specifically modified
nucleosomes are immobilised on beads and incubated with nuclear extract (NE) from mouse
ESCs. Unbound or unspecific protein binding is removed via multiple wash steps and then the
proteins bound to the nucleosomes are eluted and analysed by label-free mass spectrometry (MS).
The data obtained was analysed by three different programmes: MaxQuant, DEP and R.
bound to the nucleosome are eluted.
In order for the nucleosomes to be immobilised for the pulldown, the DNA used to
wrap around the histone octamer was tagged with biotin. To facilitate detection
of specific binding proteins, unspecific binding of contaminating proteins must be
minimised. A variety of beads coated with streptavidin (which binds biotin)
were assessed for suitability of use in pulldowns (Fig. 4.2). Bovine serum
albumin (BSA) blocked beads were removed from consideration as the presence
and abundance of BSA could mask MS-based detection of some proteins present
in the experiment - this removed M-280 and MyOne beads from consideration
(Fig. 4.2) as BSA (66.5 kDa) was eluted in both methods used to elute proteins
from the beads (see below). Streptavidin (13-14 kDa) was present in all elutions,
although in greater amounts when the beads were boiled compared to a 37 ◦C
elution. Based on the results of the initial optimisation, MyOne C1 beads
were chosen, as they are not blocked with BSA, have a small diameter (same




























































SupN   Nucleosome Supernatent
Elu       Elution from beads
Beads  Beads boiled
Figure 4.2 Bead optimisation A) SDS-PAGE analysis of the elution from four different
streptavidin beads - streptavidin (13-14 kDa) was present in all elutions. M-280 and MyOne
beads are blocked with BSA (66.5 kDa). Key for beads type contained in the figure. B) A
comparison of different elution methods on Myone C1 beads, two different elution buffers used
at two different temperatures. SupN - supernatant Elu - elution Beads - boiled beads C) Silver-
stained SDS-PAGE gel analysis of non-specific protein binding to beads.
non-specific binding), are magnetic, have a greater binding capacity, and eluted
less streptavidin in the 37 ◦C elution than the other beads tested. Magnetic beads
allow for a cleaner sample, MS preparation, and enhance reproducibility.
To minimise the presence of contaminating proteins in the bead elution, three
elution methods were compared. A gentler elution with FASP elution buffer
containing (100 mM Tris-HCl pH8, 0.1% SDS, 25 mM DTT ) at 37 ◦C or with
FASP elution buffer (supplemented with 0.2% SDS) at 55 ◦C and a harsher elution
in the presence of SDS sample loading buffer at 95 ◦C (Fig. 4.2). The 37 ◦C
elution eluted the vast majority of the nucleosomes bound with minimal elution
of streptavidin and BSA from the beads (Fig. 4.2), therefore this elution method
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was selected for further pulldown experiments.
MyOne C1 beads were tested for non-specific protein binding to the proteins
in the nuclear extract (NE) (Fig. 4.2). Beads were incubated with NE in
pulldown conditions to reveal any non-specific binding that would be encountered
in pulldown experiments with modified nucleosomes. The enrichment of different
protein bands in the elution containing nucleosomes compared to the NE input
sample illustrates the binding of specific proteins from the NE by the unmodified
nucleosomes.
Minimal non-specific protein binding to the beads was preferred, as the presence
of excess proteins may mask proteins specifically bound to the nucleosomes and
affect the enrichment seen between conditions. As can be seen from the silver
stained SDS-PAGE gel, MyOne C1 beads themselves non-specifically bound very
few proteins from the NE, especially in comparison to the beads once nucleosomes
were bound (Fig. 4.2). However, when these beads were evaluated using Mass
Spectrometry (MS), a large number (1382) of previously unseen proteins are
present bound to the beads (Fig. 4.3) even in the absence of nucleosomes,
albeit at low levels. Some of the proteins bound to MyOneC1 beads included
proteins that bind to the histone PTMs H3K27me3 or H3K4me3 including EZH2.
The presence of proteins bound to the beads themselves may decrease visible
enrichment of proteins between differently modified nucleosomes, making these
beads less suitable for the pulldown experiments planned. Till Bartke’s lab
published a similar pulldown assay in 2018 using Streptavidin Sepharose High
Performance (SHP) beads (Makowski et al., 2018). We compared these beads to
MyOne C1 beads using the same method as before and discovered that the SHP
beads bound non-specifically to fewer proteins (281 proteins, Fig. 4.3). As SHP
are not blocked with BSA and have the least amount of non-specific binding of
the beads tested, they were used for the subsequent experiments.
The amount of SHP beads required to bind 10.5 µg of nucleosomes was optimised
via a bead titration for the pulldown assay. The optimal amount of beads
would bind all the nucleosomes present with minimal excess surface area for
non-specific protein binding. Western blot analysis of histone H3 bound to
the beads and present in the supernatant showed that approximately 8 µL bead
bed volume (10.5 µL slurry) was optimal for 10.5 µg nucleosome binding. This
volume of beads was the minimal amount that bound all of the nucleosomes.
Nucleosome concentration is determined by the amount of nucleosome DNA
present as nucleosome assembly has been optimised to reduce free DNA, further
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Nucleosome N/A UnModified H3K4me3 Sym N/A UnModified H3K4me3 Sym
Protein
KMT2B - - - - 8.39E+06 7.05E+06
TAF3 - - - - - 3.41E+07
Spin1 - - 2.15E+08 - - 2.49E+08
BAP18 5.51E+07 3.91E+07 8.34E+08 - 1.03E+08 1.76E+09
PHF2 - - 2.43E+07 - 1.56E+07 6.83E+07
ING2 - - 2.44E+07 - - 8.92E+07
EZH2 5.36E+07 8.01E+08 1.09E+08 - 4.17E+07 1.41E+07
CBX7 - - - - - -
KDM5B 2.71E+07 2.61E+07 1.79E+08 - 2.39E+06 1.06E+07
Sepharose BeadsMagnetic Beads
Figure 4.3 Comparison of Myone C1 and Streptavidin Sepharose High
Performance beads. Representational (A) and proportional (B) Venn Diagrams showing
the overlap of proteins bound to both types of beads. Proteins identified with a high confidence
and peptides ≥ 2 included in the analysis. C) Table detailing LFQ values for proteins bound
to unmodified and H3K4me3/3 nucleosomes bound to the different beads. D) Western blots
(WB) using the presence of H3 bound to the beads and present in the supernatant to indicate
the amount of bound and unbound nucleosomes, respectively. Range of bead bed volume used,
4 µL to 12 µL.
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reducing the amount of proteins present in the elution that are bound to the
DNA only. The use of the minimal amount of beads necessary for binding the
nucleosomes results in fewer bead surface area being available for non-specific
protein interactions.
4.4 Label-Free Quantification of Pulldown Assays
via Mass Spectrometry
There are two main classes used in mass spectrometry (MS) based quantitative
proteomics: label-free and label-incorporated MS. There are multiple well-
established protein labelling techniques from TMT (Tandem Mass Tag), SILAC
to iTRAQ (Isobaric Tags for Relative and Absolute Quantitation) protocols
(Bantscheff et al., 2007; Patel et al., 2009). Both TMT and iTRAQ rely on
isobaric labelling of molecules. In isotope-labelling approaches, the differentially
labelled samples are combined after immunoprecipitation or purification, eluted,
combined, and taken through the sample preparation steps for MS together.
Thus, any differences in sample handling after combining individual samples
affect all the samples equally. Chemical labelling occurs later on in sample
handling and thus has reduced robustness compared to that seen in isotope-
labelling. Although protein labelling techniques are well established and have
definite benefits, they also have limitations including increased complexity of
sample preparation, increased sample preparation time, increased cost per sample,
and issues associated with incomplete labelling.
Label free (LF) mass spectrometry is a method that aims to determine the amount
of a protein in two or more samples (in comparison with each other) without
using a label that is chemically incorporated into the proteins of interest (Cox
et al., 2014; Zhu et al., 2010; Wierer and Mann, 2016; Old et al., 2005). A
drawback of LF MS is that as no label is present and each sample is prepared
separately and run sequentially, differences in sample handling have greater
effects on the samples compared to label-incorporated techniques. Label-free MS
is a faster technique and allows a greater number of sample comparisons than
label incorporated techniques, as it is not limited by the number of available
labels. Label-free mass spectrometry was employed here as it requires no
labelled media – the incorporation of amino-acid labels could affect protein
expression in mouse embryonic stem cells (ESCs) affecting the results seen.
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In addition, LF-MS allowed comparison of pulldowns performed with all the
modified nucleosomes in the study against each other. Label-free MS has been
shown to outperform TMT and iTRAQ techniques in terms of proteome coverage
and protein sequence coverage respectively (Megger et al., 2014; Latosinska et
al., 2015). SILAC and TMT labelling would only allow for triplet and ≥8
sample comparisons, respectively, while increasing the cost of each experiment
and the time required for analysis. Label-free MS results can be evaluated by
relative or absolute (iBAQ) protein quantification techniques. We utilised relative
protein quantification techniques to assess the change in protein levels between
the samples.
Protein quantification from LF-MS can be completed one of two ways: spectral
counting or peak intensity. Peak intensity was used for relative protein
quantification in this study. Previous studies have shown that peak area linearly
correlates with the abundance of protein (R2=0.991) (Chelius and Bondarenko,
2002). The data obtained from the LFQ MS was analysed for relative protein
quantification between all the samples by the MaxLFQ algorithm as described
by Cox et al. (2014). This algorithm relies on delayed normalisation using a
dominant population of proteins that change nominally between samples. This
allows the MS spectra of the different samples to be aligned and peptides to
be quantified with high confidence. All samples must contain the majority of
the same proteins to allow correct alignment of spectra between samples. The
software takes all the information from peptide ratios between samples without
resorting to arbitrarily assigning signal values to a peptide if its signal is not
detected.
Pulldown samples underwent LC-MS on a Q-Exactive mass spectrometer. The in-
line chromatography column separates the peptides in a sample by their chemical
properties resulting in hydrophilic peptides eluting earlier in the gradient. The
eluted peptides are ionized before entry into the MS and the m/z ratio of
the peptides is determined via the Oribtrap (MS1). The peptides are further
fragmented in the collision cell. These peptide fragments re-enter the Orbitrap
and their new m/z ratio is obtained as MS2. Peptide and protein identification
was based on MS2 scans.
The proteins eluted from the beads are analysed by relative protein quantification
of label-free mass spectrometry (LFQ-MS) samples (Cox et al., 2014; Cox et al.,
2011; Cox and Mann, 2008). All MS experiments were performed in triplicate
and we only considered proteins identified with a high level of confidence (number
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Figure 4.4 Comparison of Nuclear Extract Biological Replicates. A) Scatter graphs
generated by the Perseus program (version 1.6.5.0) comparing the enrichment seen for each
protein shared between biological replicates. B) Venn diagram comparing the proteins present in
all three replicates of NE preparations i) A proportional Venn diagram. ii) A representational
Venn diagram. Venn diagrams generated online by Biovenn and Jvenn respectively. Proteins
identified with a high confidence ≥ 2.
of peptides greater than two).
The Nuclear Extract (NE) used for the pulldowns was combined from three
replicates using a high salt extraction protocol (Conaway et al., 1996; LeRoy et
al., 1998). The NE replicates were combined in order to average out differences
between the replicates and obtain a mixture of proteins more representative of
those present in an ideal nuclear extraction in vivo. The variation between NE
replicas was assessed via LFQ-MS (Fig. 4.4). The relative protein intensities
between NE samples was visualised with scatter graphs and at lower LFQ
intensities the proteins present in the compared NE samples diverge more, due to
the LFQ intensities approaching the lower limit of detection. The majority (87%)
of proteins in the NE samples were present in at least two of the three biological
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replicates showing high reproducibility. The MS analysis of the NE showed the
presence of some mitochondrial proteins in the samples. This was likely due
to some mitochondria co-sedimenting with the nuclei and thus mitochondrial
proteins being extracted along with the proteins present in the nucleus. As
these proteins would not normally be present in the nucleus, unless the cell is
under stress or undergoing differentiation (Lionaki et al., 2016; Cardamone et
al., 2018), they represent a potential source of false positives and were discounted
from further analysis.
Technical replicates LFQ showed minimal change between samples run se-
quentially, and at least 94% of all proteins were shared between two of the
three and 86% in all three technical replicates of pulldowns with unmodified
nucleosomes (Fig. 4.5). This reproducibility remained similar between the
technical replicates of the modified nucleosomes - H3K4me3/3 pulldowns are
shown as an example. The variance of protein abundance increases at the
lower range of abundance. The high reproducibility of technical replicates
demonstrates that little protein variation should occur due to technical variation
and therefore subsequent pulldown samples were only analysed as single LC-MS
runs without technical replicates. Replicates using the same combined NE, but
with fresh preparation of histones and nucleosomes, with experiments performed
on different days are referred to as biological replicates. Biological replicates
of the same pulldown conditions shared fewer proteins between all replicates -
92% - although at least 82% of proteins were shared between two of the three
replicates (Fig. 4.6). The difference between the protein abundance between
the biological replicates was greater than that of the technical replicates. This
was expected due to the presence of technical variation along with biological and
experimental variation. A comparison of the proteins bound between unmodified
and H3K4me3/3 nucleosomes showed that the vast majority (84%)of proteins
identified were the same between the differently modified nucleosomes (Fig. 4.7)
and thus relative protein quantification of LFQ MS methodology can be used in
conjunction with these pulldown experiments.
Once the data had been obtained and analysed using the MAXLFQ algorithm,
further quality control measures were taken. Peptides that were only identified by
MS1 were removed. Potential contaminants, such as keratin, and false positives
were removed after applying the false discovery rate (FDR) algorithm from
MaxQuant. Only proteins identified with a high confidence by MS were included
in the analysis (peptides ≥ 2). Proteins not present in 2 of the 3 replicates
92


























































































Figure 4.5 Analysis of Mass Spectrometry Technical Replicate Runs A) Scatter plots
comparing LFQ intensity of each protein between technical replicate runs of a pulldown with
unmodified nucleosomes. B) Proportional (ii) or representational (i) Venn diagram of proteins
present in each technical replicate. C) Scatter plots comparing the LFQ intensity of proteins
shared between technical replicates of a pulldown with H3K4me3/3 nucleosomes. D) Venn
diagrams comparing the total number of proteins shared between H3K4me3/3 replicates either
proportional (ii) or representational (i). Venn diagrams generated online by Biovenn and Jvenn
respectively. All scatter plots generated by Perseus (version 1.6.5.0). Proteins identified with a
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Figure 4.6 Analysis of Mass Spectrometry Biological Replicates A) Scatter plots
comparing LFQ intensity of each protein between biological replicates of a pulldown with
unmodified nucleosomes. B) Venn diagram of proteins present in each biological replicate
either proportional (ii) or representational (i) diagrams. C) Scatter plots comparing the
LFQ intensity of proteins shared between biological replicates of the pulldowns with the
H3K4me3/3 nucleosomes. D) Venn diagrams comparing the total number of proteins shared
between H3K4me3/3 nucleosome replicates either proportional (ii) or representational(i). Venn
diagrams generated online by Biovenn and Jvenn respectively. All scatter plots generated by
generated by the Perseus program (version 1.6.5.0). Proteins identified with a high confidence













Figure 4.7 Comparison Between Differently Modified Nucleosomes. A) Proportional
and B) representational Venn diagram of proteins present in pulldowns with both unmodified
and K4me3/3 modified nucleosomes. 84% of proteins were present bound to both types of
nucleosomes, allowing identification and analysis of protein abundance and comparison between
nucleosome pulldowns using LFQ methodology. Venn diagrams generated online by Biovenn
and Jvenn respectively. Proteins identified with a high confidence (peptides ≥ 2) are shown.
performed were removed to exclude proteins present due to sample handling
variation.
Additionally, digestion methods were compared in terms of protein identifications.
The different on-bead digestion protocols affected the proteins’ abundance
negligibly. Protein abundance was most altered between FASP digestion and any
on-bead digestion duration tested (Fig. 4.8), nevertheless, approximately 78-82%
of the proteins identified were common between digestion methods. The similarity
of protein abundance between the differently digested samples is depicted via
scatter plots (Fig. 4.8). Although the shared proteins between FASP and on-bead
digestion samples exhibited a greater variation in abundance than other methods,
there is a positive correlation and the majority of proteins present overlap between
samples. On-bead digestion was selected as the optimal digestion method as
it detected the presence of several proteins at higher levels, enabling a more
accurate quantification compared to the FASP digestion method. This should
remove a number of possible false positives from the dataset. On-bead digestion
does not require SDS to elute proteins bound, thus reducing the likelihood of
MS contamination. Analysis of varying incubation times with trypsin in on-bead
digestion protocol showed very little effect, with 2 hours of incubation being
chosen due to being more time efficient. FASP digestion method (Wiśniewski
et al., 2009) was compared to the on bead digestion method as FASP allows
the optimal removal of contaminants such as detergents, however, the on-bead
digestion did not result in a significant amount of contaminates and could be
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Figure 4.8 Mass Spectrometry Digestion Optimisation. A) Scatter graphs comparing
protein abundance in various MS digestion techniques. B) Venn diagram showing overlap of
proteins present in all digestion methods (i) and a comparison of only the on-bead methods (ii).
Venn diagrams generated online by Jvenn. All scatter graphs generated by generated by the
Perseus program (version 1.6.5.0). Proteins identified with a high confidence (peptides≥ 2) are
shown.
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4.5 Pilot Pulldown Experiments with Histones
Containing Methyl-lysine Analogues (MLAs)
Initially methyl-lysine analogs (MLAs) were used as substitutes for histones
containing specifically modified lysines. MLAs are widely used in place of
endogenously modified histones. They contain a N-methyl aminoethylcysteine
in place of the methylated lysine - and behave similarly to methylated lysines
(Kenyon and Bruice, 1977; Simon et al., 2007; Lauberth et al., 2013; Francis
et al., 2009; Margueron et al., 2009). In spite of aminoethylcysteine’s similarity
to lysine, as outlined below, early pulldown experiments showed an inability of
proteins present in the nuclear extract to distinguish between differently modified
nucleosomes (see Fig. 4.9).
PRC2 places the H3K27me3 mark on histone H3 and has been shown to exhibit
a preference for H3K27me3/3 modified nucleosomes (Bartke et al., 2010). EZH2
is the catalytic subunit of this complex and was used as a proxy for PRC2
binding. The binding of SUZ12-RbAp48/46 submodule to the H3 N-terminal
tail is decreased by 100 fold in the presence H3K4me3, thus decreasing PRC2’s
affinity for H3K4me3 modified N-terminal tails (Schmitges et al., 2011; Juan
et al., 2016). If the complex was able to distinguish between H3Kc27me3
and H3Kc4me3 containing nucleosomes in this assay, EZH2 should be present
in the highest quantities bound to H3cK27me3 symmetrically modified, then
unmodified nucleosomes, and depleted in H3cK4me3 symmetrically modified
nucleosomes. However, as shown in Figure 4.9, EZH2 bound equally well to all
modified nucleosomes investigated, including those containing H3Kc4me3. The
difference in PRC2’s binding compared to previous studies could be due to use of
MLAs. Although N-methyl aminoethylcysteines are comparatively structurally
and chemically similar to methyl lysine they are slightly different, substituting
the lysine -methylene with a sulphide, resulting in a slight lengthening of the side
chain ( 0.28 Å). Moreover, the electron withdrawing effect of the thioether causes
a small increase in the acidity (−1.1 pKa unit) of the ammonium protons (Gloss
and Kirsch, 1995; Simon et al., 2007; Hopkins et al., 2005).
Native methyl-lysines have a 5-13 fold tighter binding in comparison to MLAs,
quantitatively demonstrating the difference between these substrates and indi-
cating the potential issues with utilisation of MLAs instead of native chemical





































































































Figure 4.9 Methyl-lysine Analogs A) Methyl lysine analogs are made by alkylating unique
cysteine residues to form aminoethylcysteines. Comparison between cysteine, aminoethyl-
cysteine, and lysine B) Western blot analysis showing EZH2 bound to three of the four
different nucleosomes. Control - agarose beads with no nucleosomes bound. Unmodified
- beads with unmodified (H3Kc4me0 H3Kc27me0) nucleosomes bound. H3Kc4me3 - beads
with nucleosomes symmetrically modified with H3Kc4me3 bound. H3Kc27me3 - beads with
nucleosomes symmetrically modified with H3K−c27me3 bound. Equal amounts of nucleosomes
were bound to beads as shown by Western blotting against histone H3. Comparison of H3 present
in nucleosome supernatant to beads to show complete binding of nucleosomes to beads in all
conditions. EZH2 in the nuclear extract used as a loading control as it is still present in the
nuclear extract supernatant.
LEDGF are unable to bind the MLAs with equivalent affinity as the native
modified nucleosome (Chen et al., 2014). The preference of PRC2 for H3K27me3
modified nucleosomes was established using modified nucleosomes generated by
native chemical ligation (NCL)(Bartke et al., 2010). Due to the inability of
PRC2 to distinguish between different MLA substrates in pulldown experiments
(See Fig. 4.9), it was decided to change the method of in vitro synthesis of
specifically modified nucleosomes to native chemical ligation (NCL). All further
pulldowns were completed using specifically modified histones generated via the
NCL method as described in Chapter 3.
4.6 Validation of Pulldown Assays with
Symmetrically Modified Nucleosomes
Once the NCL method of generating specifically modified histones had been
selected and the nucleosomes made, the in vitro pulldown approach had to be
validated. To validate the robustness of the chosen approach, a comparison of
proteins bound to T32C unmodified, H3K4me3/3, H3K27me3/3 nucleosomes was
undertaken. The proteins that bind to these modifications or are unable to bind
them have been previously demonstrated by multiple studies (Makowski et al.,
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2018; Bartke et al., 2010; Vermeulen et al., 2010; Eberl et al., 2013). Initially
proteins that have known binding preferences such as TAF3, CHD1, EED, CBX7
were analysed via western blot to confirm the assays validity before proceeding
to the MS analysis (Vermeulen et al., 2007; Ingen et al., 2008; Lauberth et al.,
2013; Flanagan et al., 2005; Xu et al., 2010; Morey et al., 2012).
LFQ-MS was utilised to analyse differential binding of proteins bound to the
differently modified nucleosomes. Algorithms from Perseus (version 1.6.5.0) and
R (version 3.5.3) were utilised to create volcano plots comparing the proteins
bound to unmodified, H3K4me3/3 and H3K27me3/3 nucleosomes (Fig. 4.10).
Proteins that have a 3-fold or greater change with a p-value of p<0.01 were
considered significantly enriched and highlighted in Fig. 4.10. However, some
proteins are missing from the comparison either due to not being present in
the NE or only being present in one of the three pulldown replicates. To allow
comparison of proteins present in one condition which are absent from another
(due to their inability to bind in the other condition), missing LFQ intensity
values were imputed so a pairwise analysis of the two nucleosome conditions
could be completed. This was accomplished via two ways: initially from normal
distribution in Perseus and subsequently when re-analysed, using the minprob
function in DEP 1.4.1 package (Zhang et al., 2018).
The majority of the proteins significantly enriched bound to H3K4me3/3
(H3K4me3 symmetrically modified) nucleosomes consists of proteins already
known to bind H3K4me3 including: CHD1, Spin1, CFP1 and BPTF (Flanagan
et al., 2005; Li et al., 2006; Ruthenburg et al., 2011; Clouaire et al., 2012; Brown
et al., 2017; Eberl et al., 2013; Su et al., 2014; Wang et al., 2011; Yang et al.,
2012). The proteins enriched in H3K4me3/3 nucleosome pulldowns are known to
bind to H3K4me3 directly (TAF3) or are part of complexes which do so (DPY30)
(Vermeulen et al., 2007; Ingen et al., 2008; Lauberth et al., 2013; Tremblay et al.,
2014; Bochyńska et al., 2018).
Although there are numerous protein complexes known to bind to H3K4me3
including MLL2, TFIID and SETD1A which are present in the NE, are not
enriched on the H3K4me3/me3 nucleosome. Many of these complexes contain
binding sites for other histone modifications and share subunits with multiple
complexes (Sze et al., 2017; Clouaire et al., 2012; Bledau et al., 2014; Vermeulen
et al., 2007; Ingen et al., 2008; Lauberth et al., 2013; Aloia et al., 2013; Denissov
et al., 2014; Eberl et al., 2013; Ali et al., 2014). This may result in the complexes



















































































































































































































































Figure 4.10 Validation of Pulldown Approach using Symmetrically Modified
Nucleosomes A) 6% TGE showing the assembly of nucleosomes unmodified, H3K4me3/3,
and H3K27me3/3 nucleosomes. B) Western blot analysis of proteins bound to unmodified,
H3K4me3/3, and H3K27me3/3 nucleosomes. Proteins known to bind to H3K4me3 labelled
in green, proteins known to bind H3K27me3 in red. H3K4me3, H3K27me3 and H3 shown to
confirm loading order and as loading controls. C) Volcano plots showing proteins enriched in
pulldowns with modified nucleosomes compared to unmodified nucleosomes. D) Bar graphs of
individual protein enrichment in various modified nucleosome conditions. Proteins known to
bind to H3K4me3 shown in green, proteins known to bind H3K27me3 in red. Volcano plots
were created via R version 3.5.3 and individual protein enrichment was calculated with the DEP
1.4.1 package.
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being classified as enriched on any one nucleosome. These complexes may not be
able to stably bind the nucleosome in the pulldown conditions used such as the use
of mononucleosomes instead of arrays or due to the longer length of washes utilised
in this study - this is discussed in more detail later. The presence of subunits
shared between complexes means that the presence of their shared subunit such as
DPY30 or CFP1 does not give a clear indication of which specific complex is being
recruited. Indeed, proteins that directly bind a singular modification may still be
recruited to nucleosomes containing other modifications due to interactions with
subunits that have different binding preferences.
The proteins enriched in the H3K27me3/me3 nucleosomes consist of proteins
previously identified as H3K27me3 interactors including: CBX7, Polyhomeotic
Homolog 1 (PHC1), G9a, ORC proteins and LRWD1 (Bartke et al., 2010;
Vermeulen et al., 2010; Eberl et al., 2013). These are proteins that bind directly
to H3K27me3 such as CBX7 (Bernstein et al., 2006b; Morey et al., 2012; Min
et al., 2003), or are proteins that interact with proteins that do so (PHC1, G9A,
and LRWD1) (Mozzetta et al., 2014; Shinkai and Tachibana, 2011; Tachibana et
al., 2001; Tachibana et al., 2002; Illingworth, 2019; Giri and Prasanth, 2015;
Vermeulen et al., 2010). Polyhomeotic Homolog 1 (PHC1) is expressed in
ESCs and is part of the CBX7 canonical ESC PRC1 complex that mediates
H2AK119Ub. CBX7 recruits PRC1 to areas of chromatin containing H3K27me3,
therefore its strong enrichment in H3K27me3 modified condition similar to CBX7
is expected (Bernstein et al., 2006b; Morey et al., 2012). The other CBX
variant expressed in ESCs, although a low levels, CBX6 is able to be recruited to
chromatin independently of H3K27me3 (Santanach et al., 2017; Bernstein et al.,
2006b) and therefore its lack of enrichment is expected. There were some proteins
enriched in the H3K27me3 condition compared to the unmodified condition such
as ORC proteins and LRWD1 which has been shown in previous studies to be
enriched at H3K27me3 modified tails (Bartke et al., 2010; Vermeulen et al.,
2010; Eberl et al., 2013). G9A places H3K9me2 which often co-localises with
H3K27me3 in vivo and has been shown to directly interact with PRC2 although
it does not bind directly to H3K27me3 itself (Mozzetta et al., 2014; Shinkai and
Tachibana, 2011; Tachibana et al., 2001; Tachibana et al., 2002). Unsurprisingly
G9A’s behaviour in the nucleosome pulldowns closely follows that of the PRC2
subunits.
The comparison of H3K27me3 modified nucleosomes with unmodified nucleo-
somes show fewer proteins enriched in either condition and to a lower extent
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compared to the H3K4me3/3, unmodified nucleosome comparison (Fig. 4.10).
Many of the proteins associated with H3K27me3, although potentially excluded
from binding H3K4me3, are part of complexes that can bind and be recruited to
multiple histone marks. PRC2 is able to bind both H3K27me3 and H3K27me0,
therefore, PRC2 subunits such as EZH2 and EED are present bound to both
H3K27me3/3 and unmodified nucleosomes (see Fig. 4.10). Any differences in
PRC2 bound to H3K27me3/3 and unmodified nucleosomes is small under the
conditions used in these pulldown experiments.
Western blot analysis was used to validate the LFQ-MS results. Several proteins
were chosen that are enriched on each nucleosome type to act as controls
for protein binding. TAF3 was shown to be enriched bound to H3K4me3/3
nucleosomes via LFQ-MS analysis. TAF3 is the subunit of general transcription
factor complex TFIID that binds directly to H3K4me3 and recruits TFIID, an
indicator for a transcriptional permissive chromatin state (Ingen et al., 2008;
Lauberth et al., 2013; Vermeulen et al., 2007). TAF3 (140 kDa) binds directly to
H3K4me3 and is suitable for western blot analysis (Vermeulen et al., 2007; Ingen
et al., 2008; Lauberth et al., 2013). TAF3 was therefore used as a positive control
for proteins binding solely to H3K4me3. Western blot analysis shows TAF3 bound
highly to H3K4me3 modified nucleosomes confirming results seen in the LFQ-MS
analysis. The presence of some TAF3 bound to unmodified nucleosomes could
be due to its recruitment by its various interaction partners, for example other
subunits of the TFIID complex.
An additional positive control for H3K4me3 binding was used – ING2. ING2
binds H3K4me3 directly (Peña et al., 2006; Shi et al., 2006). However, it is
part of multiple protein complexes, for example variants of the Sin3A complex,
which contain multiple binding sites for all core histones H2A, H2B, H3 and
H4, potentially allowing for some recruitment to other nucleosomes (Viiri et
al., 2009; Yoon et al., 2004; Murzina et al., 2008). ING2 is clearly enriched
bound to the H3K4me3/3 nucleosomes via western blot analysis confirming the
enrichment seen in LFQ-MS analysis (see Fig. 4.10). The binding of ING2 seen
at differently modified nucleosomes may be due to its interactions with multiple
protein complexes and their recruitment to core histones.
CBX7 binds to H3K27me3/3 modified nucleosomes (Fig. 4.10) and was therefore
selected as a positive control for protein binding selectivity for H3K27me3
(Bernstein et al., 2006b; Morey et al., 2012). CBX7 is a subunit of the PRC1
canonical complex and helps recruit PRC1 to H3K27me3 sites in chromatin
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(Wang et al., 2004b). It contains a chromodomain which binds H3K27me3 and
Morey et al. (2012) and Min et al. (2003) have shown its specific binding to
H3K27me3. CBX7 is one of the most highly expressed CBX variants in ESCs,
is essential for maintaining stem cell pluripotency and has been demonstrated to
be the main CBX in the PRC1 complex in ESCs (Santanach et al., 2017; Morey
et al., 2012). As CBX7 (28 kDa) has well characterised antibodies it is therefore
easily identified via western blot. The western blot shows CBX7 bound highly to
H3K27me3/3 nucleosomes in comparison to unmodified nucleosomes confirming
previously established results.
EZH2 was depleted from H3K4me3/3 nucleosomes (Fig. 4.10). Both Voigt
et al., 2012; Schmitges et al., 2011 demonstrated that PRC2 is inhibited from
modifying a H3 N-terminal tail previously modified with H3K4me3. H3K4me3
inhibits the binding of H3 N-terminal tails to RBAP48/NURF55, this may affect
EZH2’s catalytic activity at H3 N-terminal tails via an allosteric mechanism
communicated via conformational changes in SUZ12, shown by Schmitges et
al. (2011). There are three H3 N-terminal tail binding sites in the core PRC2
complex: EZH2’s SET domain, EED’s aromatic cage and RBAP48 (Margueron
et al., 2009; Schmitges et al., 2011; Jiao and Liu, 2015). PRC2 can still bind to
H3K4me3/3 nucleosomes; however, its binding to two of the three binding sites
is decreased. H3K4me3 binding to the RBAP48 binding site is decreased by 100-
fold (Schmitges et al., 2011; Chen et al., 2018), and H3K4me3 peptide shows no
appreciable binding to the aromatic cage of EED (Margueron et al., 2009; Xu et
al., 2010), resulting in decreased PRC2 binding to H3K4me3/3 nucleosomes (Wu
et al., 2013; Jiao and Liu, 2015; Kasinath et al., 2018). Wang et al., 2017 also
observed a decrease of PRC2 and thus EZH2 binding to H3K4me3/3 nucleosomes,
thus EZH2 works as a negative control for binding to H3K4me3 nucleosomes.
The decrease of EZH2 in H3K4me3 nucleosomes was not seen in Bartke et al.,
2010, and this difference in EZH2 binding may be explained by the different
beads used and different cell types utilised in both experiments. From previous
optimisation trials it was clear that the magnetic beads bound to more unspecific
proteins, including EZH2, than the sepharose beads used in this experiment.
The presence of EZH2 bound unspecifically to the beads could cause any slight
decrease in protein binding to be classified as not significant. In addition, Bartke
et al., 2010 used NE from HeLa cells while this study used NE from mouse
ESCs, these different cell types may contain different PRC2 variants resulting in
different binding affinities to different modifications (Kloet et al., 2016; Oliviero
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et al., 2016).
EZH2’s binding to differently modified nucleosomes was investigated with both
LFQ-MS and western blot analysis. Examination of all nucleosomes showed a
similar enrichment of EZH2 at H3K27me3/3 and unmodified nucleosomes and
a decrease at H3K4me3/3 nucleosomes via both types of analysis. The similar
abundance of EZH2 bound to both unmodified and H3K27me3/3 nucleosomes
can be explained by the presence of both H3K27me3 and H3K27me0 binding
sites within the PRC2 protein complex as previously discussed (Wang et al.,
2017; Wu et al., 2013; Margueron and Reinberg, 2011; Laugesen et al., 2019;
Holoch and Margueron, 2017). PRC2 and thus EZH2 can be recruited to both
unmodified and H3K27me3 tails.
Another possible cause for the varying results between this study and Bartke
et al., 2010 is the difference in the experimental protocols. While the protocol
used in the Bartke et al., 2010 paper used flick washes, this study used 5 minute
washes. The length of washes in this protocol results in a longer time between
binding and elution of proteins from the beads. PRC2 is a large multisubunit
complex which binds nucleosomes due to multiple low affinity interactions, this
may result in a relatively large Koff. Koff is the first-order rate constant for the
dissociation of the protein-ligand complex and is inversely related to the affinity
of the protein for the ligand. Longer washes may result in the loss of proteins
or protein complexes from the nucleosomes with larger Koff constants. Therefore
the enrichment of PRC2 on H3K27me3/3 nucleosomes compared to unmodified
nucleosomes seen in Bartke et al., 2010 may be lost via this protocol. Moreover,
different mass spectrometry techniques were utilised in these studies, LFQ-MS
compared to SILAC. SILAC may be better adapted technique to pick up smaller
alterations in protein binding as it has more reliable protein quantification and
reduction in sampling handling variance. Due to the increased effect of sample
handling variances created in the label-free methodology, it is less sensitive to
small protein changes and more likely to only identify larger protein alterations.
There could also be issues with steric hindrance of large complexes so that they
cannot bind to the modifications potentially due to beads being saturated with
nucleosomes. PRC2 has been shown to bind to dinucleosomes (Poepsel et al.,
2018), the additional nucleosome provides extra sites of interaction with the PRC2
complex potentially reducing the complexes’ overall Koff.
Validation of the experimental approach by confirmation of known protein
interactions with symmetrically modified nucleosomes via two different analyses
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allows investigation into protein interactions with asymmetrically modified
nucleosomes.
4.7 Conclusion
Initially the pulldowns used MLAs as they can be made in large quantities (Simon
and Shokat, 2012; Simon, 2010). However, the candidate histone PTM binding
proteins tested were unable to distinguish between the different modification
states of MLA-containing nucleosomes, likely due to the differences between N-
methyl aminoethyl-cysteine and methyl lysine residues. They were therefore
discarded in favour of histones made via the NCL method, and these were
subsequently used in all further pulldowns. Modified histones made using the
NCL method are chemically identical to endogenously occurring histones apart
from the T32C mutation.
The pulldown approach was optimised to maximise nucleosome assembly,
minimise non-specific protein binding, and enhance experimental reproducibility.
The protocol for MS was optimised to minimise detergent contamination, and to
improve identification and quantification of proteins. Label-free quantification
was successfully employed to compare the relative protein abundance between
MS samples. The pulldowns with the symmetrically modified nucleosomes,
H3K4me3/3 and H3K27me3/3, enriched for known H3K4me3 and H3K27me3
proteins binders respectively. The enrichment of proteins that are known to bind
these marks from the previous studies helped demonstrate that the pulldown
approach worked. The results clearly show that our experimental approach
is successful, validating previously identified protein interactions, and enables








Asymmetrically modified nucleosomes exist in different species and cells types
(Voigt et al., 2012; Shema et al., 2016; Barski et al., 2007; Choudhury et al.,
2019). Asymmetry within the cell can arise for multiple reasons: recruited
histone modifying enzymes compete for binding sites resulting in asymmetric
modifications and once one sister histone is modified it can be excluded from
modification by other enzymes until that mark is removed, resulting in further
asymmetry (Voigt et al., 2012; Schmitges et al., 2011; Liokatis et al., 2012;
Pasini et al., 2010b). In fact, some enzymes prefer (in vitro) to modify only one
copy of histone H3 in the nucleosome (Liokatis et al., 2012), making asymmetric
nucleosomes by default. The relative abundance of asymmetric nucleosomes does
not contain any information as to whether they have an important biological
function, are present due to no significant recruitment of a single type of histone
modifier, or are an intermediate state before becoming symmetrically modified.
The ability of nucleosomes to be asymmetrically modified opens up a larger
number of combinatorial possibilities for histone modification readout and
function. There are numerous protein complexes large enough to span more than
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one histone N-terminal tail and that contain multiple binding sites for various
histone modifications (Taverna et al., 2007; Rothbart et al., 2013; Ruthenburg
et al., 2011). Protein complexes such as SAGA have been shown to be bind
both H3 N-terminal tails from the same nucleosome (Ruthenburg et al., 2011;
Li and Shogren-Knaak, 2009; Li and Shogren-Knaak, 2008), and some of those
complexes involved in the placement of bivalent domains (PRC2) can bind one
H3 N-terminal tail of one nucleosome and modify the tail of a neighbouring
nucleosome potentially spreading asymmetry (Poepsel et al., 2018). The existence
and abundance of asymmetric nucleosomes in vivo, and the effect on multiple
enzymes’ catalysis suggests that they result in a specific biological function.
H3K27me0/3 and H3K4me0/3 nucleosomes may be sufficient to recruit their
cognate binding proteins and maintain the repressive or active state, respectively,
potentially with altered binding to PRC2 or TFIID subunits, or they may be
no different to unmodified nucleosomes in their protein recruitment. Although
these asymmetric nucleosomes are known to exist (Voigt et al., 2012; Sen et al.,
2016; Shema et al., 2016) how the singular asymmetric modification alters their
biological function and the identity of proteins that bind them is still unknown.
5.2 Aims
The pulldown approach using specifically modified in vitro nucleosomes has
been validated using proteins previously identified to bind H3K4me3/3 and
H3K27me3/3. The next phase of the project aimed to discover how the
asymmetry of histone modifications affects protein binding and the biological
function of asymmetric nucleosomes. The effect of asymmetric modification on
nucleosomes and subsequent protein binding will be investigated in this chapter.
All abbreviations used refer to the nucleosomes as in Figure 3.1.
5.3 Comparison of Proteins Bound to
Asymmetrically Modified Nucleosomes
Each H3 sister histone within the asymmetric octamer is tagged at its C terminus
to allow purification (Fig. 4.1) and generation of asymmetrically modified
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Figure 5.1 The Effect of C-terminal Tags on Protein Binding. Volcano Plot
comparing unmodified untagged (UnM UnT) and unmodified tagged (UnM H/S) conditions.
Proteins enriched bound to Unmodified tagged on the left of the graph, proteins enriched bound
to unmodified untagged on the right. Proteins significantly enriched (fold change ≤1.5 and
adjusted p≤0.01) are shown in black, known H3K4me3 mark binders in green and repressive
mark binders in red. Data from DEP suite analysis in R. Volcano plots were generated in
ggplot2 in R (3.5.3.).
tagged nucleosome allows proteins that are recruited specifically to the tags
themselves or have altered binding due to the presence of the tags to be identified.
Apart from TAF3, none of the proteins that bound to either H3K4me3 or
H3K27me3 show altered binding in the presence of the tags (Fig. 5.1), verifying
that the asymmetric nucleosomes with C-terminal tags on histone H3 are suitable
tools to determine the difference in binding between symmetric and asymmetric
nucleosomes. TAF3 showed increased binding to unmodified tagged nucleosome
indicating that making comparisons of protein enrichment between samples the
relative control must be taken into consideration.
The comparison of the asymmetrically modified nucleosomes with unmodified
tagged nucleosomes reveals reduced protein enrichment compared to symmetri-
cally modified nucleosomes in comparison with unmodified untagged nucleosome.
Asymmetric conditions (Fig. 5.2) show lower overall enrichment of all proteins
compared to symmetric samples. Greater protein enrichment for known mark
binders is seen in the symmetric conditions compared to all other conditions (Fig.
5.2 & Fig. 5.3). Proteins known to be recruited to H3K4me3 or H3K27me3 marks
109
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Figure 5.2 Comparison of Symmetric and Asymmetric Nucleosomes. Comparison of
symmetric H3K4me3/3 and H3K27me3/3 nucleosomes with unmodified untagged nucleosomes
and H3K4me0/3 and H3K27me0/3 nucleosomes with unmodified tagged (UnM H/S)
nucleosomes. Volcano plots comparing A)i) H3K27me3/3 and ii) H3K27me0/3 with their
respective controls B)i) H3K4me3/3 and ii) H3K4me0/3 modified nucleosomes with their
respective controls. Significant in black (fold change ≤1.5 and adjusted p ≤0.05). Proteins
of interest labelled - ”repressive” in red ”active” in green. Data from DEP suite analysis in R
version 3.5.3. Volcano plots were generated in ggplot2 in R (3.5.3.).
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are recruited to the symmetric nucleosomes in comparison to the unmodified
nucleosomes, however, there is a significant decrease in enrichment on the
asymmetric H3K4me0/3 and H3K27me0/3 nucleosomes (Fig. 5.3). This suggests
that the presence of a singular asymmetric modification on the nucleosomes is
not sufficient to recruit H3K4me3 or H3K27me3 binders.
The proteins enriched on both H3K4me3/3 and H3K4me0/3 nucleosomes com-
pared to their respective controls indicates a large alteration in binding that
is not due to the presence of tags. TAF3 is affected by the presence of
the tags - it is enriched on the UnM H/S control relative to the unmodified
untagged (UnM UnT) control, indicating that the difference in enrichment of
TAF3 on H3K4me3/3 nucleosomes compared to H3K4me0/3 nucleosomes is
probably greater in reality due to TAF3’s increased affinity for nucleosomes
carrying the tags present on the asymmetric histones. In summary, singular
asymmetrically modified nucleosomes do not enrich for any specific protein mark
binders compared to unmodified or symmetrically modified nucleosomes.
The lack of protein enrichment in the asymmetric samples may have multiple
causes. Firstly, the proteins may require the conformation of marks present
in a symmetric nucleosome to bind. Additionally, asymmetric conditions have
half the amount of the mark compared to symmetric conditions – the resulting
reduced concentration may not be sufficient for the protein to bind. Finally,
the unmodified N-terminal tail present in the asymmetric nucleosome may
disguise or compete out the enrichment of protein caused by the presence of
the single mark. To investigate what combination of these potential causes
is correct, nucleosomes containing one modified H3 and one tailless H3 copy
were prepared. A comparison of proteins binding these truncated (tailless)
nucleosomes, which contain one modified H3 and one tailless H3 in the same
nucleosome, and the asymmetrically modified nucleosomes will demonstrate
whether this decrease in protein binding is due to the presence of the unmodified
N-terminal tail in the asymmetrically modified nucleosome. If this is the case,
then the truncated asymmetric nucleosome will show similar protein binding as
the symmetric sample. If the concentration of the modification linearly affects
protein binding, then the truncated condition will bind proteins half as well as the
symmetric condition. A titration of the amount of symmetric and asymmetric
nucleosomes will elucidate whether the difference in protein enrichment is due
to the concentration of the marks present in the differently modified nucleosome

















































































































Figure 5.3 Bar graphs showing enrichment of proteins in asymmetric and
symmetric nucleosome conditions. Cxxc1 and Phf2 are known to be recruited to H3K4me3
and are labelled in green, while EZH2, Phc1, G9a and Orc2 are known to be recruited to
H3K27me3 and are labelled in red. Neither H3K4me3 nor H3K27me3 mark binders are enriched
on asymmetrically modified nucleosomes compared to symmetrically modified nucleosomes. Bar
graphs are created by the DEP package (1.4.1) in R (3.5.3.).
then the asymmetric nucleosomes should bind the same amount of protein as half
the amount of symmetric nucleosomes.
Analysis of proteins bound to H3K4me3/3, H3K4me0/3 and H3K4me3/Tailless
nucleosomes was used to investigate how active mark binders are affected by
the presence of free H3 N-terminal tails, the conformation and concentration of
marks/modifications present on the nucleosome. ING2 (Peña et al., 2006), TAF3
(Vermeulen et al., 2007; Ingen et al., 2008) and PHF2 (Wen et al., 2010), are
known to bind to the H3K4me3 mark. PHF2 and TAF3 bound H3K4me0/3 in
equal amounts to H3K4me3/Tailless (Fig. 5.4); therefore, the free unmodified H3
N-terminal tail in the asymmetric condition does not contribute to the binding of
H3K4me3 binding proteins to H3K4me3/3 nucleosomes. ING2 binds H3K4me0/3
better than H3K4me3/tailless suggesting that the presence of the unmodified H3
N-terminal tail helps ING2 binding.
ING2 still binds the H3K4me3/Tailless albeit with reduced affinity compared
to the H3K4me0/3 nucleosome, indicating that the free unmodified H3 N-









































Figure 5.4 Western Blot Analysis of Asymmetry. Western blots of proteins bound
to the titrations of differently modified H3K4me3 nucleosomes (H3K4me3/3, H3K4me0/3 and
H3K4me3/Tailless). TAF3, PHF2, and ING2 were used as representative H3K4me3 mark
binders (labelled in green), and EZH2 and RING1B for behaviour of H3K27me3 or unmodified
H3 N-terminal tail binders in red. H3K4me3 and H4 were probed as loading controls (labelled
in black).
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condition. ING2 is part of multiple complexes and may therefore be recruited to
the unmodified tail by those interactions (this will be examined further in the
discussion (see Chapter7)).
Active mark binding proteins were still present in greater amounts on the
symmetric compared to the asymmetric nucleosomes, suggesting the majority
of protein recruited is due to the presence of H3K4me3 compared to H3K4me0.
The concentration of the H3K4me3 mark in asymmetric nucleosomes did not
linearly affect either TAF3 or PHF2 binding (Fig. 5.4). 24 µg of H3K4me0/3 did
not bind the same amount of TAF3 than even 3 µg of H3K4me3/3 nucleosome.
A mixture of 12 µg of unmodified and 12 µg of H3K4me3/3 nucleosome equates
to the amount of mark present in 24 µg H3K4me0/3 and in 12 µg of H3K4me3/3.
The mix of both 12 µg unmodified and 12 µg H3K4me3/3 bound TAF3 and
PHF2 similarly to 12 µg of symmetrically modified nucleosome and better than
24 µg of asymmetrically modified nucleosome. These data indicate that it is
the conformation of the H3K4me3 marks that is important in binding both of
these proteins as the increase in mark does not compensate for the lack of the
symmetric H3K4me3 conformation. It is possible that the local concentration of
modification - present on one nucleosome - is important for protein binding. This
could be investigated via pulldowns with asymmetrically modified dinucleosomes
in specific conformations - discussed later.
EZH2 and RING1B are seen bound to lower concentrations of the H3K4me0/3
than any other condition; therefore, the free unmodified H3 N-terminal tail
is responsible for the majority of their binding. EZH2 and RING1B were
only detectable at the higher amounts of the tailless nucleosome, suggesting
that these proteins bound with much lower affinity to nucleosomes solely
containing the H3K4me3 modified tail. A decreased amount of EZH2 binds
24 µg of H3K4me3/tailless compared to 24 µg of both the asymmetric or
symmetric condition, showing the contribution of both the H3K4me3 modified
and unmodified H3 tail to EZH2 binding.
The effect of a singular asymmetrical modification on the binding of repressive
mark binder to nucleosomes was further investigated by titration of H3K27me3/3,
H3K27me0/3 and H3K27me3/tailless nucleosomes. EZH2 bound asymmetric and
symmetric H3K27me3 nucleosomes equally well (see Fig. 5.5, Fig. 5.2 & Fig. 5.3);
therefore binding to both unmodified and H3K27me3 modified H3 N-terminal
tails is similar (see Fig. 5.5 & Fig. 5.3) while it is depleted from binding H3K4me3
































Figure 5.5 Analysis of H3K27me3 Asymmetry. Western blots of proteins bound to
the titrations of differently modified H3K27me3 nucleosomes H3K27me3/3, H3K27me0/3 and
H3K27me3/tailless. EZH2, CBX7, and RING1B were used as representative H3K27me3 mark
binders (labelled in red). The presence of H3K27me3 and H4 are shown as controls.
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to both H3K27me3 and unmodified H3 N-terminal tails can be explained by the
presence of multiple binding sites for modified and unmodified H3 N-terminal
tails in the PRC2 complex (Justin et al., 2016; Jiao and Liu, 2016; Jiao and Liu,
2015; Margueron et al., 2009; Schmitges et al., 2011), although it may be due
to the technical reasons previously mentioned. The reduction in EZH2 binding
to H3K4me3/3 nucleosomes may be due to a reduction in the number of sites
available in the PRC2 complex for H3K4me3 modified tail to bind (Schmitges
et al., 2011).
CBX7 binding to asymmetrically modified nucleosomes is linearly affected by
the presence of the H3K27me3 modification. CBX7 is bound in similar amounts
to 24 µg asymmetric nucleosomes as to the 12 µg symmetrical nucleosomes. If
you double the amount of H3K27me0/3 nucleosomes you get equivalent binding
of CBX7 to H3K27me3/3 nucleosomes. RING1B binding is also affected by
the amount of H3K27me3 present in the sample (Fig. 5.5) although not in
a linear manner. 3 µgs of symmetric nucleosomes binds the same amount of
RING1B as 12 µg of asymmetric nucleosomes. This ratio seems to continue, with
a similar amount of RING1B binding 6 µg of the symmetric nucleosome and the
24 µg asymmetric nucleosome. RING1B’s binding could be a result of both the
concentration of H3K27me3 present and the conformation of the marks on the
nucleosome.
The binding of CBX7, EZH2, RING1B in the H3K27me3 nucleosome titration
mimics that seen in the H3K27me3/3 and H3K27me0/3 nucleosomes via MS
analysis. CBX7, EZH2 and RING1B are all part of multi-subunit complexes,
therefore the binding seen is as a result of all the interactions in the complex. Both
PRC1 and PRC2 have multiple variants that are recruited to different genomic
sites and therefore the subunits that are present in more than one of these variant
complexes will display binding that is a result of these interactions with different
multi-subunit complexes.
Asymmetric nucleosomes, both H3K4me0/3 and H3K27me0/3, did not enrich
for proteins bound to the H3K4me3/3 and H3K27me3/3 nucleosomes or proteins
previously identified in the literature to bind to either H3K4me3 or H3K27me3.
This result was investigated further by a titration of differently modified
nucleosomes. All proteins chosen to be investigated displayed different binding
behaviour, however, there was a division between the representative active mark
and repressive mark binders – the potential significance of which will be discussed
later (see Chapter 7).
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5.4 Characterisation of Proteins That Bind
Bivalent Nucleosomes
5.4.1 Proteins Enriched at Bivalent Domains
Although bivalent nucleosomes have been shown to exist in vivo, their function
and the biological importance of nucleosomes asymmetrically modified with both
H3K4me3 and H3K27me3 is not known. The individual modifications that make
up bivalency have been individually assessed for their effect on protein binding
both symmetrically and asymmetrically (see sections 4.6 and 5.3). The techniques
used to assess how singular asymmetric modifications affect protein binding can
also be used to evaluate the more complex nature of bivalent nucleosomes. How
does the bivalent asymmetric conformation affect the biological function of the
marked nucleosome?
The asymmetrical bivalent modified nucleosome was compared to the unmodified
tagged (H/S) nucleosome (Fig. 5.6) so that the binding of proteins affected by
the tags can be discounted. The binding of a large number of proteins is altered
between these nucleosomes indicating that bivalent nucleosomes affect protein
binding and this is not due to the presence of tags. The bivalent asymmetric
nucleosome was compared to all other nucleosomes tested, in order to isolate
those proteins that prefer to bind to the bivalent asymmetric conformation rather
than any other combination or conformation of H3K4me3 or H3K27me3 (see Fig.
5.6). The proteins previously mentioned to bind to H3K4me3 or H3K27me3 are
shown on these graphs - none of these are consistently significantly enriched on
the bivalent condition.
Neither H3K4me0/3 or H3K27me0/3 enriched for H3K4me3 or H3K27me3 mark
binders compared to the unmodified nucleosomes. Bivalent nucleosomes are
enriched for H3K27me3 marks binders such as CBX7 and EPOP compared to
the unmodified nucleosomes (see Fig. 5.6 & Fig. 5.14), therefore bivalent
asymmetric nucleosomes recruit proteins differently to predicted based on the
protein recruitment by H3K4me0/3 and H3K27me0/3 nucleosomes. The proteins
enriched bound to H3K4me3/H3K27me3 are not simply an amalgamation of
proteins enriched bound to H3K4me0/3 and H3K27me0/3 nucleosomes. The
differences in protein enrichment between the bivalent asymmetric and the















































































































































































































































Figure 5.6 Bivalent Nucleosomes Bind Specific Proteins. Volcano plots of bivalent
asymmetrically modified nucleosomes against all other modified nucleosomes tested here in a
pairwise comparison FDR=0.01. Proteins are classified as significant if Log2 fold change ≥ 1.5
and with a p-value of ≤ 0.01. A)i) The bivalent condition compared to both the untagged and
tagged unmodified conditions. ii) Bivalent condition compared to nucleosomes symmetrically
modified with either H3K4me3 or H3K27me3. ii) Bivalent condition compared to asymmetrically
modified conditions, H3K4me0/3 and H3K27me0/3. Gold labels - proteins enriched in the
bivalent condition (candidate proteins). Red labels - known H3K27me3 binders. Green labels -




































Cluster 1 - PRC2 Complex and Accessory Subunits 
Cluster 2 - Elongin B and additional PRC1 subunits
Cluster 3 - HAT Complexes and HMTs
Cluster 4 - RNA and DNA binding proteins
Cluster 5 - H3K4me3 binders and associated factors 
 - Sin3a complex and SET/MLL complex subunits
Cluster 6 - mRNA associated proteins
Cluster 7 - Proteins depleted from Bivalent nucleosomes
 -Uncharacterised possible zinc finger transcription factors,
 -IN080 complex subunits, TAF proteins.
Pum1, SRSF2,ZRANB2
SRCAP complex subunits - SRCAP DMAP1
MORF subunits - KAT6B
KMT5A, TFE3, USF1
Log 2 Fold Change of Bivalent Nucleosomes Vs. X
-7.0 7.00.0
Figure 5.7 Heatmap of Proteins Significantly Altered on Bivalent Nucleosomes.
Hierarchical clustering of the 217 proteins based on their Log2 fold change in enrichment on
bivalent nucleosomes compared to all other modified nucleosomes. Log2 fold change heatmap of
bivalent nucleosomes vs. X where X is a differently modified nucleosome. This heatmap details
proteins which are significantly altered (FDR=0.01, Log2 fold change ≥ 1.5 and with a p-value
of ≤ 0.01) in at least one of the comparisons between bivalent nucleosomes and differently
modified nucleosomes. Not all the proteins shown are significantly altered in all comparisons.
Proteins grouped in each cluster are shown. Candidate proteins grouped in each cluster are
named below each cluster. Candidate proteins are proteins that are enriched significantly on



































Figure 5.8 EPOP Enrichment on Differently Modified Nucleosomes. Bar graph
showing the enrichment of EPOP on Unmodified untagged, Unmodified tagged, H3K4me3/3,
H3K27me3/3, H3K4me0/3, H3K27me0/3 and bivalent nucleosomes. EPOP is depleted from
H3K4me3/3 nucleosomes, and enriched on H3K27me3/3 and bivalent nucleosomes. The
presence of a singular asymmetric mark (H3K4me0/3 or H3K27me0/3) does not seem to affect
EPOP binding. Bar plots were generated in the R (version 3.5.3) DEP (1.4.1 ) using the Shiny
package.
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Compared to the singularly modified asymmetric nucleosomes, the bivalent
nucleosome consistently enriched for more proteins: including members of
the PcG complexes, as well as EPOP and BPTF. However, none of the
previously mentioned H3K4me3 or H3K27me3 mark binders are enriched on
bivalent nucleosomes compared to the H3K4me3/3 and H3K27me3/3 nucleosomes
respectively. The H3K4me3 mark binders may require the conformation of the
H3K4me3 marks on the symmetrically modified nucleosome in order to bind. The
respective H3K4me3 or H3K27me3 mark binders prefer to bind to the conditions
symmetrically modified for their preferred mark.
EPOP is the only protein associated with PRC2 that is significantly enriched in
the bivalent condition compared to almost all other nucleosomes (see Fig. 5.6 &
Fig. 5.8). EPOP bound to the H3K27me3/3 nucleosome, potentially preventing
the enrichment of EPOP seen at bivalent nucleosomes to be classified as significant
in comparison. EPOP is depleted from H3K4me3/3 nucleosomes and enriched in
the H3K27me3/3 nucleosomes (see Fig. 5.6). However its binding is not affected
by the presence of a singular asymmetric mark H3K4me0/3 or H3K27me0/3
(Fig. 5.2). Therefore its enrichment at bivalent nucleosomes is not solely due
to the presence of a singular H3K27me3 present at the nucleosome as shown
by Fig. 5.6, indicating a potential method of recruitment specific to bivalent
nucleosomes. EPOP can form a variant PRC2 complex which has decreased
H3K27me3 catalytic activity (Alekseyenko et al., 2014; Smits et al., 2014; Liefke
et al., 2016). This variant PRC2 complex may be enriched bound to bivalent
nucleosomes.
The log2 fold change of proteins that are significantly altered in at least one
of the Bivalent Nucleosome Vs. X comparisons (where X is any other modified
nucleosome) are detailed in Figure 5.7. Hierarchical clustering groups the proteins
based upon their relative enrichment in each comparison, allowing proteins with a
similar pattern of enrichment to be visualised easily. These are typically proteins
that are part of the same protein complex or have similar functions. The proteins
that show altered binding in bivalent nucleosome comparisons form seven distinct
clusters based on their Log2 fold change in each bivalent nucleosome comparison.
Cluster 1 contains proteins that are slightly enriched on bivalent nucleosomes
in comparison to the majority of nucleosomes. They are highly enriched on
the bivalent nucleosome in comparison to the H3K4me3/3 nucleosome, whilst
unaltered compared to the H3K27me3/3 nucleosome. This cluster contains PRC2
complex subunits plus accessory factors (described earlier). The behaviour of
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the proteins contained in Cluster 2 – containing PRC1 subunits - follows a
similar pattern although the enrichment seen on bivalent nucleosome compared
to the majority of modified nucleosomes is greater, while depleted on the
bivalent nucleosome in comparison to H3K27me3/3 nucleosome. The behaviour
of these clusters supports their biological role (previously discussed) and previous
analysis. Cluster 3 contains proteins that are enriched on the bivalent nucleosome
compared to all other comparisons and are therefore candidates for proteins that
specifically bind to bivalent nucleosomes. Proteins in Cluster 4 are enriched
on all tagged nucleosomes compared to the bivalent nucleosome suggesting that
their behaviour is affected by the presence of the tags. This cluster is enriched
for RNA/DNA binding proteins. Proteins depleted on bivalent nucleosomes
compared to H3K4me3/3 nucleosomes, and with unaltered binding on bivalent
nucleosomes compared to the other modified nucleosomes are grouped in Cluster
5. This cluster consists of H3K4me3 binding proteins and associated factors
for example members of the SIN3A or SET/MLL complexes. mRNA associated
proteins form a separate cluster – number 6. This cluster contains several proteins
that are enriched on the bivalent nucleosome in all comparisons. The largest
cluster is Cluster 7, this is composed of proteins that are depleted from the
bivalent nucleosome in all comparisons. This cluster contains INO80 complex
subunits and many uncharacterised possible zinc finger transcription factors.
However, their behaviour is affected by the presence of the tags on the nucleosome
and therefore whether their depletion is biologically significant is unknown.
Bivalent binders are proteins that are enriched on the bivalent asymmetric
nucleosome in comparison to all other nucleosomes - shown in yellow in Figure
5.7, and Figure 5.9. The vast majority group in Cluster 3, however, Cluster
6 and Cluster 4 also have some potential candidates. However, not all the
proteins shown in the heatmaps such as Figure 5.7 are statistically significant
in all bivalent nucleosome comparisons. None of the proteins enriched on the
bivalent nucleosome in all comparisons in Cluster 4 were statistically significant
and the behaviour of the proteins contained seems to be affected by the presence
of the tags on the nucleosomes, therefore an enlarged view of this cluster was not
shown. As both Cluster 3 and 6 contain proteins that are statistically significantly
enriched on the bivalent nucleosome in all comparisons, further investigation into
these proteins was undertaken (see Fig. 5.9). Cluster 3 and 6 will be named
Bivalent Cluster 1 and 2, respectively.
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Log 2 Fold Change of Bivalent Nucleosomes Vs. X
A) B)
Figure 5.9 Enlarged View of Bivalent Clusters. Log2 fold change heatmap of bivalent
nucleosomes vs. X where X is a differently modified nucleosome. Not all the proteins shown are
significantly altered in all comparisons. A) Enlarged view of Cluster 3 from Figure 5.7 named
Bivalent Cluster 1. B) Enlarged view of Cluster 6 from Figure 5.7 named Bivalent Cluster 2.
Each protein contained within the cluster is labelled with its UniProt I.D. and candidate proteins
grouped shown in gold.
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HMT complexes (see Fig. 5.9). This cluster contains proteins from both SRCAP,
KAT6B, and HBO1 complexes and certain transcription factors. The identity of
catalytic protein subunits present in this cluster may indicate protein complexes
recruited to bivalent nucleosomes and help isolate bivalent domain function.
Investigation of the Bivalent Cluster 2 shows that it is enriched mostly for mRNA,
splicing or uncharacterised proteins (see Fig. 5.9). This cluster contains some
transcription factors, and various proteins involved in the establishment of the
premRNA spliceosome such as SRSF2 and ZRANB2.
Proteins that are statistically significantly enriched bound to the bivalent
nucleosome in all comparisons were isolated via volcano plot analysis (see Fig.
5.6). This was done to reduce the list of potential bivalent binders and isolate the
high confidence bivalent binders. There are nine proteins that are consistently
significantly enriched in the bivalent asymmetric condition compared to all other
nucleosomes: PUM1, USF1, DMAP1, ZRANB2, SRCAP, KMT5A, SRSF2,
TFE3, and KAT6B (Fig. 5.6, Fig. 5.7 & Fig. 5.9 - gold labels). There were no
proteins that were consistently significantly depleted from the bivalent condition
via this analysis. These consistently enriched proteins were termed “candidate
proteins” and prefer to bind to the bivalent asymmetric conformation present in
bivalent domains.
These enriched candidate proteins contain RNA splicing or binding proteins
(SRSF2, PUM1, and ZRANB2), bHLHzip class of transcription factors which
bind E-box sequences (TFE3, and USF1), and proteins which are part of
complexes that can modify histones (KMT5A, DMAP1, KAT6B and SRCAP).
They may contain proteins that are important in the establishment, maintenance
or biological function of bivalent domains. To confirm and verify these results, the
data was reanalysed using the R package DEP (Differential Enrichment of Protein
Data), which provides a workflow for robust analysis of proteomics data (Zhang
et al., 2018). Although the p-value and fold changes of the candidate proteins
were altered slightly with these new parameters, the majority of the candidate
proteins identified via the Perseus software remained significantly enriched in the
bivalent sample see Figure 5.11, and Figure 5.10, showing the reliability of the
analysis methods used. The candidate proteins still enriched after the second
analysis are: PUM1, SRSF2, USF1, TFE3, ZRANB2, DMAP1, SRCAP, and
KAT6B. The binding of these proteins is unaltered by the presence of the tags as
seen in Figure 5.11 and Figure 5.10.










































































































































































































































































Figure 5.10 Candidate Protein Enrichment. Bar graphs showing individual enrichment
for the candidate proteins at each nucleosome condition. None of the candidate proteins is
significantly affected by the presence of the tags on the asymmetrically modified nucleosomes.
All candidate proteins are enriched in the bivalent asymmetrically modified condition. Bar plots
were generated in the R (version 3.5.3) DEP (1.4.1 ) using the Shiny package.
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vary, with the proteins present in multiple complexes or in ubiquitous processes
such as RNA splicing having higher copy numbers. KAT6B, DMAP1 and SRCAP
all have copy numbers several orders of magnitude lower (see Fig. 5.12) (data
from Zhang et al. (2017)), this may be due to their presence in fewer complexes
and more specific biological functions. The fold change seen in a protein with
low copy numbers may be a greater proportion of the total number of protein
molecules in the cell compared to the same fold change in a protein with a high
copy number. Therefore the same fold change in a low copy number protein
may be more likely to result in a biological effect. The proteins with lower copy
numbers in the cell may have more specific binding as there are fewer molecules to
communicate their function. The copy number of proteins may have implications
for binding, as proteins with lower affinity for bivalent nucleosomes may still show
appreciable binding if present in large amounts in the cell (high copy number).
SRSF2 is a serine-arginine rich splicing factor which is required for the formation
of the pre-mRNA spliceosome and regulates alternative splicing (Edmond et al.,
2011; Pellagatti et al., 2018; Yoshida et al., 2011; Liu et al., 2000). Several
other serine-arginine rich proteins such as SRSF1 and SRSF3 have been shown
recently to bind to the H3 tail to control cell cycle progression and be targeted
by chromatin remodelling complexes (Loomis et al., 2009), potentially indicating
a mechanism for SRSF2 function. Pum1 is an RNA binding protein which
has multiple functions, including regulating the stability and function of certain
mRNAs (Van Etten et al., 2012). ZRANB2 is a relatively uncharacterised splicing
protein which is involved in regulating pre-mRNA alternative splicing (Mangs and
Morris, 2008; Adam et al., 2001). None of the proteins these candidate proteins
are known to interact with are enriched on bivalent nucleosomes.
As bivalent genes contain poised RNAPII, the selective recruitment of SRSF2
to bivalent nucleosomes suggests a method for eventual RNAPII release into
productive elongation when the gene becomes activated. SRSF2 may be pre-
emptively loaded at bivalent domains to decrease the time between activation
of bivalent domains and transcription, or its presence may result in the small
level of transcription seen at bivalent genes (Bernstein et al., 2006a; Guenther
et al., 2007; Brookes et al., 2012). The co-occurrence of PUM1 and ZRANB2
in addition to SRSF2 indicates a role for co-transcriptional, alternative splicing
in the function of bivalency. Further studies will be required to determine how
these proteins are recruited to bivalent domains, how they help interpet bivalen
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Figure 5.11 Candidate Proteins are Unaffected by Tags and Enriched in the
Bivalent Condition. Volcano plots of A) Untagged control compared to tagged control i)
candidate proteins from Perseus labelled - gold. ii) Components of the MORF complex labelled
- gold. None of the proteins are significantly affected by the presence of the tags. B)Volcano
plots of the bivalent asymmetrically modified nucleosome condition against the unmodified tagged
nucleosome condition with i) candidate proteins shown ii) components of MORF complex shown
in gold. Proteins are classified as significant if they were enriched by Log2 ≥ 1.5 and have a p
value lower than 0.01. Volcano plots were generated in ggplot2 in R (3.5.3.).
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Figure 5.12 Copy Numbers of Candidate Proteins and Complexes. Candidate proteins
are labelled in pink. Components of SRCAP complex are shown in yellow. Components of
MORF/MOZ complex shown in green. Copy numbers are the number of protein molecules per
cell. Data displayed from Zhang et al. (2017).
The transcription factors recruited to bivalent nucleosomes include USF1 and
TFE3. USF1 is present at bivalent domains and although dispensable for ESC
renewal is required for ESC differentiation (Deng et al., 2013). TFE3 has diverse
functions. It supports ESC pluripotency and is excluded from the nucleus during
differentiation (Betschinger et al., 2013; Kalkan et al., 2017). This combination
of transcription factors at the same location required both for the pluripotency
and differentiation of ESCs supports the theory of bivalent domain importance
in priming developmental genes for timing regulation during differentiation.
KMT5A places H4K20me1 which is present at bivalent domains (Cui et al., 2009)
although its significance at bivalent domains is not known. H4K20me1’s function
is still unclear with some attributing its role to gene expression (Talasz et al.,
2005; Vakoc et al., 2006; Barski et al., 2007), cell cycle control (Jorgensen et
al., 2013; Beck et al., 2012), RNAPII pausing (Kapoor-Vazirani and Vertino,
2014) and others to gene repression (Nishioka et al., 2002; Kohlmaier et al., 2004;
Karachentsev et al., 2005; Congdon et al., 2010).
DMAP1 is part of multiple complexes including NuA4 and the SRCAP complex
(Doyon et al., 2004; Cai et al., 2003; Mohan et al., 2011), of which the SRCAP
protein is the catalytic component. The SRCAP complex along with the p400
complex deposits H2A.Z in chromatin by catalysing the exchange of H2A/H2B
for H2A.Z/H2B in the nucleosome (Wong et al., 2007; Liang et al., 2016; Ruhl
et al., 2006; Gévry et al., 2007; Cai et al., 2005). H2A.Z is essential for embryo
development (Faast et al., 2001). Its role in transcription is controversial, having
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been linked to both repression (Rangasamy et al., 2003; Fan et al., 2004) and
activation (Barski et al., 2007; Zhang et al., 2005; Meneghini et al., 2003; Wan
et al., 2009; Mavrich et al., 2008; Schones et al., 2008). Its role in transcription
may therefore be context dependent (Fan et al., 2002; Li et al., 2005a; Millar
et al., 2006; Raisner et al., 2005; Swaminathan et al., 2005; Zhang et al., 2005)
as it allows both MLL and PRC2 complexes to bind to chromatin (Hu et al.,
2013b). In mouse ESCs it is enriched at active and bivalent promoters but
excluded from repressed genes (Ku et al., 2012). A knockdown of H2A.Z leads
to de-repression of bivalent genes (Hu et al., 2013b; Creyghton et al., 2008).
SRCAP and its product H2A.Z has been posited to poise inactive promoters
on which it is located for timely regulation (Wan et al., 2009; Ku et al., 2012;
Guillemette et al., 2005; Zhang et al., 2005; Giaimo et al., 2019). GAS41 (also
referred to as YEATS4) is a subunit of SRCAP that reads H3 acetylation of
K27 and K14, recruiting SRCAP and promoting the deposition of H2A.Z. A
knockdown on GAS41/YEATS4 results in a decrease of H2A.Z and H3K27me3
at bivalent domains (Hsu et al., 2018a). Other subunits of the SRCAP complex
were enriched on bivalent nucleosomes in comparison to unmodified nucleosomes
including YEATS4 and VPS72 suggesting formation of this complex is enriched
at bivalent nucleosomes (see Fig. 5.13).
KAT6B is part of the multi-subunit complex MORF and acetylates H3 at K9, K14
and K23 (Ullah et al., 2008; Voss et al., 2009; Sheikh and Akhtar, 2019; Simó-
Riudalbas et al., 2015; Qin et al., 2011; Ali et al., 2012). H3K14ac and H3K23ac
are both found at bivalent domains (Voigt et al., 2012; Karmodiya et al., 2012).
Investigation into KAT6B’s biological function via any one of these marks is
difficult as they are placed by a multiple enzymes, including KAT6B, KAT6A
and KAT7 (Sapountzi and Côté, 2011; Sheikh and Akhtar, 2019). KAT6B’s
placement of H3K14ac found at bivalent domains and SRCAP’s recruitment to
bivalent domains via GAS41 suggests a link between these complexes and their
function. The enzymatic activity of and potential link between SRCAP and
KAT6B may be necessary for bivalent domain maintenance and function.
All of these candidate proteins may help the cell mediate bivalent domain
function; however, only a few could be investigated further within the scope
of this thesis. SRCAP and KAT6B are the catalytic subunit of their respective
complexes and analysis of the heatmap (Fig. 5.9) shows the presence of additional
complex subunits in the same cluster and therefore exhibiting similar binding
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Figure 5.13 Enrichment of SRCAP Complex Subunits. Volcano plot of bivalent
nucleosome compared to unmodified tagged nucleosome. Four core SRCAP components are
enriched on the bivalent nucleosomes compared to the control. SRCAP complex subunits shown
in gold. Data from DEP suite analysis in R version 3.5.3. Volcano plots were generated in
ggplot2 in R (3.5.3.). Proteins are classified as significant if they were enriched by Log2≥1.5
and have a p value lower than 0.01.
enriched on bivalent nucleosomes in all comparisons and therefore are not shown
in Figure 5.6. Therefore KAT6B and SRCAP (Snf2 Related CREBBP Activator
Protein) (Fig. 5.14) were chosen for further investigation as they are significantly
enriched after both analyses and are the catalytic subunits of multi-protein
complexes, MORF and SRCAP respectively, both of which containing multiple
protein binding domains. The other subunits in these complexes exhibit similar
binding behaviour to KAT6B and SRCAP (see Figure 5.7 and 5.9) enriched bound
to the bivalent nucleosome supporting a role for these complexes at bivalent
domains. In addition, the histone PTMs H3K14ac, H3K23ac and H2A.Z that are
placed by MORF and SRCAP respectively, are found at bivalent domains (Voigt
et al., 2012; Karmodiya et al., 2012).
KAT6B and SRCAP are components of large multisubunit complexes giving
plausible possibilities for recruitment, modification, maintenance to bivalent
domains. Both of these proteins have low copy numbers in the cell (Fig. 5.12) and
are only present in one complex, allowing easier dissection and analysis of their
function although this increases the difficulty of visualisation of localisation in
vivo via ChIP. The low copy number of both these proteins in ESCs, in addition

































































































Figure 5.14 Selected Protein Enrichment in all Conditions. Plots showing the
enrichment of selected active mark binder TAF3 (green), repressive mark binder CBX7 (red)
and candidate proteins SRCAP (yellow) and KAT6B (gold) in all conditions. Bar plots were
generated in the R (version 3.5.3) using the DEP suite (1.4.1) and the Shiny package.
2012), indicates that these proteins are involved in distinct biological mechanisms
occurring at specific locations in the genome that are integral to differentiation
and embryonic development. The enrichment of these proteins and complex
subunits, as well as the presence of their marks at bivalent domains indicated that
SRCAP and KAT6B are good candidates for proteins bound to bivalent domains
in vivo and possible candidates for mediating their function. To resolve their
possible role in bivalent domain function we generated mESCS using CRISPR-
Cas9 expressing tagged versions of both SRCAP and KAT6B or knockouts of
these proteins. However, because we failed to obtain meaningful enrichment
in chromatin immunoprecipitation experiments with tagged SRCAP, precluding
analysis of its binding to bivalent domains in mESCs, we focused on investigating
KAT6B function.
KAT6B is a paralogue of KAT6A (Champagne et al., 1999) and shares 60%
sequence identity, while their acetyltransferase MYST domain shares 88%
sequence identity (Thomas et al., 2000). KAT6B has higher copy numbers in
mESCs than KAT6A, suggesting a higher expression level and potentially a
larger role in mESCS (Fig. 5.12) (Zhang et al., 2017). The similarity of KAT6B
and KAT6A initially made separation of their functions difficult, as most early
commercial antibodies could not distinguish between the two proteins. Because
of their similarity, generalisations can be made from one complex to the other.
More recent studies have managed to untangle some of their function. The
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MORF complex consists of 4 proteins: KAT6B, MEAF6, ING5, and BRPF1/2/3
(Ullah et al., 2008). These subunits are enriched to similar, albeit slightly
lower, levels as KAT6B in the bivalent pulldown condition compared to the
unmodified nucleosome, see Figure 5.11, suggesting KAT6B is present in this
complex when bound to bivalent nucleosomes. The MORF complex contains
multiple histone PTM reader domains: 5 PHD domains, one PWWP domain,
and one Bromodomain, potentially allowing the MORF complex to integrate the
signals of multiple histone modifications.
The N-terminal portion of KAT6B including its MYST domain shares high
similarity with Drosophila ENOK (Yang, 2004), which also assembles with
Br140, Ing5, and Eaf6 which are the Drosophila orthologs of BRPF1/2/3,
Ing4/5, and MEAF6, respectively. KAT6 complex formation and binding
domains are evolutionary conserved from yeast to humans with some slight
alterations/differences, for example Yng1 is the ortholog of ING1-2 rather than
ING5 but still contains a PHD domain which binds H3K4me3 (Huang et al.,
2016; Gordon et al., 2008). This evolutionary conservation between yeast and
humans suggests that KAT6 complexes play an important and crucial role in
a wide variety of organisms. Mutations, deletions and translocations of KAT6B
result in multiple diseases including leukemia and several developmental disorders
(Yang, 2015).
KAT6B consists of an N-terminal domain referred to either as NEMM (N-terminal
part of ENOK) due to its similarity to ENOK’s N-Terminal domain or H15
domain due to its sequence similarity to H1 and H5 histones. This is followed by
a double/tandem PHD domain, the MYST domain, and a C-Terminus consisting
of a glutamate/aspartate rich (ED) and a serine/methionine rich (SM) domain
(Klein et al., 2014; Ullah et al., 2008; Yang and Ullah, 2007; Scott et al., 2001;
Ullah et al., 2008). The ED and SM domains present in the C-Terminal tail of
KAT6B help MORF’s transcriptional activity via interaction with Runt-domain
transcription factor 2 (Runx2) (Pelletier et al., 2002; Coffman, 2003). The tandem
double PHD domain (DPD) of KAT6B is required for KAT6B association with
acetylated H3 N-terminal tails. The DPD recognises the unmethylated H3 N-
terminal tail, its binding is increased 3-4 fold in the presence of H3K14ac or
H3K9ac, but inhibited by the presence of H3K4me3 (Ali et al., 2012). The
presence of H3K14/9ac partially mitigates the effect of H3K4me3 on binding
(Klein et al., 2017). This specificity is conserved for the DPD of KAT6A/MOZ.
MOZ complexes, when recruited to H3K14ac, cannot modify lysines in the
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same peptide (Ali et al., 2012), suggesting a potential mechanism of H3K14ac
propogation by MORF/MOZ complexes. Once H3K14ac is bound by MORF’s
double plant homeodomain finger (DPF), its MYST domain may target lysines
in the H3 in the same or adjacent nucleosomes (Klein et al., 2017).
KAT6B has a wide range of substrates and its MYST domain in vitro is able to
acetylate H2A, H3 and H4; however, the association of BRPF1 and ING5 helps
narrow its acetyltransferase activity to nucleosomal H3 (Yang, 2015; Doyon et al.,
2006; Ullah et al., 2008; Qin et al., 2011). MORF’s HAT targets are still unclear
but MOZ/MORF has been suggested to place H3K14ac (Ullah et al., 2008; Ali
et al., 2012), H3K9ac (Voss et al., 2009), and H3K23ac (Sheikh and Akhtar, 2019;
Simó-Riudalbas et al., 2015; Mi et al., 2017). BRPF1 (αα 150-245) interacts with
KAT6B’s MYST domain (αα 761-782) changing MORF’s specificity from H4 to
H3 and increasing its acetyltransferase activity (Ullah et al., 2008; Doyon et al.,
2006). BRPF1 has two PHD fingers separated by a Zinc finger (PZP) and a
Bromodomain. The PZP domain binds in 2:1 stoichiometry to the nucleosome,
shifting the equilibrium to unwrapping DNA from the nucleosomes, increasing
accessibility (Klein et al., 2016). The first PHD finger binds the unmodified H3
tail, however this binding is prevented by methylated H3K4. The second PHD
finger interacts non-specifically with DNA and both PHD fingers are required for
BRPF1/MORF’s binding to H3 in vivo (Lalonde et al., 2013; Liu et al., 2012).
BRPF1’s bromodomain (αα 679-766) recognises and binds to acetylated histone
lysine residues with a preference for H3K14ac, H4K12ac, H2AK5ac while its
PWWP (αα 1126-1226) binds both H2A/H2B and H3K36me3 and is necessary
for BRPF1/MORF association with condensed chromatin (Poplawski et al., 2014;
Ruthenburg et al., 2011; Laue et al., 2008; Qin et al., 2011; Klein et al., 2016).
BRPF1 and ING5 are essential for the formation of the MORF complex, and
BRPF1 bridges the interaction between hEAF6 and ING5 by its M domain
(Ullah et al., 2008). ING5 is part of the ING family of tumour suppressor
proteins and contains a PHD domain which binds to methylated H3K4, with a
binding preference of H3K4me3>H3K4me2>H3K4me1>H3K4me0 (Champagne
et al., 2008). The inclusion of ING5 is essential for the MORF complex’s
acetyltransferase activity (Champagne et al., 2008) and causes MORF to
acetylate methylated H3K4 peptides. This allows MORF to be recruited to and
modify areas of chromatin containing H3K4me3. hEAF6 (191 αα) is the least
characterised of the MORF complex subunits. It contains a leucine zipper motif
and its expression helps the nuclear localisation of BRPF1 (Klein et al., 2014).
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Figure 5.15 Schematic Structures of MORF Complex Subunits and Protein
Domains. Domains are labelled as follows: PHD - Plant homeodomain zinc finger, ZnF
- Zinc finger, H15 - Sequence similarity to H1 and H5 histone domain, also referred to as
NEMM, MYST - Acetyltransferase domain, ED - acidic (glutamate/aspartate rich) region,
SM - Serine/methionine rich stretch, Bromo - bromodomain, PWWP - proline-tryptophan-
tryptophan-proline domain, B - domain that interacts with KAT6B’s MYST domain, M -
domain that mediates BRPF1’s interaction with ING5 and hEAF6.
Due to the number of protein domains contained within the MORF complex there
are a multitude of possible mechanisms for its recruitment to bivalent domains
(Fig. 5.15). The PHD finger of ING5 interacts with H3K4me3 helping recruit
the MORF complex while the DPF of KAT6B and PZP domain of BRPF1 can
recruit the MORF complex to H3K4me0 - present on the H3K27me3 tail of
an asymmetric bivalent nucleosome. The bromodomain of BRPF1 and DPF of
KAT6B can recognise the marks placed by the MOZ/MORF complex, resulting in
a feedforward loop and potential spreading or amplification of MORF’s signals.
MORF-like complex subunits in Drosophila, ENOK and EAF6, interact with
Polycomb (Pc) a PRC1 complex member (Strubbe et al., 2011). If this interaction
is maintained in mice and KAT6B and hEAF6 interact with CBX proteins it
provides a further mechanism for MORF’s recruitment to bivalent nucleosomes
and one that is directly dependent on H3K27me3.
5.4.2 Proteins Depleted from Bivalent Nucleosomes
We primarily focused on the proteins bound by bivalent domains as they may
mediate their biological function. However, the proteins depleted from bivalent
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Figure 5.16 Proteins Depleted from the Bivalent Nucleosome. Volcano plots showing
the proteins depleted A) from the unmodified untagged control versus the unmodified H/S control
B) from the bivalent condition in comparison to the unmodified H/S control. INO80 complex
subunits light blue, TAFs - green and BTB domain containing proteins - dark blue. Data
obtained from the DEP analysis suite in R.
initial analysis using the Max-Quant suite of programmes including Perseus did
not find any proteins that were depleted from the bivalent condition relative to
all other conditions investigated. Nevertheless, a comparison of the unmodified
H/S nucleosome versus the bivalent nucleosome, via both analyses used, shows a
large number of proteins depleted (Fig. 5.16). The proteins previously used as
controls for binding to H3K4me3 or H3K27me3 have been demonstrated not to be
affected by the presence of the tags required for the purification of asymmetrically
modified nucleosomes (see Fig. 5.1).
There are various proteins that are depleted from the bivalent condition relative
to the tagged control. These can be split into 3 groups: subunits of the INO80
complex (light blue), proteins containing a BTB domain or zinc finger (darker
blue) and a variety of transcription associated proteins (TAFs) (green) (Fig.
5.16). Unfortunately, the proteins depleted from bivalent nucleosomes compared
to unmodified tagged nucleosomes are all affected by the presence of the tags
on the octamer (Fig. 5.16). Both TAFs and BTB domain containing grouped
proteins are depleted from bivalent nucleosomes, but enriched at unmodified
tagged nucleosomes with approximately the same fold change, albeit in opposite
direction.





































































































































































Figure 5.17 INO80 Complex Subunit Enrichment. DEP plot of IN080 complex subunits
presence in all conditions. Symmetrically modified nucleosomes have a slight reduction in
the presence of INO80 subunits compared to the control. INO80 subunits are enriched at
asymmetrically singularly modified nucleosomes due to the tags present on histone H3, however
they are depleted from bivalent asymmetrically modified nucleosomes. The depletion of the
subunits from bivalent nucleosomes is generally greater than the enrichment seen in the other
asymmetric nucleosomes.
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approximately 2−fold bound to nucleosomes containing the tags (see Fig. 5.17),
they are depleted, around 4−fold, from the bivalent condition. This indicates that
the decrease is due to the presence of the bivalent marks. Due to their increased
affinity towards the tagged nucleosomes we cannot say whether the depletion
seen in the bivalent condition compared to unmodified H/S is biologically
significant. IN080 is a part of the SWR1 family of ATP-dependent chromatin
remodelling complexes (Bao and Shen, 2007; Brahma et al., 2017; Papamichos-
Chronakis et al., 2011) and the depletion of IN080 from bivalent nucleosomes
may reduce the rate of exchange of H2A.Z/H2B for H2A/H2B from bivalent
domains, keeping them poised for quick transcription and thus biologically
relevant. Further pulldown experiments with bivalent untagged nucleosomes
would allow investigation into this depletion - detailed later.
The enrichment of proteins on the tagged versus the untagged control indicates
that these proteins may interact with the surface of the nucleosome that contains
the tags as well as the histone marks. As a result of these complicating
variables it cannot be known whether the depletion of the proteins from the
bivalent nucleosome in comparison to the tagged control is biologically significant.
However, all the proteins that were depleted from bivalent nucleosomes are also
enriched in the tagged control vs untagged control, suggesting that they are
unlikely to be significant. The lack of certainty about the actual state of binding
of these proteins meant they were excluded from further immediate study. In
order to assess whether the proteins depleted from the bivalent condition are
biologically relevant and not due to the presence of tagged histone H3, generation
of untagged bivalent H3K4me3/H3K27me3 and comparison with unmodified
untagged nucleosomes would be required.
5.5 Conclusion
Although multiple previous studies have investigated the biological function
of symmetrically modified nucleosomes and the proteins that bind them, the
full effect of an asymmetric, singular modification has yet to be investigated.
How the asymmetric state affects identity and kinetics of protein binding was
unknown. The use of singularly asymmetrically modified nucleosomes showed
the lack of protein enrichment in comparison to unmodified nucleosomes. The
presence of a single H3K4me3 mark is not sufficient to recruit active mark binders
including TAF3 and PHF2 at amounts similar to H3K4me3/3 nucleosomes.
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Additionally, the inhibition of EZH2 binding to H3K4me3/3 is reduced with
H3K4me0/3; therefore it is unlikely that H3K4me0/3 nucleosomes are able to
maintain the active state in vivo. H3K27me0/3 recruits PRC2 components
similarly to H3K27me3/3 although it is less efficient in recruiting components of
the PRC1 complex such as CBX7. The reduction in CBX7 binding is H3K27me3
concentration dependent. The recruitment of proteins to singularly modified
asymmetrically modified nucleosomes may allow prediction of the transcriptional
state of these nucleosomes in vivo.
The difference in the behaviour of proteins binding symmetrically modified,
asymmetrically modified or unmodified nucleosomes raises the question whether
the effects seen are due to the local concentration of histone PTMs, or the
conformation of the PTMs in a symmetric nucleosome. The titration of both
symmetrically and asymmetrically nucleosomes showed that with certain proteins
including TAF3 and PHF2, the overall concentration of the nucleosomes and the
marks does not result in a linear increase in protein binding. However, the local
concentration of marks on the beads or the nucleosomes themselves may affect
the protein binding. Electrophoretic Mobility Shift Assays (EMSAs) with purified
TAF3 binding to nucleosomes in solution without immobilisation on beads would
allow the effect of the beads to be seen clearly. Increasing the amount of beads
relative to the concentration of nucleosomes (data not shown) showed an increase
in TAF3 binding when the nucleosomes were more dilute and not saturated on the
beads. This indicates that there may be steric hindrance between proteins binding
the nucleosomes and the present of either other nucleosomes on the same bead or
other proteins binding the adjacent nucleosome. This may also explain the lack
of other TFIID subunits present bound to H3K4me3/3 nucleosome. Pulldowns
with dinucleosomes may help proteins with high Koff constants or large protein
complexes to bind due to the additional interaction surfaces provided by the
additional nucleosome. Pulldowns with asymmetrically modified dinucleosomes
in various conformations would allow investigation whether it is the specific
conformation of PTMs present on a symmetric nucleosome that is required for
protein binding or whether the local concentration of PTMs present on the
nucleosome or dinucleosome is sufficient for the protein to bind.
Once the effect of the singular modifications was known, investigation into
bivalent nucleosomes containing H3K4me3 on one H3 N-terminal tail and
H3K27me3 on the other sister H3 could begin. Due to complicating presence
of the tags no proteins solely depleted from bivalent asymmetric modified
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nucleosomes could be determined. There are multiple methods that have been
recently developed in order to generate asymmetrically modified nucleosomes,
without the use of tags including the XY (Ichikawa et al., 2017) or ’link and cut’
tag (“lnc-tag”) (Lechner et al., 2016) methodology. The lnc-tag methodology
relies on a transient crosslinking strategy between two H3 molecules each carrying
distinct PTMs, forcing the assembly of them into the same histone octamer and
later on the creation of an asymmetrical nucleosome. This lnc-tag contains a
TEV cleavage site, allowing cleavage of the tag and resulting in an asymmetric
nucleosome without tags and the crosslink removed (Lechner et al., 2016). The
XY methodology generates asymmetric histones octamers, via the use of a pair
of obligate H3 histone dimers termed H3X and H3Y. These obligate dimers were
created via the mutation of a total of 7 mutated residues located at the site of
the H3/H3 interface - H3X (C96S, C110A, L126A, and I130V) and H3Y (C96S,
L109I, and C110W) (Ichikawa et al., 2017). The use of either of these approaches
would allow the generation of asymmetric nucleosomes both bivalently modified
and asymmetric mono-modified nucleosomes without the complications caused
by the presence of the tags.
The proteins that bound to the bivalent nucleosome were not simply an
amalgamation of the proteins bound to H3K4me0/3 and H3K27me0/3. EPOP
is enriched at bivalent nucleosomes, along with CBX7 and EZH2, suggesting the
enrichment of PRC2/EPOP complex at bivalent domains as well as a canonical
PRC1 complex. I identified several proteins including KAT6B that prefer to
bind to this bivalent asymmetric conformation. These are proteins that are
enriched bound to bivalent nucleosomes in comparison to any other conformation
or combination of marks. KAT6B was chosen for further investigation into its




Recruitment of KAT6B to Bivalent
Domains in vivo and its Role in
Neuronal Differentiation
6.1 Introduction
There are relatively few studies that took an unbiased approach to find novel
binders of bivalent domains (Beringer et al., 2016; Gao et al., 2018; Ma et
al., 2016; Yang et al., 2018; Hsu et al., 2018a; Ku et al., 2012). This study
aimed to identify previously unrecognised proteins bound to bivalent domains
and determine their function, thereby helping to elucidate bivalent domain
function within cells. The techniques used in previous chapters have identified
several proteins that preferentially bind to bivalently modified nucleosomes. If
the identified proteins are involved in interpretation of the bivalent domain in
vivo, we would expect to see them at bivalent domains in vivo and a knockout
(KO) of the protein to affect bivalent domain function. If the protein is
involved in regulating bivalent domain function, a KO would potentially result
in the aberrant expression of genes that are bivalent; either in ESCs or during
differentiation while having not effect on the self-renewal of ESCs. The previous
chapter showed that KAT6B was enriched bound to bivalent nucleosomes and




In this chapter I aim to explore the role of KAT6B within the cell and
its possible role in regulating bivalent domains. This investigation aims to
discover proteins that bind bivalent domains and from their identification
and characterisation elucidate bivalent domain function. Previous chapters
identified proteins bound to bivalently modified nucleosomes in vitro; however,
their function and role in vivo with respect to bivalent domains has yet to
be characterised. Time constraints limited the scope of investigation to a
singular protein - KAT6B. The utilisation of several techniques including CRISPR
(”Clustered Regularly Interspaced Short Palindromic Repeats”) genome editing,
chromatin immunoprecipitation (ChIP), and neuronal cell differentiation helped
characterise KAT6B function with ESCs and throughout differentiation. ChIP
and differentiation assays were performed in collaboration with several Voigt
lab members. Cell lines including HA-FLAG-KAT6B and KAT6B(-/-) were
generated with CRISPR (type II) allowing deeper analysis of KAT6B function and
importance within ESCs. ChIP was used to analyse the distribution of KAT6B
within the genome, how KAT6B localisation is altered upon removal of bivalency
and the effect on a selection of histone marks upon removal of KAT6B. Neuronal
differentiation of KAT6B(-/-) ESCs allowed examination of KAT6B’s importance
and function throughout differentiation.
6.3 KAT6B Binds to Bivalent Domains In Vivo
This study has shown that KAT6B binds to bivalent nucleosomes in vitro
however, its binding to bivalent domains has not yet been demonstrated in
vivo. Confirmation of KAT6B’s binding to bivalent domains is required before
we can closely examine KAT6B and its role in cells. None of the previous
studies into KAT6B function have managed to directly detect KAT6B binding
in vivo, instead they relied on the indirect readout of the marks it places, for
example H3K14ac and H3K23ac. Since multiple enzyme complexes place the
same marks, KAT7 places H3K23ac and KAT6A or GCN5 place H3K14ac (Lo
et al., 2000; Sheikh and Akhtar, 2019; Baell et al., 2018) these readouts are
consequently open to confusion. The majority of available commercial antibodies
fail to distinguish between KAT6B and KAT6A due to their homology, making
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them inadvisable for experimental use (data not shown). In order to distinguish
between KAT6A and KAT6B we tagged endogenous KAT6B via CRISPR in order
to allow identification of genomic locations bound by KAT6B, this also enabled
us to purify the MORF complex via the tagged KAT6B. KAT6B was tagged
with a 3 X FLAG 1 X HA tag (Fig. 6.1) to enable its purification and allow the
use of high affinity antibodies to increase sensitivity of KAT6B detection in vivo
and in vitro. The general method of screening for positive CRISPR clones and
confirmation of successful generation of desired cell lines is shown in Figure 6.1
illustrated with the generation of tagged KAT6B.
The CRISPR strategy used to tag KAT6B is detailed in Figure 6.1. PCR
Screening of positive single cell-derived colonies was accomplished using various
selected primers and allowed identification of homozygous or heterozygous cells
containing tagged Kat6b. The initial PCR allows the selection of cells containing
the tag. These then undergo a second PCR that allows determination of whether
the cells are homozygous or heterozygous for tagged Kat6b. These results were
confirmed by sequencing and at the protein level by analysis via western blot
(Fig. 6.1). All other cell lines generated by CRISPR and used in this thesis
underwent a similar PCR screening, sequencing and western blot confirmation
process. The combination of low copy numbers of KAT6B in ESCs (Zhang et
al., 2017) and low sensitivity or insufficient specificity of commercial antibodies
for KAT6B meant that western blot confirmation of untagged KAT6B binding in
the in vitro pulldown experiments was ineffective (data not shown); therefore, the
nucleosome pulldowns were repeated using nuclear extract from the tagged-Kat6b
cell lines, enabling the use of higher sensitivity antibodies. In this way, the MS
results were confirmed by western blot analysis (Fig. 6.2). The tagged KAT6B
(HA-KAT6B) is present in greater amounts bound to bivalent nucleosomes (Fig.
6.2).
As the tagged cell lines had enabled detection of KAT6B with the use of
HA antibodies which are viable for use in ChIP experiments, the distribution
of KAT6B in the genome was investigated. A comparison of H3K4me3 and
H3K27me3 in both wild-type and HA-KAT6B cell lines was done in order to
ensure that the tagging of KAT6B did not affect levels of these modifications
(data not shown). KAT6B’s binding to a selection of genes including active,
inactive/repressed, and bivalent genes was analysed (Fig. 6.3). KAT6B binds in
similar amounts to both active and bivalent gene promoters but is depleted from
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Figure 6.1 CRISPR Strategy for the Generation of Tagged-KAT6B A) Schematic
of CRISPR strategy for introducing a 1 X HA 3 X FLAG tag into the Kat6b genomic locus -
not to scale - including the sequence of the guide RNA and PAM (highlighted in purple). The
location and sequence of the tag is detailed along with the location of the PAM in relation to the
target sequence. Location of the single stranded oligo deoxynucleotide (ssODN) donor homology
is shown along with PCR primer positions. The (BsrGI) enzyme restriction site created by the
desired mutations for potential use in Southern blotting is shown in blue. B) PCR screening for
positive single cell-derived colonies. i) PCR 1 amplifies the part of the tag allowing identification
of cells with alleles containing tagged-Kat6b. Only the cell colonies that were positive in PCR1
were then assessed via PCR2. ii) PCR 2 amplifies a region of the KAT6B gene that includes the
complete sequence encoding the DNA sequence for the tag allowing identification of homozygous
or heterozygous cells. A non-specific DNA band is present around 550 bp. The genotype of each
clone is detailed in the table above. Each band from PCR 2 was gel-extracted and sequenced.
C) Western blot analysis of previously identified (via PCR genotyping) positive cell lines. The
cell lines illustrated in part B do not directly correspond to those seen in part C. Approximately
hundred cell colonies were screened by PCR, only those positive via PCR were then screened
via western blot. The presence of the tagged KAT6B is verified by the HA antibody. Numbered

















































Figure 6.2 Confirmation of KAT6B Binding. Western blot analysis of proteins bound
to beads only (–), unmodified, H3K4me3/3, H3K27me3/3 and bivalent nucleosomes. H3K4me3
binders labelled in green, H3K27me3 binders labelled in red, KAT6B labelled in gold. H3K4me3,












































































































A) i) ii) iii)
Figure 6.3 ChIP of HA-KAT6B. A) Real-time PCR ratios reflect the enrichment of
indicated sites when ES cells are subjected to ChIP with a selection of genes covering active,
inactive and bivalent genomic regions are shown. Results for i) H3K4me3 antibody, ii)
H3K27me3 antibody, iii) HA-KAT6B antibody. WT - HA-KAT6B cells. All experiments were
performed in triplicate with the standard error of the experiments shown. H3K4me3 is present
at both active promoters and bivalent domains. H3K27me3 is present at repressed promoters,
gene bodies and bivalent domains. HA-KAT6B is present bound to both active and bivalent
promoters. ChIP was completed by Dr Philipp Voigt with help from Kim Webb, Viktória Major
and myself.
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its recruitment by H3K4me3, its mark’s association with active transcription and
placement of H3K14ac and H3K23ac both which are found at active promoters
(Sheikh and Akhtar, 2019; Klein et al., 2017). The presence of KAT6B at
bivalent domains is in agreement with the in vitro MS data. The presence
of KAT6B bound to bivalent domains in vivo (Fig. 6.3) could be due to one
of two reasons: KAT6B is specifically recruited to the combination of histone
PTMs at bivalent domains, or the KAT6B is recruited by the H3K4me3 mark
and is not affected by the presence of H3K27me3. ENOK a KAT6B homolog
in Drosophila has been shown to interact with PRC1 (Scott et al., 2001), if
this interaction remains in mammals, KAT6B could be recruited to H3K27me3
marked domains via interaction with PRC1. However, KAT6B is not recruited
to repressed domains in vivo (Fig. 6.3), showing that this interaction, if present
in mice, is not sufficient for KAT6B recruitment to repressed domains. However,
the lack of KAT6B bound at repressed domains and a decrease of H3K14ac and
H3K23ac is in accordance with current literature, showing a decrease of H3K14ac
modification at repressed genes (Karmodiya et al., 2012).
KAT6B is bound in equivalent amounts at both active and bivalent domains
in vivo, this is different to the prediction made from the in vitro MS results.
That may be ascribed to a variety of reasons: the dynamic modification state of
nucleosomes in vivo; proteins present in vivo not present in the nuclear extract
obtained, which might modify KAT6B’s recruitment; or a lower concentration of
bivalent nucleosomes at individual genomic locations in comparison to the in vitro
experiment. In addition, there are marks present on nucleosomes in vivo that are
not present in the in vitro experiment such as KAT6B’s own marks H3K14ac and
H3K23ac, which can affect KAT6B binding.
Based on the observation of KAT6B at bivalent domains we generated tagged
KAT6B ESCs with either catalytically inactive MLL2 or EZH2 knockout (Fig.
6.4). All of these cell lines used to analyse KAT6B distribution across the genome
were generated from N-terminally tagged KAT6B cell line designated 2F. Removal
of EZH2 and MLL2 enzymatic activity should remove H3K27me3 and H3K4me3
from bivalent domains (Denissov et al., 2014; Lee et al., 2006; Boyer et al., 2006;
Hu et al., 2013a) thereby determining whether KAT6B’S recruitment to bivalent
domains is due to the presence of H3K4me3, H3K27me3, or the combination of
both marks.
Catalytically inactive (CI) MLL2 dramatically reduced the presence of H3K4me3
specifically at bivalent domains (Fig. 6.5) (Denissov et al., 2014). Although
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Leu Thr Tyr Asp Tyr Lys Phe Pro Ile Glu Asp






 *   *  Ala  *  Ser Pro Arg Lys Phe Pro Ala
AT TAA TAA GCT TGA TCA CCT CGG AAA TTT CCT GCT G
AT AAA GAA ACT TGC CCA CCT CGG AAA TTT CCT GCT G





ii) EZH2 Exon 6 KO
Primers
Asn  *   *  Gly Ser  *   *  Gln Phe Pro Asn His Met Ile Phe Ser 
Exon 8 
Protein Coding Region *
Guide RNA
GC AAC AAA AAG AGT TCC AAG AAA CAG TTT CCA AAT GAC ATG ATC TTC AGC GC
GC AAC tAA tAG gGa TCC tAG tAA CAG TTT CCA AAc cAt ATG ATa TTC AGC GC




















































Figure 6.4 CRISPR Strategy and Confirmation of Cell Lines. CRISPR Strategy and
Confirmation of MLL2 CI, EZH1 and EZH2 KO Cell Lines A) Schematic of CRISPR strategy
for generation of i) catalytic inactive MLL2 (CI) ii) EZH2 KO and iii) EZH1 KO cell lines
- not to scale. The location of the desired mutations are detailed along with the location of
the PAM (highlighted in purple) in relation to the target sequence. Placement of the ssODN
donor homology is shown along with PCR primer positions. The sequence of the guide RNA
is detailed, and enzyme restriction sites created for potential use in Southern blotting by the
desired mutation are shown in blue. Numbered primers equate to the primer sequence detailed
in Table 2.5. B) Western blot (WB) analysis of previously identified positive cell lines. The
presence or absence of the proteins are shown by either an antibody specific to the protein itself
or by reduction of the mark the enzyme places (an indirect readout). The cell lines shown were

















































































































Figure 6.5 Confirmation of KAT6B Binding In Vivo. ChIP analysis of HA-KAT6B
binding and the presence of H3K4me3 and H3K27me3 modifications at selected promoters. i)
H3K4me3 ChIP at active, bivalent and inactive promoters/gene bodies. ii) H3K27me3 ChIP
at active, bivalent, and inactive promoters or gene bodies. iii) HA-ChIP (KAT6B) at active,
bivalent, and inactive promoters or gene bodies. WT - HA-KAT6B, MLL2 Y2688A - HA-
KAT6B and MLL2 CI, EZH1/2 dKO - HA-KAT6B EZH1/2 knockout. All experiments were
performed in triplicate with the standard error of the experiments shown. ChIP was completed
by Dr Philipp Voigt with help from Kim Webb, Viktória Major and myself.
tagged-KAT6B EZH2 -/- decreases the amount of H3K27me3 present at bivalent
domains there was residual H3K27me3 remaining (data not shown). It was
therefore decided to create a double knockout (dKO) of EZH2 and EZH1 to ensure
complete removal of H3K27me3, yielding Kat6b tagged, EZH1/2 dko ESCs (see
Fig. 6.4). This combination of mutations removed H3K27me3 present at all
genomic loci analysed including bivalent domains (Fig. 6.5).
Removal of EZH1/2 and consequent reduction in H3K27me3 levels resulted in
increased levels of H3K4me3 particularly at bivalent domains, while removal of
MLL2 did not result in an increase of H3K27me3 levels at bivalent domains.
Removal of H3K4me3 at bivalent domains resulted in a decrease of KAT6B,
while KAT6B was unaffected by the reduction in H3K27me3 at bivalent domains
(see Fig. 6.5), this result is slightly different than predicted from the in vitro MS
results. This could be due to different modification states of nucleosomes in vivo
– containing a greater variety of marks – which may affect KAT6B recruitment,
for example H3K23ac. KAT6B may be recruited to bivalent domains by multiple
mechanisms in vivo including by proteins absent from the nuclear extract but
present in vivo. KAT6B may be recruited to bivalent domains by H3K4me3 and
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is unaffected by the co-localisation of H3K27me3. KAT6B may be recruited by
the specific bivalent conformation in vivo however, the effect of H3K27me3 on
KAT6B recruitment is masked by unknown interactions.
Does H3K27me3 play a role in the function or recruitment of KAT6B to bivalent
domains? KAT6B’s similarity with the Drosophila melanogaster protein ENOK
led to the hypothesis that KAT6B may be recruited to bivalent domains by
interaction with PRC1 components. PRC1 can be recruited by multiple methods
including KDM2B and H3K27me3/CBX proteins; not all of these pathways
are reliant on the presence of H3K27me3. KAT6B is not effected by the
decrease of H3K27me3 at bivalent domains in vivo, suggesting that either KAT6B
does not interact with PRC1 in ESCs, or that it interacts with PRC1 and is
recruited by mechanisms not dependent on H3K27me3. Purification of the tagged
KAT6B allowed analysis of interacting proteins (Fig. 6.6). Examination of the
proteins that were co-purified with HA-KAT6B showed no PRC1 components.
Consequently, it is unlikely that KAT6B interacts with subunits of PRC1 in
mouse ESCS and may be recruited by a different method to bivalent domains.
The presence of H3K27me3 is not required to recruit KAT6B in vivo; however,
its effect on KAT6B function has not been investigated. The potential effect
of H3K27me3 on KAT6B was investigated by HAT (Histone AcetylTransferase)
assays. H3K27me3 stimulates the catalytic activity of KAT6B (Fig. 6.6).
This stimulation could help the placement of KAT6B marks/modifications and
therefore increase recruitment of the enzyme, stabilise binding and help amplify
its function. The increased catalytic activity seen at H3K27me3 modified
nucleosomes may be due to H3K27me3 interaction with KAT6B’s MYST domain,
which binds close to H3K27me3 in order to place the H3K23ac. It is possible the
H3K4me3 is required for recruitment while H3K27me3 simultaneously stabilises
the binding interactions and increases KAT6B’s catalytic activity; however,
currently no crystal structure has been attempted with a bivalent nucleosome.
KAT6B is recruited mostly to bivalent nucleosomes in vitro, and is bound to
both active and bivalent domains in vivo however, in the HAT assay the greatest
catalytic activity seen is on H3K27me3/3 nucleosomes. These in vitro assays
measure different events: the pulldown assay measures enrichment or binding of a
protein, while the HAT assay measures catalytic activity. The catalytic activity of
KAT6B on H3K27me3/3 nucleosomes does not require stable binding, explaining
the lack of enrichment of KAT6B at H3K27me3/3 in vitro and at repressed




























































Figure 6.6 KAT6B Purification and HAT Assay.| A) Mass spectrometry analysis of the
purified tagged HA-KAT6B and co-purified proteins. B) Histone acetyltransferase (HAT) assay.
Purified KAT6B is incubated with four different types of nucleosomes: unmodified, symmetrically
modified with H3K4me3 or H327me3 and bivalent asymmetrically modified nucleosomes. The
activity of the purified HA-KAT6B is evaluated by the intensity of the 3H band. KAT6B exhibits
most activity when incubated with nucleosomes symmetrically modified with H3K27me3. The
coomassie of each condition shows equal amounts of nucleosomes in each condition. HAT assays
were completed by Kim Webb.
activity is stimulated by the presence of symmetrically modified H3K27me3/3
nucleosomes; however, in vivo, at repressed domains the presence of KAT6B’s
marks, H3K14ac and H3K23ac, are depleted in comparison to both active and
bivalent domains. Additional factors in the cell and potentially the NE may
regulate KAT6B’s binding and catalytic activity in vivo, reducing activity at
inactive domains. Proteins present in vivo and in the NE may prevent KAT6B
binding to inactive domains or H3K27me3/3 nucleosomes, respectively – either by
selection of H3K4me3 modified nucleosomes or by competition for H3K27me3/3
nucleosomes.
6.3.1 The Function of KAT6B
The previous section confirmed KAT6B’s recruitment to bivalent domains in vivo
but its function still remains obscure. Although KAT6B is a known histone
acetyltransferase, it was only identified in 2000 (Thomas et al., 2000). Due
to its similarity with KAT6A its function in ESCs has been difficult to isolate
and previously unknown functions, including its role in placement of H3K23ac
have been identified as recently as 2015 (Simó-Riudalbas et al., 2015). A paper
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published in 2019 showed its importance in ESCs for regulation of NANOG and
OCT4 binding and neuronal differentiation (Cosentino et al., 2019).
To fully investigate KAT6B’s function in the cell and its importance at bivalent
domains we generated KAT6A and KAT6B individual and double knockouts
(Fig. 6.7). Due to the similarity of the proteins and overlap of their marks,
we predicted a redundancy in function and therefore to fully remove the marks
and function of KAT6B a double knockout (dKO) would be required. Although
initial recruitment and placement of the histone PTMs may be specific to each
enzyme, for example KAT6B or KAT6A, once the marks (H3K14ac) are placed
then multiple enzymes can be recruited in a feedback mechanism to maintain it.
As a result the knockout of a singular protein will not be sufficient to remove the
mark from that genomic location. This was confirmed by ChIP of cell lines with a
singular KO (Fig. 6.7 & Fig. 6.8). Knockout of either KAT6A or of KAT6B does
not significantly reduce H3K14ac or H3K23ac marks placed by both KAT6A
and KAT6B, however, removal of both enzymes does decrease the prevalence
of the mark. KAT6B KO results in a definite increase in both H3K4me3 and
H3K27me3 placement especially at bivalent domains, while this effect is not seen
in the KAT6A or double KO. The singular knockout could cause a specific effect
that is ameliorated with removal of KAT6A, or this may be due to a specific
clonal effect. The increase of H3K4me3 at active promoters from KAT6B KO
does not seem to result in an increase in mRNA expression (Fig. 6.8).
To gain a more complete picture of KAT6B’s importance in whole cell and
in development, the cell lines generated by CRISPR were differentiated into
glutamatergic neurons. E14 ESCs were differentiated using a protocol adapted
from Bibel et al., 2007 (Fig. 6.9). As can be seen from images taken during the
differentiation process there are clear phenotypic differences between the cell lines
(Fig. 6.9). The KO cells were slightly flatter and more spread out than E14 WT
cells in their undifferentiated state. Their differences in the genotype resulted in
an obvious phenotypic difference by day 15 of the differentiation protocol. The
knockout cells are unable to form dendrites, and KAT6B KO or dKO cells do not
express the neuronal marker – Tuj1 (Fig. 6.9). KAT6B and KAT6A KO cells are
unable to differentiate into neurons.
Analysis of gene expression throughout differentiation enabled insight into the
cause of the differentiation defect. The general markers for ESCs (pluripotency
factors) including Oct4 and Nanog are expressed in slightly lower amounts in




Protein Coding Region *
25 26 2728
29
TCC TAA TGA TAG CCA TGC TAA GAT CTA CGC AAT
TCC AAA GGA CCG CCG TGT AAT GAT CTA CGC AAT
Ser  *   *   *  Pro Cys  *  Asp Leu Arg Asn






A) KAT6B KO B)
Exon 3
Protein Coding Region5’ UTR *
CAT TGA TAA TAG GAT ACT TAG TGA AGT GTC GAT TGG
CAT GGA AAA TTG GAT ACT AAG CAA AGT GTG GAT TGG
His Gly Lys Leu Asp Thr Lys Gln Ser Val Asp Trp
































Figure 6.7 CRISPR Strategy and Confirmation of KAT6A and KAT6B KO Cell
Lines. CRISPR strategy (not to scale) for A) KAT6B KO and B) KAT6A KO. KAT6A/B
double KO cells lines are both strategies combined. Both the original and mutated sequences
including the guide RNA are shown with the PAM highlighted in purple. Any enzyme restriction
sites created for potential use in Southern blotting by the designed mutations are shown in blue.
Placement of the ssODN donor homology is shown along with PCR primer positions. Numbered
primers equate to the primer sequence detailed in Table 2.5. C) Western blot confirmation of
the knockout cell lines. KAT6A KO was unable to be confirmed by western blot at the protein
level as all antibodies tested showed insufficient specificity. KAT6A KO was instead confirmed



































































































































































































Figure 6.8 KAT6A and KAT6B KO ChIP A) ChIP quantitative real time PCR detection
of i) H3K14ac, ii) H3K4me3, iii) H3K27me3, iv) H3K23ac in E14 WT in blue, KAT6A KO in
pink, KAT6B KO in yellow and KAT6A/B dKO in purple, cell lines. B) RT-qPCR expression
analysis, normalised to GAPDH, of selected genes in E14 WT in turquoise, KAT6A KO in red,
KAT6B KO in orange and KAT6A/B dKO in blue, cell lines. All experiments were performed
in triplicate with the standard error of the experiments shown. ChIP was completed by Dr
Philipp Voigt with help from Kim Webb, and Viktória Major.
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Figure 6.9 Differentiation of Cell Lines. A) Schematic representation of the neuronal
differentiation protocol. B) Cells at various stages of neuronal differentiation were grown on
glass coverslips, permeabilized, fixed, and processed for in situ staining using antibodies as
indicated. C) Quantitative real time PCR was used to follow the expression and regulation of
a selection of genes known to be important in pluripotency and neuronal differentiation. All
experiments were performed in triplicate with the standard error of the experiments shown.
Neuronal differentiation assays were completed by Marie Warburton, with the RT-PCR being
completed by Dr Philipp Voigt. The immunofluorescence microscopy was performed Dr Katy
McLaughlin.
154
The slight decrease in Nanog and Oct4 expression seen in KAT6B-/- ESCs was
not observed by Costino 2019. This slight decrease may explain the slight visual
differences seen in the undifferentiated cells. The defect in differentiation becomes
more evident by day 6 with neuronal genes such at Pax6 and Mash1 failing to be
properly upregulated. KAT6B and KAT6A are needed for proper differentiation
of ESCs. The KAT6B KO ESC defect in neural differentiation was previously
observed by the Guberman lab in 2019 (Cosentino et al., 2019).
6.4 Conclusion
CRISPR was used to tag KAT6B allowing purification of the protein, identifica-
tion of interacting proteins and detection of binding sites by ChIP in vivo. No
PRC1 subunits were co-purified with HA-KAT6B suggesting that KAT6B does
not strongly interact with any PRC1 components in mouse ESCs and is therefore
not recruited to bivalent domains by interaction with PRC1. KAT6B was
confirmed to bind to both active and bivalent domains in vivo and to be recruited
by H3K4me3. Although H3K27me3 did not seem to directly recruit KAT6B, its
presence was shown to increase KAT6B’s catalytic activity in vitro. Mutations
or truncations of protein domains contained within the MORF complex such
as the KAT6B’s MYST domain or ING5’s PHD domain would help isolate the
mechanisms of H3K27me3’s stimulation of enzymatic activity and of KAT6B’s
recruitment to bivalent domains.
KAT6A and KAT6B have redundant functions and can be recruited to the histone
PTMs placed by the other enzyme, this is demonstrated by the requirement of
a KAT6A/B dKO in order to decrease the level of H3K14ac or H3K23ac at
specific locations. KAT6B(-/-), KAT6A (-/-) and dKO cells have defects in neuronal
differentiation, suggesting that the marks they place or the complexes themselves
are important in development. Generation of cell lines with catalytically
inactive KAT6B or KAT6A would help distinguish between the importance
of the MORF/MOZ complex binding, and the histone PTMs placed by the
MORF/MOZ complex. Both singular KOs have defects in differentiation, with
KAT6B(-/-) having the most severe phenotype, indicating that the function of
these enzymes are important and both KAT6A and KAT6B have essential, non-
redundant, roles in differentiation. Pluripotency genes were downregulated in
all cell lines; however, the KAT6B and KAT6A deficient cell lines had difficulty
upregulating neuronal specific genes. Genome-wide RNA expression analysis at
155
each stage of differentiation would give a more complete and thorough analysis
of the genome-wide effects of the KAT6B knockout.
There are slight differences between the results obtained by in vitro and in
vivo experiments (discussed further in Chapter 7), which can be attributed to
multitude of differences between these types of experiments. The pulldown
experiments investigated protein binding to the simplest type of bivalent
nucleosome, this helps to simplify the experiment and isolate protein binding
events that are solely reliant on the bivalent mark conformation. However, the
simplified experiment lacks the multitude of complicating factors found in the
nucleus such as a range of different histone PTMs, the dynamics of nucleosome
modification or interactions with nucleosomal arrays, to name but a few. As a
result of the in vitro experiment not fully encapsulating the interactions occurring
in vivo, there are some difference between the in vivo and in vitro results.
The results from an in vitro experiment gives results that have clear, defined
causes but may not fully explain the in vivo system due to the system’s lack of
complexity. However, they do provide some clarification of biological mechanisms
and isolate events, that when combined, help to explain the more complicated
events occurring within the cell. The in vitro approach can be applied to more
complex combinations of marks at bivalent nucleosomes, and also investigate the




In this thesis, I aimed to isolate the proteins bound to bivalent asymmetrically
modified nucleosomes and identify how the asymmetry of nucleosome modifi-
cations can effect protein binding. Establishment, optimisation and validation
of an in vitro pulldown approach, utilising specifically modified nucleosomes,
demonstrated the effect histone modifications have on protein recruitment. This
technique allowed identification of proteins recruited to bivalent nucleosomes and
determined the effect a singular asymmetric modification can have on protein
binding. KAT6B was identified bound to bivalent nucleosomes in vitro and was
demonstrated to bind bivalent domains in vivo via the generation of KAT6B
tagged cell lines. The role of KAT6B in ESCs and during differentiation was
investigated via differentiation of KAT6B KO ESCs. The identification of
proteins that bind to bivalent nucleosomes in vitro, and bivalent domains in
vivo further elucidates the potential biological function of bivalent domains. The
effects of asymmetric marks on protein recruitment will help in the identification
and classification of the transcriptional state of chromatin in vivo.
7.1 Histone Mark Binders in Embryonic Stem Cells
To validate the experimental approach used, the proteins enriched on the sym-
metrically modified H3K4me3/3 and H3K27me3/3 nucleosomes were investigated
and compared to findings in the literature. The proteins bound to symmetrically
modified nucleosomes in vitro largely correlate with previously described binding
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preferences seen by Bartke et al., 2010, Vermeulen et al., 2007 and Vermeulen
et al., 2010. Proteins containing reader domains such as PHD fingers and Tudor
domains known to bind the H3K4me3 mark on H3 N-terminal tail peptides or
modified nucleosomes also bound to H3K4me3/3 nucleosomes here, including
ING2, TAF3, Spin1 and BPTF (Ali et al., 2014; Shi et al., 2006; Yang et al.,
2012).
The H3K4me3/3 nucleosome enriched for proteins that bind directly to the
H3K4me3 mark and for proteins that interact with H3K4me3 binders. BAP18
and DPY30 are enriched bound to H3K4me3/3 nucleosomes however, they do not
bind H3K4me3 directly, they interact with complexes which contain subunits that
bind directly to H3K4me3; such as BPTF in the NURF complex and CFP1 in
the SET1 complex resulting in the recruitment of both BAP18 and DPY30 to
H3K4me3/3 respectively (Tremblay et al., 2014; Vermeulen et al., 2010; Sun et
al., 2016; Eberl et al., 2013; Mahadevan and Skalnik, 2016). These proteins bind
to the active H3K4me3 mark, mediating a range of functions from recruitment
of proteins that enable the recruitment of the pre-initiation complex (PIC) via
TAF3 binding to H3K4me3 (Lauberth et al., 2013; Vermeulen et al., 2007) or
that repress active genes as in the case of ING2 and SIN3a repression (Shi et al.,
2006; Grzenda et al., 2009) which can lead to the removal of activating marks
such as histone acetylation and H3K4me3.
The presence of all these proteins that differ in function at the same genomic
location reinforces the idea that although H3K4me3 is correlated with active gene
expression and helps initiate RNAPII transcription, it needs to be reinforced by
the presence of other marks and maintained at that genomic location. There is a
balance between active and repressive marks and chromatin states and there
are always proteins that can bind and cause the chromatin state to change
unless there is reinforcement and maintenance of a specific mark. Without
reinforcement and maintenance of H3K4me3, it would be removed by multiple
demethylases including KDM5B and the gene not expressed (Kidder et al., 2014).
The chromatin state is therefore always composed of multiple chromatin marks
and it is the interplay of these marks and their cumulative effects that results in
the chromatin state and its transcriptional output.
The proteins known to bind specifically to H3K27me3 such as CBX7 (Morey et
al., 2012), which contains a chromodomain, are enriched bound to symmetrically
modified H3K27me3 nucleosomes. CBX7 is a canonical PRC1 complex subunit
along with PHC1, also required for the canonical PRC1 formation. PHC1 is also
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enriched bound to H3K27me3/3 and is required for PRC1 mediated compaction
of DNA (Isono et al., 2013; Wani et al., 2016; Kundu et al., 2017). PHC1 does
not contain a H3K27me3 binding site and is likely recruited to H3K27me3/3 via
interaction with CBX7.
Other members of the Polycomb family are not enriched bound to the nucleosome
symmetrically modified for H3K27me3. As previously mentioned, the other
CBX proteins are mutually exclusive and have different binding preferences and
are therefore recruited to different genomic environments. The other PRC1
subunits such as RING1 and PCGF variants are present in multiple PRC1
complexes. Therefore, if some PRC1 variant complexes are present bound to
multiple differently modififed nucleosomes then their enrichment on H3K27me3/3
nucleosomes will be decreased and classified as not significant. This data suggests
that there is a variant of PRC1 recruited in vitro specifically to H3K27me3/3
nucleosomes, a canonical PRC1 complex containing both CBX7 and PHC1.
As both CBX7 and PHC1 are the most highly expressed CBX and PHC protein
variant in ESCs, the majority of the ESC canonical PRC1 complex will contain
them. This indicates that the vast majority of canonical PRC1 complex in ESCs
are recruited specifically to H3K27me3/3 nucleosomes. Components of the origin
recognition complex (ORC) including LRWD1 are seen enriched bound to the
H3K27me3/3 nucleosome replicating earlier results shown in Bartke et al., 2010
and Vermeulen et al., 2010. These results confirm previously known interactions
and validate the experimental approach used in this study.
EZH2, the catalytic subunit of PRC2, was depleted from H3K4me3/3 nucleo-
somes. PRC2 is inhibited from placing the H3K27me3 modification on a tail
previously modified with H3K4me3, and has been shown by ChIP-Seq to be
associated with CpG islands and genomic regions containing H3K27me3 (Voigt et
al., 2012; Schmitges et al., 2011; Mendenhall et al., 2010; Li and Reinberg, 2011).
PRC2 contains H3K27me3 binding sites but does not contain any H3K4me3
binding sites, suggesting that PRC2 has a preference to be bound at chromatin
containing H3K27me3 rather than H3K4me3, although this has yet to be robustly
demonstrated in vitro. Bartke et al., 2010 did not see any inhibition in EZH2
binding to H3K4me3 modified nucleosomes. Although in more recent results
Bartke’s lab does see this inhibition in EZH2 binding to H3K4me3/3 nucleosomes.
PRC2 components including EZH2 are not seen enriched in the H3K27me3/3
compared to the unmodified nucleosome, opposing results seen in Bartke et al.
(2010). The potential reasons for this have been discussed previously in Chapter
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5.
In contrast to the H3K4me3/3 nucleosome, the presence of H3K27me3 did not
prevent recruitment of any proteins that would bind normally to the unmodified
H3 N-terminal tail.
7.2 The Effect on Protein Binding of a Singular
Asymmetric Mark
The proteins that have been identified as binding symmetrically modified
nucleosomes did not demonstrate the same behaviour in the context of asymmet-
rically modified nucleosomes. Neither H3K4me3 nor H3K27me3 asymmetrically
modified nucleosomes enriched for any known H3K4me3 or H3K27me3 mark
protein binders in comparison to the unmodified nucleosome. This could result
from two possible causes: a requirement for a higher concentration of either
mark to bind or the protein requires a symmetric nucleosome to bind. These
potential reasons were investigated via a nucleosome titration (see Chapter 5). A
selection of proteins that bind differently to symmetrically modified nucleosomes
and asymmetrically nucleosomes were investigated. The binding preferences of
TAF3, PHF2, and ING2 for H3K4me3 modified nucleosomes were examined while
EZH2, CBX7, and RING1B were examined for the differences in binding to both
H3K4me3 or H3K27me3 modified nucleosomes. Each protein examined displayed
different recruitment to the tested nucleosomes.
TAF3, a component of the basal transcription factor complex TFIID, has a PHD
finger which binds to H3K4me3 (Ingen et al., 2008; Vermeulen et al., 2007),
however, TAF3 is bound to H3K4me3/3 but not to H3K4me3/0 nucleosomes.
Only at the highest concentration of asymmetric nucleosomes did TAF3 bind,
the level of binding seen is less than the amount of TAF3 bound to the lowest
concentration of H3K4me3/3 nucleosomes. The difference in TAF3 binding to
symmetric and asymmetric nucleosomes is unlikely to be due to concentration of
the mark present and likely to do with the conformation of H3K4me3 marks
presented on a symmetrically modified nucleosome; however, the mechanism
by which this is communicated is unknown. Pulldowns with the symmetrically
modified nucleosomes have a higher local concentration of modifications i.e. on
the individual nucleosome. This may result in an increase in TAF3 binding,
160
consistent with allovalent model of binding - discussed below.
There is no evidence for the dimerization of TAF3 in vivo, suggesting that this
affect may be communicated by the wide variety of proteins that interact with
TAF3. TAF3’s binding behaviour may be partially explainable by allovalency.
Allovalency refers to an interaction between two molecules where you have more
than one identical binding sites in tandem on a disordered region of a ligand
and one receptor site (Klein et al., 2003; Locasale, 2008; Olsen et al., 2017).
These two identical binding sites compete for the single receptor site as only one
binding site can interact at one time. The presence and competition of the two
binding sites increases affinity of the receptor for the ligand. In terms of TAF3
binding, the PHD domain of TAF3 is the receptor site, while the two H3K4me3
are the identical ligand binding sites. This mode of binding would explain the
requirement for symmetrically modified nucleosome for TAF3 to bind - due to
both ligand binding sites needing to be on the same ligand, in this case the
nucleosome, for allovalent binding to occur. The difference in TAF3 binding is
not linearly proportional to the concentration of H3K4me3 modification present
indicating co-operative binding – fitting with the allovalent model. However,
when considering the larger protein complexes involved, that is TFIID, and
the multiple interaction sites present in TFIID and on the nucleosome itself,
the mechanism of binding becomes more complex. TAF3 could be recruited to
H3K4me3/3 nucleosomes via the interaction of other TFIID subunits and their
non-identical binding sites with the rest of the nucleosome via multivalency or
via fuzzy binding (Olsen et al., 2017).
PHF2 is a lysine demethylase that is recruited to H3K4me3 by its PHD domain
and mediates H3K9me2 demethylation leading to gene activation (Baba et al.,
2011). PHF2 displays similar behaviour to TAF3, indicating that for both of these
H3K4me3 binding proteins the conformation of the symmetrically nucleosomes
is important in regulating binding. These results are indicative of a wider
binding behaviour that is seen for all H3K4me3 binders bound to the H3K4me3/3
nucleosome condition in the mass spectrometry experiment. This indicates that
a singular H3K4me3 modification is not sufficient to maintain the presence of
these active mark binders potentially due to the requirement of a symmetric
conformation in order to bind and therefore H3K4me0/3 nucleosomes may not
be adequate to maintain an active chromatin state.
ING2 contains a PHD finger which binds to H3K4me3 and is recruited to
H3K4me3/3 nucleosomes (Peña et al., 2006). ING2 is able to recruit both
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deacetylases (HDACs) and histone methyltransferases (HMTs). Its interaction
with Sin3a-HDAC1, helps to remove activating acetylation marks leading to
gene repression (Shi et al., 2006; Doyon et al., 2006; Peña et al., 2006)
while helping modulate histone methylation (Goeman et al., 2008). Although,
ING2 binds H3K4me3, and is enriched at H3K4me3/3 nucleosomes, it is not
enriched at asymmetrically modified H3K4me0/3 nucleosomes. The titration
experiment showed that ING2 has highest affinity for H3K4me3/3 nucleosomes.
The asymmetric H3K4me3/me0 nucleosomes exhibited higher binding than the
asymmetric H3K4me3/- tailless nucleosomes, signifying that ING2 is partially
recruited by unmodified H3 N-terminal tail. Goeman et al. (2008) demonstrated
ING2’s preference for binding H3K4me3 and ability to bind unmodified H3 albeit
weakly. This weak binding affinity could be the cause of the increased ING2
recruitment to H3K4me3/me0 compared to the H3K4me3/- (tailless) nucleosome.
While the behaviour of TAF3 and PHF2 in the titration experiment recapitulates
the binding preference seen in the MS experiment, ING2 shows more subtle
binding preferences in the titration experiment. As a consequence of ING2’s
decreased recruitment to H3K4me0/me3 and its ability to bind H3K4me0, the
difference between binding may not be classified as significant via the MS
technique.
The Sin3/HDAC corepressor complex can be recruited by multiple transcription
factors - it is possible that a number of these can bind H3K4me0 and help ING2
recruitment (Chandru et al., 2018; Knoepfler and Eisenman, 1999; Grzenda
et al., 2009). RbAp48/46’s interaction with histones is important for PRC2’s
nucleosomal recognition and may help with Sin3a recruitment (Shi et al., 2017;
Grzenda et al., 2009). RbAp48/46’s interaction with H2A and H4 is not the
cause of ING2’s recruitment to H3K4me0 tail as this interaction is present in the
H3K4me3/- nucleosomes; however, it may help stabilise ING2 at unmodified tails
(Zhang et al., 1999; Grzenda et al., 2009).
ING2’s behaviour is different to that of both TAF3 and PHF2, it is recruited in
small amounts to unmodified H3 N-terminal tails: this difference in behaviour
may be due to the difference in interacting proteins. The reader domains present
in the proteins that interact with TAF3 and PHF2 are selective for active marks
(Filippakopoulos et al., 2012; Su et al., 2016; Nuland et al., 2013), while ING2
interacts with a variety of complexes containing reader domains for repressive
marks as well as other core histones (Murzina et al., 2008; Shi et al., 2006;
Viiri et al., 2009; Grzenda et al., 2009). This liberal recruitment of ING2
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and possibly the Sin3 complex allows removal of acetylation marks, potentially
demethylation of H3K4me3, and continued binding of Sin3, resulting in spreading
of deacetylation and potential establishment of a repressive chromatin state.
The role of ING2’s permissive recruitment may allow maintenance of ING2’s
presence and therefore HDAC, HMT and SIN3 complexes at active genes longer,
recruitment to a more diverse range of chromatin targets, spreading of ING2’s
function and reinforcement of a repressive state.
EZH2, the catalytic subunit of PRC2, is recruited equally to both H3K27me3/3,
H3K27me0/3 and unmodified nucleosomes. A clear depletion is seen when
comparing H3K27me3/- tailless and H3K27me0/3, indicating that the unmodified
H3 tail does contribute to EZH2 binding. It does not distinguish between the
unmodified H3 N-terminal tail and one modified with H3K27me3, reproducing
the binding pattern seen in the MS results.
RING1B, a component of the PRC1 complex, has higher binding affinity
for H3K27me3/3, indicating that RING1B binds better to H3K27me3 than
H3K27me0. This binding is not proportional to the H3K27me3 present,
indicating that it is a combination of both concentration of mark and the
conformation of the marks that affects RING1B binding. RING1B is poorly
recruited by H3K27me3/tailless, suggesting that the presence of RING1B at the
H3K27me0/me3 is partially recruited or stabilised by the free H3 N-terminal tail;
however, the mechanism of this is unclear. The decrease in RING1B binding
at H3K27me0/3 compared to H3K27me3/3 nucleosomes echoes the decrease in
RING1B present between these conditions when analysed by MS. This decrease
may prevent the enrichment of RING1B at H3K27me0/3 compared to unmodified
nucleosomes being classified as significant.
CBX7 is a subunit of canonical PRC1 complexes and recruits PRC1 to sites of
H3K27me3 by its chromodomain (Morey et al., 2012; Bernstein et al., 2006b;
Min et al., 2003; Wang et al., 2004b). CBX7 is bound to H3K27me3 modified
nucleosomes proportional to the amount of H3K27me3 present. There is a
minor decrease of CBX7 bound to H3K27me3/tailless compared to H3K27me0/3
nucleosomes, indicating that the free H3 N-terminal tail may have a small role
in stabilising CBX7 bound at nucleosomes, potentially via stabilisation of the
PRC1 complex. There is a visible difference in both RING1B and CBX7 binding
to symmetric, asymmetric and tailless nucleosomes in the titration experiment.
However, MS analysis does not classify the enrichment of RING1B and CBX7
at H3K27me3/0 compared to unmodified nucleosomes as significant. The fold
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changes indicated by the MS analysis may be lower than seen by other methods
and decreased compared to in vivo.
The inhibition of H3K4me3 on EZH2 binding seen in the MS results is shared
by RING1B and is replicated in the titration experiments. The inhibition of
binding is partially relived by the presence of an unmodified H3 N-terminal
tail in H3K4me0/3 nucleosomes. Although the inhibition of binding is clear,
at higher concentrations of H3K4me3/3, binding of both EZH2 and RING1B to
the nucleosomes is detectable. This indicates that RING1B and EZH2 may bind
these nucleosomes but at low amounts and that given a high enough concentration
of a reactant the binding is detectable, or that the inhibition of binding can
be partially relieved by increased amounts of the nucleosome. The H3K4me3
inhibition of binding affects EZH2 to a greater extent than RING1B demonstrated
in both the titration and MS experiments. RING1B binding to H3K4me3/tailless
indicates RING1B’s and therefore PRC1’s ability to be recruited with low binding
affinity to the H3K4me3 modified H3 N-terminal tail. As both RING1B and
EZH2 are the subunits of PRC1 and PRC2 respectively the binding behaviour
observed is not solely due to either protein but is instead due to multiple
interactions between the Polycomb subunits in the relevant complex and the
nucleosome.
The ability of EZH2 and RING1B to bind to both H3K27me3 and H3K27me0 tails
will allow the spread of H3K27me3, H2AK119ub and transcriptional repression.
This helps establish new repressive domains, encourage the switch of chromatin
states from active to repressive and maintain repression via by modification and
binding of unmodified, H3K4me0/3 or H3K27me3/3 nucleosomes respectively.
CBX7’s specific binding to H3K27me3 modified nucleosomes will help maintain
already established repressive states, and initiate chromatin compaction - rein-
forcing repression.
Although all proteins investigated display different preferences for recruitment,
there is one clear division. Proteins that bind and are associated with
establishment of transcriptional repression have more permissive binding, while
those associated with transcriptional activation have more limited binding
parameters. TAF3 and PHF2 not only require H3K4me3 present to bind but
also a symmetrically modified nucleosome, while ING2, EZH2, and RING1B can
bind both modified and unmodified H3 N-terminal tails and can be recruited
with different affinity to symmetrically, asymmetrically and unmodified modified
nucleosomes. This finding is in agreement with previous studies that have
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proposed a sampling mechanism for PcG recruitment, resulting in broad repressed
domains (Klose et al., 2013).
All proteins examined are part of multiple complexes containing subunits with
different reader domains, therefore the recruitment seen is potentially a result
of all these binding affinities. Although many SET family proteins contain
subunits, including CFP1, that can sample chromatin by binding to unmethylated
CGIs, the number of different SET domains containing enzymes that bind to
and enforce “open” chromatin or active transcription is much larger, resulting in
specification of recruitment and potentially a reduction in sampling mechanisms
(Yu et al., 2017; Xu et al., 2011). TAF3 and PHF2 have specific roles, which
are not required at all “open” chromatin and therefore their recruitment is
more restricted. Further experiments will be needed to investigate this reduced
affinity to H3K4me0/3 mononucleosomes. Whether the inhibition of PHF2 and
TAF3 binding to H3K4me3/0 mononucleosomes can be relieved by H3K4me0/3
dinucleosomes or more complex arrays requires further experiments. These can
be completed in the same experimental set up, with dinucleosomes in a specific
configuration or randomly assembled.
This permissive binding of EZH2 and RING1B to H3K4me0/3 may account for
the overlap of PRC1/2 with H3K4me3 domains in vivo, while the exclusion
of PRC1/2 from H3K4me3 domains, or areas where KDM2B recruitment is
the dominant method of PRC1 recruitment may indicate regions consisting
of symmetrically modified H3K4me3 nucleosomes (Ku et al., 2008; Farcas
et al., 2012; Bernstein et al., 2006a). The specific binding of TAF3 to
symmetrically modified H3K4me3 may allow identification of H3K4me3 marked
regions composed of H3K4me3/3 nucleosomes and isolation of H3K4me0/3
domains. Previous studies have identified genes marked with H3K4me3, that
have no discernible expression or RNAPII present (Vastenhouw and Schier, 2012).
Our in vitro studies have indicated that these regions may be composed of
nucleosomes asymmetrically modified for H3K4me3, resulting in TAF3 being
unable to bind and recruit the pre-initiation complex to these genes. These
asymmetric H3K4me3 nucleosomes may have an important role in restricting the
establishment of a repressive domains and poising the genes for activation. While
symmetric H3K4me3 modification prevents PRC2’s placement of H3K27me3
in vitro, asymmetric H3K4me0/3 allows the placement of H3K27me3 on the
opposing H3 tail (Voigt et al., 2012; Schmitges et al., 2011). PRC2 cannot place
H3K27me3 on the same H3 N-Terminal tail containing H3K4me3, consequently
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H3K4me3 demethylases would need to be recruited and H3K4me3 removed before
a fully repressive state could be established. Asymmetric H3K4me3 modified
nucleosomes may not recruit TAF3 and thus not form a productive PIC with
RNAPII; however, they may poise the gene for activation by reducing the number
tails needing to be modified before the PIC can form, or by allowing other
TFs to bind – providing a platform to easily bind RNAPII (Vastenhouw and
Schier, 2012; Grzybowski et al., 2015; Barski et al., 2009). The presence of
H3K4me0/3 nucleosomes may act to prime the genes to switch from repressed to
active transcription.
Asymmetric H3K4me3 nucleosomes have been identified in yeast, suggesting
their conservation throughout evolution, indicating possible conservation of
function and mechanism of regulation (Takahashi et al., 2011; Miller et al.,
2001; Choudhury et al., 2019). The only H3K4 methyltransferase in yeast,
Set1c, dimerises and thereby prefers to symmetrically methylate nucleosomes
(Choudhury et al., 2019). The sole H3K4me3 demethylase in yeast, Jhdh2 is
a member of the KDM5 protein family and contains a conserved PHD1 zinc
finger that binds H3K4me0 and is found in mammalian KDM5 members (Zhang
et al., 2014; Torres et al., 2015). Jhdh2 has a preference for demethylating
H3K4me0/3 nucleosomes, suggesting a preference for symmetrically H3K4me3/3
nucleosomes or unmodified nucleosomes in yeast. SET1 is recruited to H3K4me3
by the SPP1 subunit, indicating a feedback mechanism, and a system for
asymmetrically modified nucleosomes to become symmetric (He et al., 2019).
Instead of SET1 acting on a singular nucleosome, SET1 could bind a H3 tail
of one nucleosome and methylate the H3 tail of a neighbouring nucleosome
helping to spread H3K4me3 asymmetry. As yet, there have been no studies
looking at SET1’s catalytic activity when bound to asymmetrically modified
nucleosomes in comparison to unmodified nucleosomes. A catalytic study of Set1c
bound to unmodified or asymmetrically modified nucleosomes would highlight
the importance of H3K4me3 asymmetry in vivo and potentially predict the
interaction of mammalian COMPASS members with H3K4me3 asymmetry.
The conservation of the SET domain-WRAD (composed of WDR5, RBBP5,
ASH2L and DPY30) scaffold is one of the most conserved protein groups
in eukaryotic chromatin modifiers (Ernst and Vakoc, 2012; Ali and Tyagi,
2017; Takahashi et al., 2011). The function of the WRAD complex and
its requirement for catalytic activity, even without the catalytic domain, is
maintained throughout evolution. The discovery of dimerization in SET1
166
indicates that members of the mammalian COMPASS family may be dimerised.
The mammalian SET/COMPASS family although evolutionary well conserved
has many more members and specialised functions than the SET1 complex
in yeast. SET1A/B complexes are most closely related to Set1c in function
and sequence, while the MLL complexes have more diverse subunits and more
specific functions. It is possible that in mammals dimerised SET1A/B complexes
may preferentially generate symmetrically modified nucleosomes, while the MLL
complexes place the asymmetric H3K4me3. Structural studies of the mammalian
COMPASS members via crystallisation or mutational experiments may elucidate
whether this dimerization of COMPASS members is conserved in mammals and
enzymatic assays would explain how this correlates with enzymatic function.
Whether MLL2 prefers to place asymmetric or symmetric H3K4me3 may indicate
control of bivalent domain formation and maintenance.
These results have highlighted the importance of examining individual protein
binding using nucleosomes rather than peptides. Previous studies reliant on
peptide binding assays or symmetrically modified nucleosomes have predicted
that the presence of one mark, that binds the protein via peptide assays and
replicates this binding in symmetrically modified nucleosomes, is sufficient for
binding. The use of asymmetrically modified nucleosomes has demonstrated the
importance of the nucleosome structure and the conformation of marks presented
to the enzyme in determining protein recruitment and binding.
7.3 Differences Between Asymmetry and Bivalency
The H3K4me3/3 nucleosomes enriched for proteins which bind directly to or
interact with proteins that bind directly to H3K4me3 and prevents enrichment of
proteins that would bind to H3K27me3. The enrichment of proteins bound to the
H3K27me3/3 nucleosome is lower than that seen in the H3K4me3/3 nucleosome,
and fewer proteins are enriched in comparison to the unmodified nucleosome in
total in comparison to H3K4me3/3. The decreased number of enriched proteins
on H3K27me3/3 does not mean the consequences of recruitment are less. The
direct H3K27me3 binders seem to be able to bind to a greater variety of sites
although with varying affinity or be part of complexes that can recruit them
to a great variety of modifications and are therefore more permissive in their
recruitment. This could be due to a more permissive binding site of the proteins
or resulting from the variety recruitment mechanisms as a consequence of multiple
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reader domains within the repressive protein complex. The enrichment seen on
symmetrically modified nucleosomes seems to be lost when investigating protein
binding to singularly asymmetrically modified nucleosomes.
Bivalent nucleosomes enriched for a greater variety of proteins and with higher
fold changes of enrichment than either of the singularly modified asymmetric
nucleosomes. The bivalent condition is not enriched for H3K4me3 binders,
consistent with data seen for H3K4me3 monovalently asymmetrically modified
nucleosomes. Although H3K4me3 may not recruit binders by itself it can recruit
proteins through interaction with other modifications. In addition, the presence of
H3K4me3 prevents the placement of H3K27me3 on the tail that carries H3K4me3
and the formation of a repressive domain (Voigt et al., 2012; Schmitges et al.,
2011). In contrast to H3K4me3 binders, proteins that bind to H3K27me3,
although not enriched in the H3K27me0/3 asymmetric condition, are enriched
on the bivalent nucleosome in comparison to unmodified nucleosomes. Although
bivalent nucleosomes lose H3K4me3 mark binders they retain H3K27me3 mark
binders, including CBX7 and EZH2. The retention of H3K27me3 protein
binders was unexpected, as previous experiments have shown that they are
inhibited from binding the H3K4me3 tail and are not enriched on H3K27me0/3.
The difference seen in repressive mark binders between H3K27me3 containing
symmetric, monovalent asymmetric, and bivalent asymmetric nucleosomes results
not only from the presence of H3K27me3 and permissive binding but potentially a
hitherto unknown consequence of having both H3K27me3 and H3K4me3 present
on the same nucleosome. There may be a distinct recruitment pathway for
H3K27me3 binders specific to the bivalent asymmetric conformation potentially
by recruitment of different recruitment proteins or conformational changes in the
the H3K27me3 protein binders themselves.
EPOP is the only protein associated with PRC2 that is significantly enriched in
the bivalent condition compared to almost all other nucleosomes (see Fig. 5.6
and Fig. 5.8). EPOP is depleted from H3K4me3/3 nucleosomes and enriched in
the H3K27me3/3 nucleosomes (see Fig. 5.6). However its binding is not affected
by the presence of a singular asymmetric mark H3K4me0/3 or H3K27me0/3
(Fig. 5.2). EPOP’s enrichment at bivalent nucleosomes is not solely due to the
presence of a singular H3K27me3 present at the nucleosome as shown by Figure
5.6, indicating a potential method of specific recruitment to bivalent nucleosomes.
EPOP has been previously shown to link PRC2 and Elongin BC complex which
has been found to localise at bivalent domains and has been suggested to be
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required to maintain low levels of transcription at bivalent genes (Beringer et
al., 2016; Liefke et al., 2016). Cell lines depleted for EPOP have a decreased
amount of RNAPII at the transcription start sites, and decreased transcription
of bivalent genes (Beringer et al., 2016; Liefke et al., 2016), the presence of EPOP
at bivalent domains may therefore help to recruit RNAPII. EPOP’s presence at
bivalent domains reduces the binding of JARID2-containing PRC2, reducing the
deposition of H3K27me3 and helping to prevent the establishment of a repressive
domain (Beringer et al., 2016; Liefke et al., 2016). EPOP has also been indicated
to have a role in regulating the deposition and removal of H3K4me3, although
the mechanism for this has yet to be shown (Liefke et al., 2016). The presence
of EPOP binding to bivalent nucleosomes in vitro supports a role of EPOP in
the function of bivalent domains in vivo (Fig. 5.6 and Fig. 5.8). However,
Elongin BC is not seen enriched bound to bivalent domains, this may be due to
few PRC2-EPOP complexes interacting with Elongin BC or as a result of both
ElonginB and C being present in multiple complexes including multiple ubiquitin
ligase complexes (Okumura et al., 2012) and precluding it from being enriched
significantly even if it does interact with PRC2-containing EPOP (PRC2/EPOP)
in the pulldowns. The interaction between with PRC2/EPOP may be more
transitory and therefore the stringency of the washes may remove it from bivalent
domains before analysis.
The lack of recruitment of H3K4me3 binders, although not surprising in light of
what was observed for asymmetric H3K4me0/3 nucleosomes, does pose questions
about how the poised RNAPII seen at bivalent domains in vivo can be recruited
and modified. RNAPII is seen at both active and bivalent domains, although
it is more enriched at active domains (Ku et al., 2012; Stock et al., 2007;
Mantsoki et al., 2018). Only TAF3 of the TFIID subunits is enriched bound
to the H3K4me3 symmetrically modified nucleosomes in vitro, and it is not
enriched bound to the bivalent nucleosome. The lack of TAF3 recruitment to
bivalent nucleosomes correlates with the in vivo data demonstrating a decreased
presence of TFIID and RNAPII at bivalent domains (Ku et al., 2012; Ferrai et
al., 2017; Stock et al., 2007). Many subunits that compose TFIID are shared
with other complexes that are not recruited directly to H3K4me3, therefore
these subunits may not be enriched on any one modified nucleosome due to their
presence in multiple complexes that are recruited to various differently modified
nucleosomes (Koutelou et al., 2010; Grant et al., 1998). TFIID’s composition
and structure is dynamic indicating the possibility for different recruitment
mechanisms depending on the promoter in question (Mousson et al., 2008;
169
Timmers and Sharp, 1991; Maston et al., 2012). All TAF dependent recruitment
mechanisms may influence TFIID’s recruitment, however, the strength of this
influence may alter depending on the composition of the promoter and the
TFIID complex in question. Although no TAF or TF was enriched at the
bivalent condition, the recruitment of TAF3 to H3K4me3 is not required for
RNAPII recruitment as RNAPII can be recruited solely by TBP’s interaction
with the TATA box (Majello et al., 1998; Mencía et al., 2002). There was a
lack of general transcription factor (GTF) binding to the bivalent asymmetric
nucleosome; however, the bivalent nucleosome investigated was of the simplest
possible configuration and composition.
The lack of other transcription machinery recruited to the H3K4me3/3 nu-
cleosome may indicate the requirement of multiple low affinity interactions
required for the assembly of such a large complex which is not stable in the
in vitro conditions used due to technical effects such as the number, length
and stringency of washes in the pulldown experiments, or the requirement of
an array of nucleosomes to allow the PIC to assemble and bind. The length of
the washes between protein binding and elution may result in the loss of protein
complexes with low overall Koff value potentially including the TFIID complex.
The saturation of beads with nucleosomes may result in steric hindrance resulting
in large protein complexes being unable to bind the nucleosome causing subunits
that are not directly bound to the modification to be unable to be recruited
to the nucleosome. Indeed increasing the amount of beads whilst keeping the
concentration of H3K4me3/3 nucleosomes the same, resulted in an increase of
TAF3 binding (data not shown) although these experiments were not analysed
via MS and therefore the behaviour of the other TFIID subunits is unknown.
TFIID recruitment may require more than just TAF3 binding to recruit other
transcription factors. It is possible that bivalent domains recruit TFIID and
RNAPII due to many low affinity interactions, however, for this to be replicated
in vitro it may require a bivalent nucleosomal array. Moreover, the additional
chromatin marks present at bivalent domains in vivo may help with TFIID and
RNAPII recruitment.
There are multiple additional PTMs that are found associated with bivalent
domains, including H3K14ac, H3K9ac, and histone variants H2A.Z and H3.3 (Ku
et al., 2012; Cui et al., 2009; Roh et al., 2006; Barski et al., 2007; Sen et al., 2016;
Banaszynski et al., 2013). The presence of both H3K4me3 and H3K14ac has been
shown to have a synergistic effect on the recruitment of TFIID (Vermeulen et al.,
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2007). This effect is unaltered by the presence of H3K27me3 on the same tail as
H3K4me3 (Nuland et al., 2013). H3K9ac helps to stabilise the presence of TFIID
at promoters (Krasnov et al., 2016; Vermeulen et al., 2007). The combination of
H3K4me3 and H3K14ac at bivalent domains may result in recruitment of TFIID
and subsequently the PIC, while H3K9ac helps stabilise TFIID binding helping
maintain poised RNAPII at bivalent domains. The binding of both H3K14ac and
H3K9ac not only helps with the recruitment of RNAPII but also, via interaction
with TAFII250 of TFIID, to stabilise it (Agalioti et al., 2002).
The relationship between H2A.Z and RNAPII is complicated; the C-terminus of
yeast H2A.Z interacts with RNAPII, promoting its recruitment, however, there
is an inverse relation between the presence of H2A.Z and transcription (Li et al.,
2005a; Adam et al., 2001). This may be as a result of the chromatin remodeller
FACT, and its subunit SPT16, which remove H2A.Z in coding regions (Jeronimo
et al., 2015). The depletion of H2A.Z in coding regions correlates with the lack of
H3K36me3 on H2A.Z containing nucleosomes (Jeronimo et al., 2015; Chen et al.,
2012). A knockdown of H2A.Z results in a decrease of the RNAPII recruitment
at TSSs in both human and yeast cells, suggesting a evolutionarily conserved
function (Adam et al., 2001; Hardy et al., 2009). The presence of H2A.Z may
therefore help with the recruitment and poising of RNAPII at bivalent promoters.
In addition to H2A.Z’s role in RNAPII recruitment to bivalent domains, it has
been shown to allow access of multiple chromatin modifiers, including MLL and
PcG complexes (Hu et al., 2013b; Weber et al., 2014; Guillemette et al., 2005; Li
et al., 2005a; Creyghton et al., 2008). This access can be used to maintain, modify
or communicate bivalent domain function. The presence of PRC1 and PRC2 as
well as their marks, H3K27me3 and H2AK119ub, is inhibitory for productive
transcription (Lau and So, 2015; Francis et al., 2004; Aranda et al., 2015; Zhou
et al., 2008; Wang et al., 2004a; Napoles et al., 2004; Agger et al., 2007; Burgold
et al., 2008; Nakagawa et al., 2008) although the mechanisms by which they
enforce repression are still debated. These combinations of factors may result
in small amounts of RNAPII recruitment and stabilisation at bivalent promoters
but no transcriptional elongation.
The ability of H3K27me3 to recruit PcG complexes PRC1 and PRC2 in the
context of the bivalent asymmetric nucleosome means that not only are the
bivalent domains poised for activation via poised RNAPII but also for repression.
After H3K4me3 removal, the bound PRC2, potentially in a conformation similar
to that seen in Poepsel et al. (2018), would be able to modify the H3 tail with
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H3K27me3. The presence of PRC2 and PRC1 may help reinforce the presence of
H3K27me3 at bivalent domains, counteracting removal of H3K27me3 catalysed
by JMJD3 and UTX (Agger et al., 2007; De Santa et al., 2007; Lan et al., 2007;
Lee et al., 2006).
The presence of H3K27me3 and its ability to recruit PRC1 components even when
in a bivalent conformation explains the co-occurrence of bivalency and H2A.Zub
(Ku et al., 2012). Bivalent domains are enriched for H2A.Z which often contains
both acetylation and ubiquitination marks. This ubiquitination may help to poise
RNAPII at bivalent domains by decreasing FACT recruitment, inhibiting active
RNAPII elongation and blocking the release of RNAPII from initiation (Stock
et al., 2007; Zhou et al., 2008). H2A.Zub inhibits the recruitment of BRD2
(Surface et al., 2016), a protein enriched at bivalent domains that encourages
RNAPII transcription (LeRoy et al., 2008). Removal of H2A.Zub decreases
the recruitment of PRC2 and leads to depletion of H3K27me3 while increasing
BRD2 recruitment and productive elongation (Surface et al., 2016). H2A.Z found
at bivalent domains is usually dually modified with both ubiquitination and
acetylation (Ku et al., 2012). The combination of these two marks at bivalent
domains suggests another method of poising the gene for regulation with H2A.Z
containing opposing marks. The presence of both H3K27me3 and H2A.Z are
incompatible with DNA methylation (Zilberman et al., 2008; Hagarman et al.,
2013; Meehan and Pennings, 2017). The presence of these at bivalent domains
may prevent the establishment of DNA methylation and the formation of a stable
repressive domain.
In order to investigate the importance of these additional chromatin signatures
present at bivalent domains the pulldown experiment could be extended to
nucleosomes modified with these additional modifications or histone variants
H2A.Z and H3.3. These experiments could show how more complex chromatin
modifications affect bivalent domain function and subsequent mark deposition.
Does the presence of H3K14ac combined with H3K4me3 allow H3K4me0/3 or
H3K4me3/H3K27me3 nucleosomes to recruit RNAPII? Is RNAPII at bivalent
domains recruited or poised by H2A.Zub/ac? Does a nucleosome containing
H3K4me3K9acK14ac poise RNAPII in the context of a bivalent nucleosome or
a nucleosomal array? The use of nucleosomal arrays, additional modifications
and specific DNA sequences may act to recruit further proteins involved in
transcriptional regulation and recruit a network of proteins more similar to that
bound to bivalent domains in vivo. The added PTMs, and histone variants
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initially with mononucleosomes and then with nucleosomal arrays will increase the
intricacy of the biological readout but, if done systematically, will allow deeper
insight to the complexity of bivalent domains.
7.4 Bivalent Nucleosomes Recruit Specific
Proteins In Vitro
The proteins that bind bivalent nucleosomes are not simply a combination of
proteins that bind the singularly modified asymmetric nucleosomes or even an
amalgamation of proteins that bind the symmetrically modified nucleosomes.
This study has uncovered proteins that prefer to bind to the bivalent asymmetric
nucleosome conformation, including PUM1, TFE1, SRCAP, KAT6B, SRSF2,
DMAP1, USF1, and ZRANB2. The presence of these proteins may help maintain
and communicate the biological function of bivalency to the cell. These proteins
have a diverse range of functions, some of which oppose each other, indicating
once again the co-occurrence of opposing functions, marks, such as H2A.Zub/ac,
and proteins at bivalent domains. Due to time constraints only SRCAP and
KAT6B were investigated further.
A number of components of SRCAP are enriched on the bivalent nucleosome in
comparison to the unmodified nucleosome. However, the two unique components
of the SRCAP complex were enriched on bivalent nucleosomes compared to all
other nucleosomes investigated; SRCAP and DMAP1. The SRCAP complex
is critical for the deposition of H2A.Z/H2B dimers, found at bivalent domains
(Wong et al., 2007). The recruitment of these proteins in vitro along with
the co-occurrence of their mark at bivalent domains supports a biological
significance for the proteins found bound to the bivalent asymmetric nucleosomes
in vitro. Multiple mechanisms for recruitment of SRCAP to chromatin have
been proposed, including the recruitment of GAS41 (YEATS4) to H3K14ac and
H3K27ac marks (Hsu et al., 2018a; Hsu et al., 2018b). The enrichment of SRCAP
and DMAP1 on bivalent nucleosomes suggests the presence of another previously
unknown recruitment mechanism – dependent on H3K4me3 and H3K27me3 co-
localisation. This mechanism may be direct although currently there is no
evidence to suggest direct binding via the protein domains present in the SRCAP
complex. It is therefore more likely to be through indirect recruitment through
another protein either contained in the candidate list or a protein present in
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multiple complexes, preventing them from being classified as enriched on bivalent
domains. The presence of H2A.Z at bivalency has been previously remarked upon
and its function is debated as mentioned previously.
KAT6B, the catalytic component of the MORF complex, a MYST histone
acetyltransferase (HAT) is also found enriched in the bivalent condition. KAT6B
catalyses the acetylation of histone H3 resulting in the placement of H3K14ac
and H3K23ac (Voigt et al., 2012; Karmodiya et al., 2012; Ullah et al., 2008;
Voss et al., 2009; Sheikh and Akhtar, 2019; Simó-Riudalbas et al., 2015; Qin
et al., 2011; Ali et al., 2012). H3K14ac contributes to recruitment of the SRCAP
complex, indicating a link between these two complexes and their functions (Hsu
et al., 2018a). KAT6B is unable to modify the nucleosomes used in the in vitro
experiment due to removal of cofactors such as acetyl-CoA via dialysis in NE
preparation. SRCAP and KAT6B may be recruited independently to bivalent
domains or they may interact through the deposition of H3K14ac and by protein-
protein interactions. The presence of both the catalytic components of MORF
and SRCAP on bivalent nucleosomes suggests the co-operation of these two
complexes in mediating bivalent domain function. The placement of H3K14ac
may have additional functions apart from SRCAP recruitment. BRD2 binds to
acetylated H4K5, H4K12 and H3K14 and can help promote transcription (LeRoy
et al., 2008; Hargreaves et al., 2009; Cheung et al., 2017; Draker et al., 2012;
Hnilicová et al., 2013). The recruitment of KAT6B may not only help H2A.Z
deposition but also help stabilise poised RNAPII via the placement of H3K14ac
and H3K23ac. The interactions and potential synergy between KAT6B and
SRCAP at bivalent domains needs be investigated further possibly via double
knockout cell lines of both proteins to see how this affects bivalent domains.
The binding of KAT6B to bivalent domains was confirmed in vivo. Nevertheless
the exact mechanism of recruitment to bivalent asymmetric nucleosomes remains
partially unclear. The interaction between PRC1 and MORF seen in Drosophila
(Strubbe et al., 2011) is not present in mouse ESCs preventing PRC1’s interaction
with either H3K27me3 or H2AK119ub to mediate recruitment of KAT6B/MORF.
The MORF complex does not contain any known reader domains for H3K27me3,
although, it does contain reader domains that recruit MORF to both H3K4me0
and H3K4me3 (Ullah et al., 2008; Klein et al., 2014; Dreveny et al., 2014;
Champagne et al., 2008). KAT6B could be recruited to bivalent nucleosomes via a
previously unknown interaction or the double PHD finger of KAT6B may recruit
MORF via its interaction with H3K4me0 on the tail containing H3K27me3.
174
In order to investigate KAT6B’s binding and function in vivo, cell lines with
tagged-KAT6B were generated. KAT6B is present at both active and bivalent
domains as suggested by previous studies that investigated H3K14ac placement
(Karmodiya et al., 2012; Guenther et al., 2007; Hsu et al., 2018b). The removal
of H3K4me3 by the inactivation of MLL2 decreased the recruitment of KAT6B
mainly at bivalent domains. While the deletion of both EZH1 and EZH2
removed H3K27me3 genome-wide it did not decrease KAT6B recruitment at
bivalent domains. KAT6B is still present at bivalent domains at lower levels
when H3K4me3 is removed, indicating that KAT6B recruitment is only partially
dependent on the presence of H3K4me3 and bivalency suggesting another method
for KAT6B recruitment. The deposition of its own mark also helps further
recruitment of the KAT6A/B complex (Ali et al., 2012; Klein et al., 2017)
resulting in a feedback mechanism and may be partially responsible for the low
levels of KAT6B remaining. H3K27me3 present at bivalent domains may not act
to recruit KAT6B in vivo by any known mechanism.
Further research is required in order to fully isolate and determine the mechanism
of KATB6’s recruitment to bivalent domains. A sequence of protein truncations
combined with mutations of important residues within protein domains will
allow determination of which protein subunit or combination of subunits recruits
KAT6B to bivalent domains. This may also elucidate the importance of
H3K27me3 for recruitment, stability, or catalytic activity of KAT6B. Mutation of
the ING5 PHD domain would allow confirmation of its role in recruiting KAT6B
to both active and bivalent domains, while mutational analysis of KAT6B’s double
PHD domain would help isolate the domain responsible for MORF’s recruitment
to bivalent domains. It is possible that the bivalent nucleosomes could “trap”
KAT6B in a specific conformation, potentially at a stage of the enzymatic reaction
that prevents the transfer of the acetyl group. This would increase the amount
of KAT6B bound while explaining the lack of catalytic activity seen in vivo and
in vitro.
A different role for H3K27me3 and its importance for KAT6B’s function was sug-
gested by a HAT assay performed with the specifically modified nucleosomes. The
purified MORF complex showed increased catalytic activity towards H3K27me3
symmetrically modified nucleosomes. The difference between the presence of
KAT6B and its marks in vivo, analysed via ChIP, and the activity of the purified
MORF complex towards H3K27me3/3 nucleosomes in the HAT assay suggests
a further interaction or factor missing from the purified MORF complex. This
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interaction may affect the activity of KAT6B at repressive domains in vivo.
The MYST family of acetyltransferases is poorly researched and so far the
structure and catalytic mechanism of only one of the MYST family members
has been solved – ESA1 (Yan et al., 2000). There are two different catalytic
mechanisms of KAT6B proposed, but neither has been confirmed. This
uncertainty of MYST binding and catalytic mechanism means it is difficult to
predict how H3K27me3 may cause this increase in catalytic activity. The double
PHD domain on MOZ twists an 11 residue stretch of the H3 N-terminal tail into
an α helical structure, allowing summation of H3K4me3 and H3K14ac effects on
the MYST domain (Dreveny et al., 2014). This demonstrates a mechanism for
modified residues more than 11 αα distant to the target residue to affect KAT6B’s
function. Currently no structure of a mammalian MYST domain bound to a
defined peptide substrate has been solved, therefore the expanse of peptide that
interacts with the domain and influences MYST binding and catalytic activity is
unknown. The binding of a peptide to an enzyme is not solely due to the target
residue, interactions with the residues alongside the substrate residue contribute
to specificity of substrate-enzyme binding. Due to the proximity of residue H3K27
with H3K23, H3K27me3 may interact with MORF’s active site, the MYST
domain, when depositing the H3K23ac modification. It may be this interaction
with the MYST domain that causes the increase in catalytic activity observed in
the HAT assay. This interaction of H3K27me3 with the MYST domain may
have multiple functions, not only increasing KAT6B’S catalytic activity but
also stabilising the binding of the MORF complex at bivalent domains (see Fig.
7.1). H3K27me3’s effect on MORF requires further investigation to elucidate its
mechanism and biological function. Crystallisation of KAT6B or KAT6B’s MYST
domain bound to a peptide would allow determination of H3K27me3’s role in
MYST activity and binding. Once catalytic residues are determined, mutational
analyses combined with in vitro catalytic assays would show the importance of
each residue, elucidate KAT6B’s catalytic mechanism and indicate the mechanism
of H3K27me3 stimulation. Crosslinking mass spectrometry could be used to
determine interactions between a bivalent nucleosome and the MORF complex.
This would help identify the potential role H3K27me3 has in recruitment or
stimulation of KAT6B’s catalytic activity.
Generation and neuronal differentiation of KAT6B KO mouse ESCs cell lines
allowed investigation into KAT6B’s role in ESCs and at bivalent domains. There
are no obvious phenotypic or gene expression differences between E14 control and
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Figure 7.1 Potential Interactions of the MORF Complex with Histone
Modifications. Domains are labelled as follows: PHD - Plant homeodomain zinc finger,
ZnF - Zinc finger, H15 - Sequence similarity to H1 and H5 histone domain, also referred to
as NEMM, MYST - Acetyltransferase domain, ED - acidic (glutamate/aspartate rich) region,
SM - Serine/methionine rich stretch, Bromo - bromodomain, PWWP - proline-tryptophan-
tryptophan-proline domain, B - domain that interacts with KAT6B’s MYST domain, M -
domain that mediates BRPF1’s interaction with ING5 and hEAF6. The potential interaction
of KAT6B’s MYST domain with H3K27me3 shown with a red arrow.
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KAT6A/B KO cell lines. This suggests that removal of KAT6B does not affect
the expression of actively transcribed genes, even though previously obtained data
demonstrates its presence at these genes. The differences between the cell lines
and the importance of KAT6B becomes clearer as the cells start to differentiate.
From day 2 onwards KAT6B KO cell lines fail to properly upregulate genes
required for neuronal differentiation and for exit from pluripotency. This
phenotype is replicated, although to a lesser extent, in KAT6A KO cell lines and
amplified in the double KO. The importance of KAT6B and the marks it places
to upregulate genes in differentiation is supported by the failure of KAT6B KO,
KAT6A KO and KAT6A/B KO cell lines to form neuronal cells. The removal of
KAT6B does not affect the expression of genes involved in pluripotency expressed
in ESCs; however, it does affect the upregulation of genes that are required for
differentiation, including genes that are bivalent in ESCs. Whether this result
is representative for ESC differentiation in general or specific to neuronal linage
specific genes is unknown. Further differentiation experiments are required to see
whether KAT6B is essential for successful ESCs differentiation into other lineages
as well.
7.5 Summary
This work has provided important advances into understanding the unique
network of proteins that bind bivalent asymmetric nucleosomes in vitro. Further
experiments are required to elucidate how the addition of further marks and
substitution of histone variants found at bivalent domains affects this network.
While investigating bivalency and histone PTM asymmetry, the inability of
both H3K27me3 and H3K4me3 marks to enrich for proteins when present in
asymmetric rather than symmetric fashion was discovered. This asymmetric
effect may have important consequences in vivo and should be investigated
further. Identification of sites consisting of asymmetric H3K4me3, potentially
by construction of a recombinant protein that is able to bind this asymmetric
state, would allow determination of their biological significance. The proteins
identified bound to bivalent nucleosomes in vitro support the co-occurrence of
chromatin modifications previously found at bivalent domains in vivo. The co-
occurrence of H3K4me3, and H3K27me3 at bivalent domains seem to recruit
proteins that involved in both activation and repression of transcription and
reinforce the bivalent nature of the domain.
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This combination of proteins and marks found occurring at bivalent domains,
supports the theory of bivalent domains poising the genes for timely regulation
during differentiation. One member of the network of proteins that prefers to
bind the bivalent asymmetric nucleosome conformation is KAT6B. KAT6B binds
bivalent nucleosomes both in vitro and in vivo, and is important for embryonic
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